Efficient	O
targeting	O
of	O
protein	O
antigen	O
to	O
the	O
dendritic	O
cell	O
receptor	O
DEC	B
-	I
205	I
in	O
the	O
steady	O
state	O
leads	O
to	O
antigen	O
presentation	O
on	O
major	B
histocompatibility	I
complex	I
class	I
I	I
products	I
and	O
peripheral	O
CD8	B
+	I
T	I
cell	I
tolerance	O
.	O

To	O
identify	O
endocytic	O
receptors	O
that	O
allow	O
dendritic	O
cells	O
(	O
DCs	O
)	O
to	O
capture	O
and	O
present	O
antigens	O
on	O
major	B
histocompatibility	I
complex	I
(	O
MHC	B
)	O
class	O
I	O
products	O
in	O
vivo	O
,	O
we	O
evaluated	O
DEC	B
-	I
205	I
,	O
which	O
is	O
abundant	O
on	O
DCs	O
in	O
lymphoid	O
tissues	O
.	O

Ovalbumin	B
(	I
OVA	I
)	I
protein	I
,	O
when	O
chemically	O
coupled	O
to	O
monoclonal	B
alpha	I
DEC	I
-	I
205	I
antibody	I
,	O
was	O
presented	O
by	O
CD11c	B
+	O
lymph	O
node	O
DCs	O
,	O
but	O
not	O
by	O
CD11c	B
-	O
cells	O
,	O
to	O
OVA	B
-	O
specific	O
,	O
CD4	B
+	I
and	O
CD8	B
+	I
T	O
cells	O
.	O

Receptor	O
-	O
mediated	O
presentation	O
was	O
at	O
least	O
400	O
times	O
more	O
efficient	O
than	O
unconjugated	O
OVA	B
and	O
,	O
for	O
MHC	B
class	I
I	I
,	O
the	O
DCs	O
had	O
to	O
express	O
transporter	B
of	I
antigenic	I
peptides	I
(	O
TAP	B
)	O
transporters	O
.	O

When	O
alpha	O
DEC	O
-	O
205	O
:	O
OVA	O
was	O
injected	O
subcutaneously	O
,	O
OVA	O
protein	O
was	O
identified	O
over	O
a	O
4	O
-	O
48	O
h	O
period	O
in	O
DCs	O
,	O
primarily	O
in	O
the	O
lymph	O
nodes	O
draining	O
the	O
injection	O
site	O
.	O

In	O
vivo	O
,	O
the	O
OVA	O
protein	O
was	O
selectively	O
presented	O
by	O
DCs	O
to	O
TCR	B
transgenic	I
CD8	I
+	O
cells	O
,	O
again	O
at	O
least	O
400	O
times	O
more	O
effectively	O
than	O
soluble	O
OVA	O
and	O
in	O
a	O
TAP	O
-	O
dependent	O
fashion	O
.	O

Targeting	O
of	O
alpha	B
DEC	I
-	I
205	I
:	I
OVA	I
to	O
DCs	O
in	O
the	O
steady	O
state	O
initially	O
induced	O
4	O
-	O
7	O
cycles	O
of	O
T	O
cell	O
division	O
,	O
but	O
the	O
T	O
cells	O
were	O
then	O
deleted	O
and	O
the	O
mice	O
became	O
specifically	O
unresponsive	O
to	O
rechallenge	O
with	O
OVA	O
in	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
.	O

In	O
contrast	O
,	O
simultaneous	O
delivery	O
of	O
a	O
DC	O
maturation	O
stimulus	O
via	O
CD40	B
,	O
together	O
with	O
alpha	B
DEC	I
-	I
205	I
:	O
OVA	B
,	O
induced	O
strong	O
immunity	O
.	O

The	O
CD8	B
+	I
T	O
cells	O
responding	O
in	O
the	O
presence	O
of	O
agonistic	B
alpha	I
CD40	I
antibody	I
produced	O
large	O
amounts	O
of	O
interleukin	B
2	I
and	O
interferon	B
gamma	I
,	O
acquired	O
cytolytic	O
function	O
in	O
vivo	O
,	O
emigrated	O
in	O
large	O
numbers	O
to	O
the	O
lung	O
,	O
and	O
responded	O
vigorously	O
to	O
OVA	B
rechallenge	O
.	O

Therefore	O
,	O
DEC	B
-	I
205	I
provides	O
an	O
efficient	O
receptor	O
-	O
based	O
mechanism	O
for	O
DCs	O
to	O
process	O
proteins	O
for	O
MHC	B
class	I
I	I
presentation	O
in	O
vivo	O
,	O
leading	O
to	O
tolerance	O
in	O
the	O
steady	O
state	O
and	O
immunity	O
after	O
DC	O
maturation	O
.	O

A	O
major	O
role	O
for	O
Scar	B
/	O
WAVE	B
-	I
1	I
downstream	O
of	O
GPVI	B
in	O
platelets	O
.	O

BACKGROUND	O
:	O
The	O
small	B
GTPase	I
Rac1	I
plays	O
a	O
critical	O
role	O
in	O
lamellipodia	O
assembly	O
in	O
platelets	O
on	O
matrix	O
proteins	O
in	O
the	O
absence	O
or	O
presence	O
of	O
G	B
protein	I
-	I
coupled	I
receptor	I
(	O
GPCR	B
)	O
agonists	O
.	O

Rac	B
mediates	O
actin	B
assembly	O
via	O
Scar	B
/	O
WAVE	B
,	O
a	O
family	O
of	O
scaffolding	O
proteins	O
that	O
direct	O
actin	B
reorganization	O
by	O
relaying	O
signals	O
from	O
Rac	B
to	O
the	O
Arp2	B
/	I
3	I
complex	I
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
role	O
of	O
Scar	B
/	O
WAVE	B
-	I
1	I
in	O
mediating	O
platelet	O
activation	O
and	O
cytoskeletal	O
reorganization	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Using	O
specific	O
antibodies	O
,	O
we	O
demonstrate	O
that	O
murine	O
platelets	O
,	O
like	O
human	O
platelets	O
,	O
express	O
Scar	B
/	O
WAVE	B
-	I
1	I
and	O
Scar	B
/	O
WAVE	B
-	I
2	I
.	O

Lamellipodia	O
formation	O
in	O
Scar	B
/	O
WAVE	B
-	I
1	I
(	O
-	O
/	O
-	O
)	O
platelets	O
is	O
markedly	O
inhibited	O
on	O
immobilized	O
collagen	B
-	I
related	I
peptide	I
(	O
CRP	B
)	O
and	O
on	O
laminin	B
,	O
both	O
of	O
which	O
signal	O
through	O
the	O
collagen	B
receptor	I
GPVI	I
.	O

In	O
contrast	O
,	O
lamellipodia	O
formation	O
on	O
collagen	B
,	O
which	O
requires	O
release	O
of	O
the	O
GPCR	B
agonists	O
ADP	O
and	O
thromboxane	O
A	O
(	O
2	O
)	O
,	O
is	O
not	O
altered	O
.	O

Immobilized	O
fibrinogen	B
supports	O
limited	O
formation	O
of	O
lamellipodia	O
in	O
murine	O
platelets	O
,	O
which	O
is	O
not	O
altered	O
in	O
Scar	B
/	O
WAVE	B
-	I
1	I
(	I
-	I
/	I
-	I
)	I
platelets	O
.	O

As	O
with	O
Rac1	B
(	I
-	I
/	I
-	I
)	I
platelets	O
,	O
Scar	B
/	O
WAVE	B
-	I
1	I
(	I
-	I
/	I
-	I
)	I
platelets	O
exhibit	O
a	O
marked	O
inhibition	O
of	O
aggregation	O
in	O
response	O
to	O
CRP	B
,	O
whereas	O
the	O
response	O
to	O
the	O
GPCR	B
agonist	O
thrombin	B
is	O
not	O
altered	O
.	O

Platelet	O
aggregation	O
on	O
immobilized	O
collagen	B
under	O
shear	O
,	O
which	O
is	O
dependent	O
on	O
signaling	O
by	O
matrix	O
and	O
GPCR	B
agonists	O
,	O
was	O
unaltered	O
in	O
the	O
absence	O
of	O
Scar	B
/	O
WAVE	B
-	I
1	I
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
a	O
major	O
role	O
for	O
Scar	B
/	O
WAVE	B
-	I
1	I
in	O
mediating	O
platelet	O
cytoskeletal	O
reorganization	O
and	O
aggregate	O
formation	O
downstream	O
of	O
activation	O
by	O
GPVI	B
but	O
not	O
by	O
GPCR	O
agonists	O
.	O

DNA	O
damage	O
activates	O
the	O
SAC	B
in	O
an	O
ATM	B
/	O
ATR	B
-	O
dependent	O
manner	O
,	O
independently	O
of	O
the	O
kinetochore	O
.	O

The	O
DNA	O
damage	O
checkpoint	O
and	O
the	O
spindle	O
assembly	O
checkpoint	O
(	O
SAC	O
)	O
are	O
two	O
important	O
regulatory	O
mechanisms	O
that	O
respond	O
to	O
different	O
lesions	O
.	O

The	O
DNA	O
damage	O
checkpoint	O
detects	O
DNA	O
damage	O
,	O
initiates	O
protein	O
kinase	O
cascades	O
,	O
and	O
inhibits	O
the	O
cell	O
cycle	O
.	O

The	O
SAC	O
relies	O
on	O
kinetochore	O
-	O
dependent	O
assembly	O
of	O
protein	O
complexes	O
to	O
inhibit	O
mitosis	O
when	O
chromosomes	O
are	O
detached	O
from	O
the	O
spindle	O
.	O

The	O
two	O
checkpoints	O
are	O
thought	O
to	O
function	O
independently	O
.	O

Here	O
we	O
show	O
that	O
yeast	O
cells	O
lacking	O
the	O
DNA	O
damage	O
checkpoint	O
arrest	O
prior	O
to	O
anaphase	O
in	O
response	O
to	O
low	O
doses	O
of	O
the	O
DNA	O
damaging	O
agent	O
methyl	O
methane	O
sulfonate	O
(	O
MMS	O
)	O
.	O

The	O
arrest	O
requires	O
the	O
SAC	B
proteins	I
Mad1	I
,	O
Mad2	B
,	O
Mad3	B
,	O
Bub1	B
,	O
and	O
Bub3	B
and	O
works	O
through	O
Cdc20	B
and	O
Pds1	B
but	O
unlike	O
the	O
normal	O
SAC	B
,	O
does	O
not	O
require	O
a	O
functional	O
kinetochore	O
.	O

Mec1	B
(	O
ATR	B
)	O
and	O
Tel1	B
(	O
ATM	B
)	O
are	O
also	O
required	O
,	O
independently	O
of	O
Chk1	B
and	O
Rad53	B
,	O
suggesting	O
that	O
Mec1	B
and	O
Tel1	B
inhibit	O
anaphase	O
in	O
response	O
to	O
DNA	O
damage	O
by	O
utilizing	O
SAC	B
proteins	I
.	O

Our	O
results	O
demonstrate	O
cross	O
-	O
talk	O
between	O
the	O
two	O
checkpoints	O
and	O
suggest	O
that	O
assembling	O
inhibitory	O
complexes	O
of	O
SAC	B
proteins	I
at	O
unattached	O
kinetochores	O
is	O
not	O
obligatory	O
for	O
their	O
inhibitory	O
activity	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
there	O
are	O
novel	O
,	O
important	O
targets	O
of	O
ATM	B
and	O
ATR	B
for	O
cell	O
cycle	O
regulation	O
.	O

A	O
point	O
mutation	O
in	O
translation	B
initiation	I
factor	I
2B	I
leads	O
to	O
a	O
continuous	O
hyper	O
stress	O
state	O
in	O
oligodendroglial	O
-	O
derived	O
cells	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
eukaryotic	B
translation	I
initiation	I
factor	I
2B	I
(	O
eIF2B	B
)	O
cause	O
Childhood	O
Ataxia	O
with	O
CNS	O
Hypomyelination	O
(	O
CACH	O
)	O
,	O
also	O
known	O
as	O
Vanishing	O
White	O
Matter	O
disease	O
(	O
VWM	O
)	O
.	O

The	O
disease	O
is	O
manifested	O
by	O
loss	O
of	O
brain	O
myelin	O
upon	O
physiological	O
stress	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
showed	O
that	O
fibroblasts	O
isolated	O
from	O
CACH	O
/	O
VWM	O
patients	O
are	O
hypersensitive	O
to	O
pharmacologically	O
-	O
induced	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O

Since	O
brain	O
cells	O
from	O
affected	O
individuals	O
are	O
not	O
available	O
for	O
research	O
,	O
we	O
wished	O
to	O
assess	O
the	O
effect	O
of	O
eIF2B	B
mutation	O
on	O
oligodendroglial	O
-	O
derived	O
cells	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
A	O
rat	O
oligodendroglial	O
-	O
derived	O
cell	O
line	O
was	O
used	O
for	O
a	O
stable	O
knock	O
-	O
down	O
of	O
eIF2B5	B
followed	O
by	O
stable	O
expression	O
of	O
mutated	O
eIF2B5	B
(	O
R195H	O
)	O
cDNA	O
.	O

In	O
response	O
to	O
a	O
pharmacological	O
ER	O
-	O
stress	O
agent	O
,	O
eIF2B5	B
(	I
R195H	I
)	I
expressing	O
cells	O
exhibited	O
heightened	O
ER	O
-	O
stress	O
response	O
demonstrated	O
by	O
hyper	O
induction	O
of	O
ATF4	B
,	O
GADD34	B
,	O
Bip	B
,	O
PDIA1	B
,	O
PDIA3	B
,	O
PDIA4	B
and	O
PDIA6	B
proteins	O
.	O

Moreover	O
,	O
even	O
in	O
the	O
absence	O
of	O
a	O
pharmacological	O
stress	O
agent	O
,	O
eIF2B5	B
(	I
R195H	I
)	I
-	O
expressing	O
cells	O
exhibited	O
high	O
basal	O
levels	O
of	O
ATF4	B
,	O
GADD34	B
and	O
ER	B
-	I
associated	I
Bip	I
,	O
PDIA1	B
and	O
PDIA3	B
.	O

SIGNIFICANCE	O
:	O
The	O
data	O
provide	O
evidence	O
that	O
oligodendroglial	O
-	O
derived	O
cells	O
expressing	O
a	O
mutated	O
eIF2B	B
constantly	O
use	O
their	O
stress	O
response	O
mechanism	O
as	O
an	O
adaptation	O
mean	O
in	O
order	O
to	O
survive	O
.	O

The	O
current	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
effects	O
of	O
eIF2B5	B
mutation	O
on	O
ER	O
homeostasis	O
in	O
oligodendroglial	O
-	O
derived	O
cells	O
.	O

Thymosin	B
beta4	I
mediated	O
PKC	B
activation	O
is	O
essential	O
to	O
initiate	O
the	O
embryonic	O
coronary	O
developmental	O
program	O
and	O
epicardial	O
progenitor	O
cell	O
activation	O
in	O
adult	O
mice	O
in	O
vivo	O
.	O

Hypoxic	O
heart	O
disease	O
is	O
a	O
predominant	O
cause	O
of	O
disability	O
and	O
death	O
worldwide	O
.	O

Since	O
adult	O
mammalian	O
hearts	O
are	O
incapable	O
of	O
regeneration	O
after	O
hypoxia	O
,	O
attempts	O
to	O
modify	O
this	O
deficiency	O
are	O
critical	O
.	O

As	O
demonstrated	O
in	O
zebrafish	O
,	O
recall	O
of	O
the	O
embryonic	O
developmental	O
program	O
may	O
be	O
the	O
key	O
to	O
success	O
.	O

Because	O
thymosin	B
beta4	I
(	O
TB4	B
)	O
is	O
beneficial	O
for	O
myocardial	O
cell	O
survival	O
and	O
essential	O
for	O
coronary	O
development	O
in	O
embryos	O
,	O
we	O
hypothesized	O
that	O
it	O
reactivates	O
the	O
embryonic	O
developmental	O
program	O
and	O
initiates	O
epicardial	O
progenitor	O
mobilization	O
in	O
adult	O
mammals	O
.	O

We	O
found	O
that	O
TB4	B
stimulates	O
capillary	O
-	O
like	O
tube	O
formation	O
of	O
adult	O
coronary	O
endothelial	O
cells	O
and	O
increases	O
embryonic	O
endothelial	O
cell	O
migration	O
and	O
proliferation	O
in	O
vitro	O
.	O

The	O
increase	O
of	O
blood	B
vessel	I
/	I
epicardial	I
substance	I
(	O
Bves	B
)	O
expressing	O
cells	O
accompanied	O
by	O
elevated	O
VEGF	B
,	O
Flk	B
-	I
1	I
,	O
TGF	B
-	I
beta	I
,	O
Fgfr	B
-	I
2	I
,	O
Fgfr	B
-	I
4	I
,	O
Fgf	B
-	I
17	I
and	O
beta	B
-	I
Catenin	I
expression	O
and	O
increase	O
of	O
Tbx	B
-	I
18	I
and	O
Wt	B
-	I
1	I
positive	O
myocardial	O
progenitors	O
suggested	O
organ	O
-	O
wide	O
recall	O
of	O
the	O
embryonic	O
program	O
in	O
the	O
adult	O
epicardium	O
.	O

TB4	B
also	O
positively	O
regulated	O
the	O
expression	O
and	O
phosphorylation	O
of	O
myristoylated	B
alanine	I
-	I
rich	I
C	I
-	I
kinase	I
substrate	I
(	O
Marcks	B
)	O
,	O
a	O
direct	O
substrate	O
and	O
indicator	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

PKC	B
inhibition	O
significantly	O
reduced	O
TB4	O
initiated	O
epicardial	O
thickening	O
,	O
capillary	O
growth	O
and	O
the	O
number	O
of	O
myocardial	O
progenitors	O
.	O

Our	O
results	O
demonstrate	O
that	O
TB4	B
is	O
the	O
first	O
known	O
molecule	O
capable	O
of	O
organ	O
-	O
wide	O
activation	O
of	O
the	O
embryonic	O
coronary	O
developmental	O
program	O
in	O
the	O
adult	O
mammalian	O
heart	O
after	O
systemic	O
administration	O
and	O
that	O
PKC	B
plays	O
a	O
significant	O
role	O
in	O
the	O
process	O
.	O

In	O
vivo	O
Angiotensin	B
II	I
AT1	I
receptor	I
blockade	O
selectively	O
inhibits	O
LPS	O
-	O
induced	O
innate	O
immune	O
response	O
and	O
ACTH	B
release	O
in	O
rat	O
pituitary	O
gland	O
.	O

Systemic	O
lipopolysaccharide	O
(	O
LPS	O
)	O
administration	O
induces	O
an	O
innate	O
immune	O
response	O
and	O
stimulates	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
.	O

We	O
studied	O
Angiotensin	B
II	I
AT	I
(	I
1	I
)	I
receptor	I
participation	O
in	O
the	O
LPS	O
effects	O
with	O
focus	O
on	O
the	O
pituitary	O
gland	O
.	O

LPS	O
(	O
50	O
microg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
enhanced	O
,	O
3h	O
after	O
administration	O
,	O
gene	O
expression	O
of	O
pituitary	B
CD14	I
and	O
that	O
of	O
Angiotensin	B
II	I
AT	I
(	I
1A	I
)	I
receptors	I
in	O
pituitary	O
and	O
hypothalamic	O
paraventricular	O
nucleus	O
(	O
PVN	O
)	O
;	O
stimulated	O
ACTH	B
and	O
corticosterone	O
release	O
;	O
decreased	O
pituitary	B
CRF	I
(	I
1	I
)	I
receptor	I
mRNA	I
and	O
increased	O
all	O
plasma	O
and	O
pituitary	O
pro	O
-	O
inflammatory	O
factors	O
studied	O
.	O

The	O
AT	B
(	I
1	I
)	I
receptor	I
blocker	O
(	O
ARB	O
)	O
candesartan	O
(	O
1mg	O
/	O
kg	O
/	O
day	O
,	O
s	O
.	O
c	O
.	O
daily	O
for	O
3	O
days	O
before	O
LPS	O
)	O
blocked	O
pituitary	O
and	O
PVN	O
AT	B
(	I
1	I
)	I
receptors	I
,	O
inhibited	O
LPS	O
-	O
induced	O
ACTH	B
but	O
not	O
corticosterone	O
secretion	O
and	O
decreased	O
LPS	O
-	O
induced	O
release	O
of	O
TNF	B
-	I
alpha	I
,	O
IL	B
-	I
1beta	I
and	O
IL	B
-	I
6	I
to	O
the	O
circulation	O
.	O

The	O
ARB	O
reduced	O
LPS	O
-	O
induced	O
pituitary	O
gene	O
expression	O
of	O
IL	B
-	I
6	I
,	O
LIF	B
,	O
iNOS	B
,	O
COX	B
-	I
2	I
and	O
IkappaB	B
-	I
alpha	I
;	O
and	O
prevented	O
LPS	O
-	O
induced	O
increase	O
of	O
nNOS	B
/	O
eNOS	B
activity	O
.	O

The	O
ARB	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
TNF	B
-	I
alpha	I
and	O
IL	B
-	I
1beta	I
gene	I
expression	O
,	O
IL	B
-	I
6	I
or	O
IL	B
-	I
1beta	I
protein	I
content	O
or	O
LPS	O
-	O
induced	O
decrease	O
of	O
CRF	B
(	I
1	I
)	I
receptors	I
.	O

When	O
administered	O
alone	O
,	O
the	O
ARB	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
and	O
basal	O
PGE	O
(	O
2	O
)	O
mRNA	O
in	O
pituitary	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
pituitary	O
gland	O
is	O
a	O
target	O
for	O
systemically	O
administered	O
LPS	O
.	O

AT	B
(	I
1	I
)	I
receptor	I
activity	O
is	O
necessary	O
for	O
the	O
complete	O
pituitary	O
response	O
to	O
LPS	O
and	O
is	O
limited	O
to	O
specific	O
pro	O
-	O
inflammatory	O
pathways	O
.	O

There	O
is	O
a	O
complementary	O
and	O
complex	O
influence	O
of	O
the	O
PVN	O
and	O
circulating	O
cytokines	O
on	O
the	O
initial	O
pituitary	O
response	O
to	O
LPS	B
.	O

Our	O
findings	O
support	O
the	O
proposal	O
that	O
ARBs	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
.	O

Caenorhabditis	B
elegans	I
protein	I
arginine	I
methyltransferase	I
PRMT	I
-	I
5	I
negatively	O
regulates	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

Arginine	O
methylation	O
of	O
histone	B
and	O
non	O
-	O
histone	B
proteins	O
is	O
involved	O
in	O
transcription	O
regulation	O
and	O
many	O
other	O
cellular	O
processes	O
.	O

Nevertheless	O
,	O
whether	O
such	O
protein	O
modification	O
plays	O
a	O
regulatory	O
role	O
during	O
apoptosis	O
remains	O
largely	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
the	O
Caenorhabditis	O
elegans	O
homolog	O
of	O
mammalian	B
type	I
II	I
arginine	I
methyltransferase	I
PRMT5	I
negatively	O
regulates	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

We	O
show	O
that	O
inactivation	O
of	O
C	B
.	I
elegans	I
prmt	I
-	I
5	I
leads	O
to	O
excessive	O
apoptosis	O
in	O
germline	O
following	O
ionizing	O
irradiation	O
,	O
which	O
is	O
due	O
to	O
a	O
CEP	B
-	I
1	I
/	O
p53	B
-	O
dependent	O
up	O
-	O
regulation	O
of	O
the	O
cell	O
death	O
initiator	O
EGL	B
-	I
1	I
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
CBP	B
-	I
1	I
,	O
the	O
worm	O
ortholog	O
of	O
human	B
p300	I
/	I
CBP	I
,	O
functions	O
as	O
a	O
cofactor	O
of	O
CEP	B
-	I
1	I
.	O

PRMT	B
-	I
5	I
forms	O
a	O
complex	O
with	O
both	O
CEP	B
-	I
1	I
and	O
CBP	B
-	I
1	I
and	O
can	O
methylate	O
the	O
latter	O
.	O

Importantly	O
,	O
down	O
-	O
regulation	O
of	O
cbp	B
-	I
1	I
significantly	O
suppresses	O
DNA	O
damage	O
-	O
induced	O
egl	B
-	I
1	I
expression	O
and	O
apoptosis	O
in	O
prmt	B
-	I
5	I
mutant	I
worms	O
.	O

These	O
findings	O
suggest	O
that	O
PRMT	B
-	I
5	I
likely	O
represses	O
CEP	B
-	I
1	I
transcriptional	O
activity	O
through	O
CBP	B
-	I
1	I
,	O
which	O
represents	O
a	O
novel	O
regulatory	O
mechanism	O
of	O
p53	B
-	O
dependent	O
apoptosis	O
.	O

Identification	O
of	O
novel	O
gene	O
amplifications	O
in	O
breast	O
cancer	O
and	O
coexistence	O
of	O
gene	O
amplification	O
with	O
an	O
activating	O
mutation	O
of	O
PIK3CA	B
.	O

To	O
identify	O
genetic	O
events	O
that	O
characterize	O
cancer	O
progression	O
,	O
we	O
conducted	O
a	O
comprehensive	O
genetic	O
evaluation	O
of	O
161	O
primary	O
breast	O
tumors	O
.	O

Similar	O
to	O
the	O
"	O
mountain	O
-	O
and	O
-	O
hill	O
"	O
view	O
of	O
mutations	O
,	O
gene	O
amplification	O
also	O
shows	O
high	O
-	O
and	O
low	O
-	O
frequency	O
alterations	O
in	O
breast	O
cancers	O
.	O

The	O
frequently	O
amplified	O
genes	O
include	O
the	O
well	O
-	O
known	O
oncogenes	O
ERBB2	B
,	O
FGFR1	B
,	O
MYC	B
,	O
CCND1	B
,	O
and	O
PIK3CA	B
,	O
whereas	O
other	O
known	O
oncogenes	O
that	O
are	O
amplified	O
,	O
although	O
less	O
frequently	O
,	O
include	O
CCND2	B
,	O
EGFR	B
,	O
FGFR2	B
,	O
and	O
NOTCH3	B
.	O

More	O
importantly	O
,	O
by	O
honing	O
in	O
on	O
minimally	O
amplified	O
regions	O
containing	O
three	O
or	O
fewer	O
genes	O
,	O
we	O
identified	O
six	O
new	O
amplified	O
genes	O
:	O
POLD3	B
,	O
IRAK4	B
,	O
IRX2	B
,	O
TBL1XR1	B
,	O
ASPH	B
,	O
and	O
BRD4	B
.	O

We	O
found	O
that	O
both	O
the	O
IRX2	B
and	O
TBL1XR1	B
proteins	O
showed	O
higher	O
expression	O
in	O
the	O
malignant	O
cell	O
lines	O
MCF10CA1h	O
and	O
MCF10CA1a	O
than	O
in	O
their	O
precursor	O
,	O
MCF10A	O
,	O
a	O
normal	O
immortalized	O
mammary	O
epithelial	O
cell	O
line	O
.	O

To	O
study	O
oncogenic	O
roles	O
of	O
TBL1XR1	B
,	O
we	O
performed	O
knockdown	O
experiments	O
using	O
a	O
short	O
hairpin	O
RNA	O
approach	O
and	O
found	O
that	O
depletion	O
of	O
TBL1XR1	B
in	O
MCF10CA1h	O
cells	O
resulted	O
in	O
reduction	O
of	O
cell	O
migration	O
and	O
invasion	O
as	O
well	O
as	O
suppression	O
of	O
tumorigenesis	O
in	O
mouse	O
xenografts	O
.	O

Intriguingly	O
,	O
our	O
mutation	O
analysis	O
showed	O
the	O
presence	O
of	O
activation	O
mutations	O
in	O
the	O
PIK3CA	B
gene	I
in	O
a	O
subset	O
of	O
tumors	O
that	O
also	O
had	O
DNA	O
copy	O
number	O
increases	O
in	O
the	O
PIK3CA	B
locus	I
,	O
suggesting	O
an	O
additive	O
effect	O
of	O
coexisting	O
activating	O
amino	O
acid	O
substitution	O
and	O
dosage	O
increase	O
from	O
amplification	O
.	O

Our	O
gene	O
amplification	O
and	O
somatic	O
mutation	O
analysis	O
of	O
breast	O
primary	O
tumors	O
provides	O
a	O
coherent	O
picture	O
of	O
genetic	O
events	O
,	O
both	O
corroborating	O
and	O
novel	O
,	O
offering	O
insight	O
into	O
the	O
genetic	O
underpinnings	O
of	O
breast	O
cancer	O
progression	O
.	O

The	O
tetraspanin	B
KAI1	I
/	O
CD82	B
is	O
expressed	O
by	O
late	O
-	O
lineage	O
oligodendrocyte	O
precursors	O
and	O
may	O
function	O
to	O
restrict	O
precursor	O
migration	O
and	O
promote	O
oligodendrocyte	O
differentiation	O
and	O
myelination	O
.	O

In	O
the	O
adult	O
mammalian	O
brain	O
,	O
oligodendrocyte	O
progenitors	O
can	O
differentiate	O
into	O
mature	O
oligodendrocytes	O
during	O
remyelination	O
.	O

Mechanisms	O
that	O
regulate	O
migration	O
and	O
differentiation	O
of	O
progenitors	O
are	O
of	O
great	O
importance	O
in	O
understanding	O
normal	O
development	O
and	O
demyelinating	O
/	O
remyelinating	O
conditions	O
.	O

In	O
a	O
microarray	O
analysis	O
comparing	O
adult	O
and	O
neonatal	O
O4	O
-	O
positive	O
(	O
+	O
)	O
cells	O
,	O
we	O
found	O
that	O
the	O
tetraspanin	O
KAI1	B
/	O
CD82	B
is	O
far	O
more	O
highly	O
expressed	O
in	O
adult	O
O4	O
(	O
+	O
)	O
cells	O
than	O
in	O
neonatal	O
O4	O
(	O
+	O
)	O
cells	O
(	O
Lin	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

CD82	B
is	O
a	O
metastasis	O
suppressor	O
,	O
and	O
its	O
expression	O
is	O
often	O
downregulated	O
or	O
lost	O
in	O
the	O
advanced	O
stages	O
of	O
metastatic	O
cancer	O
.	O

We	O
hypothesized	O
that	O
CD82	B
could	O
be	O
a	O
factor	O
that	O
restricts	O
migration	O
and	O
promotes	O
differentiation	O
of	O
maturing	O
oligodendrocytes	O
.	O

Western	O
blot	O
analysis	O
of	O
isolated	O
adult	O
O4	O
(	O
+	O
)	O
cells	O
confirms	O
the	O
elevated	O
levels	O
of	O
CD82	B
,	O
which	O
continues	O
to	O
be	O
expressed	O
as	O
these	O
become	O
O1	O
(	O
+	O
)	O
in	O
vitro	O
.	O

In	O
the	O
adult	O
rat	O
white	O
matter	O
,	O
CD82	B
is	O
coexpressed	O
with	O
CC1	B
and	O
olig2	B
but	O
not	O
with	O
NG2	B
or	O
GFAP	B
.	O

Immature	O
cells	O
of	O
the	O
neonatal	O
forebrain	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
infected	O
in	O
vivo	O
with	O
a	O
retrovirus	O
that	O
constitutively	O
expresses	O
CD82	B
do	O
not	O
remain	O
immature	O
but	O
differentiate	O
into	O
either	O
CC1	B
(	O
+	O
)	O
and	O
MBP	B
(	O
+	O
)	O
myelinating	O
oligodendrocytes	O
in	O
the	O
white	O
matter	O
or	O
zebrinII	B
(	O
+	O
)	O
astrocytes	O
in	O
the	O
cortex	O
.	O

Their	O
migration	O
from	O
the	O
SVZ	O
is	O
severely	O
restricted	O
.	O

In	O
contrast	O
,	O
downregulation	O
of	O
CD82	B
in	O
SVZ	O
cells	O
in	O
vivo	O
,	O
using	O
retroviral	O
-	O
expressed	O
short	B
hairpin	I
RNAs	I
(	O
shRNAs	B
)	O
,	O
prevents	O
their	O
differentiation	O
into	O
myelinating	O
oligodendrocytes	O
.	O

shRNA	B
-	O
expressing	O
cells	O
remained	O
PDGF	B
receptor	I
alpha	I
positive	O
,	O
olig2	B
(	O
+	O
)	O
,	O
or	O
NG2	B
(	O
+	O
)	O
or	O
became	O
CC1	B
(	O
+	O
)	O
nonmyelinating	O
oligodendrocytes	O
or	O
GFAP	B
(	O
+	O
)	O
astrocytes	O
.	O

CD82	B
thus	O
appears	O
to	O
be	O
a	O
critical	O
molecule	O
in	O
the	O
regulation	O
of	O
oligodendrocyte	O
progenitor	O
migration	O
and	O
myelination	O
.	O

Zebrafish	O
chordin	B
-	I
like	I
and	O
chordin	B
are	O
functionally	O
redundant	O
in	O
regulating	O
patterning	O
of	O
the	O
dorsoventral	O
axis	O
.	O

Chordin	B
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
cysteine	O
-	O
rich	O
domain	O
-	O
containing	O
proteins	O
that	O
bind	O
and	O
modulate	O
signaling	O
of	O
various	O
TGFbeta	B
-	I
like	I
ligands	I
.	O

Chordin	B
-	I
like	I
1	I
and	I
2	I
(	O
CHL1	B
and	I
2	I
)	O
are	O
two	O
members	O
of	O
this	O
group	O
that	O
have	O
been	O
described	O
in	O
human	O
,	O
mouse	O
,	O
and	O
chick	O
.	O

However	O
,	O
in	O
vivo	O
roles	O
for	O
CHL1	B
and	I
2	I
in	O
early	O
development	O
are	O
unknown	O
due	O
to	O
lack	O
of	O
loss	O
-	O
of	O
-	O
function	O
analysis	O
.	O

Here	O
we	O
identify	O
and	O
characterize	O
zebrafish	O
,	O
Danio	O
rerio	O
,	O
CHL	B
(	O
Chl	B
)	O
.	O

The	O
chl	B
gene	I
is	O
on	O
a	O
region	O
of	O
chromosome	O
21	O
syntenic	O
with	O
the	O
area	O
of	O
murine	O
chromosome	O
7	O
bearing	O
the	O
CHL2	B
gene	I
.	O

Inability	O
to	O
identify	O
a	O
separate	O
zebrafish	O
gene	O
corresponding	O
to	O
the	O
mammalian	B
CHL1	I
gene	I
suggests	O
that	O
Chl	B
may	O
serve	O
roles	O
in	O
zebrafish	O
distributed	O
between	O
CHL1	B
and	O
CHL2	B
in	O
other	O
species	O
.	O

Chl	B
is	O
a	O
maternal	O
factor	O
that	O
is	O
also	O
zygotically	O
expressed	O
later	O
in	O
development	O
and	O
has	O
spatiotemporal	O
expression	O
patterns	O
that	O
differ	O
from	O
but	O
overlap	O
those	O
of	O
zebrafish	B
chordin	I
(	O
Chd	B
)	O
,	O
suggesting	O
differences	O
but	O
also	O
possible	O
overlap	O
in	O
developmental	O
roles	O
of	O
the	O
two	O
proteins	O
.	O

Chl	B
,	O
like	O
Chd	B
,	O
dorsalizes	O
embryos	O
upon	O
overexpression	O
and	O
is	O
cleaved	O
by	O
BMP1	B
,	O
which	O
antagonizes	O
this	O
activity	O
.	O

Loss	O
-	O
of	O
-	O
function	O
experiments	O
demonstrate	O
that	O
Chl	B
serves	O
as	O
a	O
BMP	B
antagonist	O
with	O
functions	O
that	O
overlap	O
and	O
are	O
redundant	O
with	O
those	O
of	O
Chd	B
in	O
forming	O
the	O
dorsoventral	O
axis	O
.	O

Antitumor	O
and	O
antiangiogenic	O
effect	O
of	O
the	O
dual	O
EGFR	B
and	O
HER	B
-	I
2	I
tyrosine	I
kinase	I
inhibitor	O
lapatinib	O
in	O
a	O
lung	O
cancer	O
model	O
.	O

BACKGROUND	O
:	O
There	O
is	O
strong	O
evidence	O
demonstrating	O
that	O
activation	O
of	O
epidermal	B
growth	I
factor	I
receptors	I
(	O
EGFRs	B
)	O
leads	O
to	O
tumor	O
growth	O
,	O
progression	O
,	O
invasion	O
and	O
metastasis	O
.	O

Erlotinib	O
and	O
gefitinib	O
,	O
two	O
EGFR	B
-	O
targeted	O
agents	O
,	O
have	O
been	O
shown	O
to	O
be	O
relevant	O
drugs	O
for	O
lung	O
cancer	O
treatment	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
lapatinib	O
,	O
a	O
dual	O
tyrosine	B
kinase	I
inhibitor	O
of	O
EGFR	B
and	O
HER	B
-	I
2	I
receptors	I
,	O
is	O
clinically	O
effective	O
against	O
HER	B
-	I
2	I
-	O
overexpressing	O
metastatic	O
breast	O
cancer	O
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
the	O
activity	O
of	O
lapatinib	O
against	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

METHODS	O
:	O
We	O
selected	O
the	O
lung	O
cancer	O
cell	O
line	O
A549	O
,	O
which	O
harbors	O
genomic	O
amplification	O
of	O
EGFR	B
and	O
HER	B
-	I
2	I
.	O

Proliferation	O
,	O
cell	O
cycle	O
analysis	O
,	O
clonogenic	O
assays	O
,	O
and	O
signaling	O
cascade	O
analyses	O
(	O
by	O
western	O
blot	O
)	O
were	O
performed	O
in	O
vitro	O
.	O

In	O
vivo	O
experiments	O
with	O
A549	O
cells	O
xenotransplanted	O
into	O
nude	O
mice	O
treated	O
with	O
lapatinib	O
(	O
with	O
or	O
without	O
radiotherapy	O
)	O
were	O
also	O
carried	O
out	O
.	O

RESULTS	O
:	O
Lapatinib	O
dramatically	O
reduced	O
cell	O
proliferation	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
DNA	O
synthesis	O
(	O
P	O
<	O
0	O
.	O
006	O
)	O
,	O
and	O
colony	O
formation	O
capacity	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
in	O
A549	O
cells	O
in	O
vitro	O
.	O

Furthermore	O
,	O
lapatinib	O
induced	O
G1	O
cell	O
cycle	O
arrest	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
apoptotic	O
cell	O
death	O
(	O
P	O
<	O
0	O
.	O
0006	O
)	O
and	O
reduced	O
cyclin	B
A	I
and	I
B1	I
levels	O
,	O
which	O
are	O
regulators	O
of	O
S	O
and	O
G2	O
/	O
M	O
cell	O
cycle	O
stages	O
,	O
respectively	O
.	O

Stimulation	O
of	O
apoptosis	O
in	O
lapatinib	O
-	O
treated	O
A549	O
cells	O
was	O
correlated	O
with	O
increased	O
cleaved	O
PARP	B
,	O
active	O
caspase	B
-	I
3	I
,	O
and	O
proapoptotic	O
Bak	B
-	I
1	I
levels	O
,	O
and	O
reduction	O
in	O
the	O
antiapoptotic	O
IAP	B
-	I
2	I
and	O
Bcl	B
-	I
xL	I
protein	I
levels	O
.	O

We	O
also	O
demonstrate	O
that	O
lapatinib	O
altered	O
EGFR	B
/	O
HER	B
-	I
2	I
signaling	O
pathways	O
reducing	O
p	B
-	I
EGFR	I
,	O
p	B
-	I
HER	I
-	I
2	I
,	O
p	B
-	I
ERK1	I
/	I
2	I
,	O
p	B
-	I
AKT	I
<	O
/	O
ma	O
AKT	B
,	O
c	B
-	I
Myc	I
and	O
PCNA	B
levels	O
.	O

In	O
vivo	O
experiments	O
revealed	O
that	O
A549	O
tumor	O
-	O
bearing	O
mice	O
treated	O
with	O
lapatinib	O
had	O
significantly	O
less	O
active	O
tumors	O
(	O
as	O
assessed	O
by	O
PET	O
analysis	O
)	O
(	O
P	O
<	O
0	O
.	O
04	O
)	O
and	O
smaller	O
in	O
size	O
than	O
controls	O
.	O

In	O
addition	O
,	O
tumors	O
from	O
lapatinib	O
-	O
treated	O
mice	O
showed	O
a	O
dramatic	O
reduction	O
in	O
angiogenesis	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSION	O
:	O
Overall	O
,	O
these	O
data	O
suggest	O
that	O
lapatinib	O
may	O
be	O
a	O
clinically	O
useful	O
agent	O
for	O
the	O
treatment	O
of	O
lung	O
cancer	O
.	O

Arecoline	O
induces	O
HA22T	O
/	O
VGH	O
hepatoma	O
cells	O
to	O
undergo	O
anoikis	O
-	O
involvement	O
of	O
STAT3	B
and	O
RhoA	B
activation	O
.	O

BACKGROUND	O
:	O
Our	O
previous	O
study	O
showed	O
that	O
,	O
in	O
basal	O
cell	O
carcinoma	O
cells	O
,	O
arecoline	O
reduces	O
levels	O
of	O
the	O
tumor	O
cell	O
survival	O
factor	O
interleukin	B
-	I
6	I
(	O
IL	B
-	I
6	I
)	O
,	O
increases	O
levels	O
of	O
tumor	O
suppressor	O
factor	O
p53	B
,	O
and	O
elicits	O
cell	O
cycle	O
arrest	O
,	O
followed	O
by	O
apoptosis	O
.	O

In	O
preliminarily	O
studies	O
,	O
we	O
observed	O
that	O
arecoline	O
induces	O
detachment	O
of	O
the	O
human	O
-	O
derived	O
hepatoma	O
cell	O
line	O
HA22T	O
/	O
VGH	O
from	O
the	O
extracellular	O
matrix	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
explored	O
the	O
fate	O
of	O
the	O
detached	O
HA22T	O
/	O
VGH	O
cells	O
and	O
investigated	O
the	O
underlying	O
mechanism	O
.	O

METHODS	O
:	O
HA22T	O
/	O
VGH	O
cells	O
or	O
primary	O
cultured	O
rat	O
hepatocytes	O
were	O
treated	O
with	O
arecoline	O
,	O
then	O
changes	O
in	O
morphology	O
,	O
viability	O
,	O
apoptosis	O
,	O
and	O
the	O
expression	O
of	O
surface	B
beta1	I
-	I
integrin	I
,	O
apoptosis	O
-	O
related	O
proteins	O
,	O
and	O
IL	B
-	I
6	I
were	O
examined	O
.	O

Furthermore	O
,	O
activation	O
of	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
pathway	O
and	O
the	O
RhoA	B
/	O
Rock	B
signaling	O
pathway	O
,	O
including	O
p190RhoGAP	B
and	O
Src	B
homology	I
-	I
2	I
domain	I
-	I
containing	I
phosphatase	I
SHP2	I
,	O
was	O
examined	O
.	O

RESULTS	O
:	O
A	O
low	O
concentration	O
of	O
arecoline	O
(	O
&	O
lt	O
;	O
or	O
=	O
100	O
microg	O
/	O
ml	O
)	O
caused	O
cytoskeletal	O
changes	O
in	O
HA22T	O
/	O
VGH	O
cells	O
,	O
but	O
not	O
hepatocytes	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
beta1	B
-	I
integrin	I
expression	O
and	O
followed	O
by	O
apoptosis	O
,	O
indicating	O
that	O
HA22T	O
/	O
VGH	O
cells	O
undergo	O
anoikis	O
after	O
arecoline	O
treatment	O
.	O

IL	B
-	I
6	I
expression	O
and	O
phosphorylation	O
of	O
STAT3	B
,	O
which	O
provides	O
protection	O
against	O
anoikis	O
,	O
were	O
inhibited	O
and	O
levels	O
of	O
downstream	O
signaling	O
proteins	O
,	O
including	O
Bcl	B
-	I
XL	I
and	O
Bcl	B
-	I
2	I
,	O
were	O
decreased	O
,	O
while	O
Bax	B
expression	O
,	O
mitochondrial	O
cytochrome	B
c	I
release	O
,	O
and	O
caspase	B
-	I
3	I
activity	O
were	O
increased	O
.	O

In	O
addition	O
,	O
phosphorylation	O
/	O
activation	O
of	O
p190RhoGAP	B
,	O
a	O
RhoA	B
inhibitor	O
,	O
and	O
of	O
its	O
upstream	O
regulator	O
,	O
SHP2	B
,	O
was	O
inhibited	O
by	O
arecoline	O
treatment	O
,	O
while	O
Rho	B
/	O
Rock	B
activation	O
was	O
increased	O
.	O

Addition	O
of	O
the	O
RhoA	B
inhibitor	O
attenuated	O
the	O
effects	O
of	O
arecoline	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrated	O
that	O
arecoline	O
induces	O
anoikis	O
of	O
HA22T	O
/	O
VGH	O
cells	O
involving	O
inhibition	O
of	O
STAT3	B
and	O
increased	O
RhoA	B
/	O
Rock	B
activation	O
and	O
that	O
the	O
STAT3	B
and	O
RhoA	B
/	O
Rock	B
signaling	O
pathways	O
are	O
connected	O
.	O

Blocking	O
of	O
ERK1	B
and	O
ERK2	B
sensitizes	O
human	O
mesothelioma	O
cells	O
to	O
doxorubicin	O
.	O

BACKGROUND	O
:	O
Malignant	O
mesotheliomas	O
(	O
MM	O
)	O
have	O
a	O
poor	O
prognosis	O
,	O
largely	O
because	O
of	O
their	O
chemoresistance	O
to	O
anti	O
-	O
cancer	O
drugs	O
such	O
as	O
doxorubicin	O
(	O
Dox	O
)	O
.	O

Here	O
we	O
show	O
using	O
human	O
MM	O
lines	O
that	O
Dox	O
activates	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERK1	O
and	O
2	O
)	O
,	O
causally	O
linked	O
to	O
increased	O
expression	O
of	O
ABC	B
transporter	I
genes	I
,	O
decreased	O
accumulation	O
of	O
Dox	O
,	O
and	O
enhanced	O
MM	O
growth	O
.	O

Using	O
the	O
MEK1	B
/	I
2	I
inhibitor	O
,	O
U0126	O
and	O
stably	O
transfected	O
sh	B
ERK1	I
and	O
sh	B
ERK2	I
MM	I
cell	O
lines	O
,	O
we	O
show	O
that	O
inhibition	O
of	O
both	O
ERK1	B
and	O
2	O
sensitizes	O
MM	O
cells	O
to	O
Dox	O
.	O

RESULTS	O
:	O
U0126	O
significantly	O
modulated	O
endogenous	O
expression	O
of	O
several	O
important	O
drug	O
resistance	O
(	O
BCL2	B
,	O
ABCB1	B
,	O
ABCC3	B
)	O
,	O
prosurvival	O
(	O
BCL2	B
)	O
,	O
DNA	O
repair	O
(	O
BRCA1	B
,	O
BRCA2	B
)	O
,	O
hormone	O
receptor	O
(	O
AR	B
,	O
ESR2	B
,	O
PPARgamma	B
)	O
and	O
drug	O
metabolism	O
(	O
CYP3A4	B
)	O
genes	O
newly	O
identified	O
in	O
MM	O
cells	O
.	O

In	O
comparison	O
to	O
shControl	O
lines	O
,	O
MM	O
cell	O
lines	O
stably	O
transfected	O
with	O
sh	B
ERK1	I
or	O
sh	B
ERK2	I
exhibited	O
significant	O
increases	O
in	O
intracellular	O
accumulation	O
of	O
Dox	O
and	O
decreases	O
in	O
cell	O
viability	O
.	O

Affymetrix	O
microarray	O
analysis	O
on	O
stable	O
sh	B
ERK1	I
and	O
sh	B
ERK2	I
MM	O
lines	O
showed	O
more	O
than	O
2	O
-	O
fold	O
inhibition	O
(	O
p	O
&	O
lt	O
;	O
=	O
0	O
.	O
05	O
)	O
of	O
expression	O
of	O
ATP	B
binding	I
cassette	I
genes	I
(	O
ABCG1	B
,	O
ABCA5	B
,	O
ABCA2	B
,	O
MDR	B
/	O
TAP	B
,	O
ABCA1	B
,	O
ABCA8	B
,	O
ABCC2	B
)	O
in	O
comparison	O
to	O
shControl	O
lines	O
.	O

Moreover	O
,	O
injection	O
of	O
human	O
MM	O
lines	O
into	O
SCID	O
mice	O
showed	O
that	O
stable	O
sh	O
ERK1	B
or	O
sh	O
ERK2	B
lines	O
had	O
significantly	O
slower	O
tumor	O
growth	O
rates	O
in	O
comparison	O
to	O
shControl	O
lines	O
after	O
Dox	O
treatment	O
.	O

CONCLUSIONS	O
:	O
These	O
studies	O
suggest	O
that	O
blocking	O
ERK1	B
and	I
2	I
,	O
which	O
play	O
critical	O
roles	O
in	O
multi	O
-	O
drug	O
resistance	O
and	O
survival	O
,	O
may	O
be	O
beneficial	O
in	O
combination	O
with	O
chemotherapeutic	O
drugs	O
in	O
the	O
treatment	O
of	O
MMs	O
and	O
other	O
tumors	O
.	O

T	B
-	I
bet	I
-	O
mediated	O
differentiation	O
of	O
the	O
activated	O
CD8	B
+	I
T	O
cell	O
.	O

The	O
T	B
-	I
box	I
transcription	O
factor	O
,	O
T	B
-	I
bet	I
promotes	O
the	O
differentiation	O
of	O
short	O
-	O
lived	O
effector	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
at	O
the	O
expense	O
of	O
central	O
memory	O
cells	O
.	O

How	O
T	B
-	I
bet	I
mediates	O
these	O
effects	O
,	O
and	O
whether	O
they	O
are	O
directly	O
caused	O
by	O
T	B
-	I
bet	I
alone	O
are	O
unknown	O
,	O
because	O
expression	O
of	O
T	B
-	I
bet	I
requires	O
stimulation	O
of	O
the	O
T	O
cell	O
by	O
inflammatory	O
and	O
growth	O
cytokines	O
,	O
which	O
may	O
have	O
T	B
-	I
bet	I
-	O
independent	O
functions	O
involving	O
T	O
-	O
cell	O
differentiation	O
.	O

We	O
developed	O
an	O
in	O
vitro	O
system	O
of	O
ectopic	O
T	B
-	I
bet	I
expression	O
that	O
avoids	O
the	O
effects	O
of	O
inflammatory	O
cytokines	O
to	O
determine	O
which	O
aspects	O
of	O
the	O
T	B
-	I
bet	I
phenotype	O
may	O
be	O
accounted	O
for	O
by	O
T	B
-	I
bet	I
alone	O
.	O

Ectopic	B
T	I
-	I
bet	I
expression	O
by	O
OT	B
-	I
I	I
CD8	I
(	I
+	I
)	I
T	I
cells	I
stimulated	O
by	O
the	O
H2	B
-	I
Kb	I
(	I
SIINFEKL	I
)	I
complex	I
and	O
cultured	O
with	O
2	O
ng	O
/	O
mL	O
IL	B
-	I
2	I
induced	O
a	O
coordinated	O
change	O
in	O
gene	O
expression	O
leading	O
to	O
down	O
-	O
regulation	O
of	O
CD127	B
and	O
SOCS	B
-	I
1	I
and	O
up	O
-	O
regulation	O
of	O
CD122	B
and	O
IL	B
-	I
15	I
<	O
/	O
IL	B
-	I
15	I
receptor	O
α	O
,	O
switching	O
the	O
cellular	O
survival	O
cytokine	O
from	O
IL	B
-	I
7	I
to	O
IL	B
-	I
15	I
.	O

T	B
-	I
bet	I
expression	O
and	O
2	O
ng	O
/	O
mL	O
IL	B
-	I
2	I
also	O
led	O
to	O
a	O
capacity	O
for	O
IFN	B
-	I
γ	I
and	O
Fas	B
ligand	I
expression	O
,	O
confirming	O
a	O
role	O
in	O
eliciting	O
these	O
effector	O
functions	O
.	O

Finally	O
,	O
ectopic	B
T	I
-	I
bet	I
promoted	O
the	O
expression	O
of	O
B	B
lymphocyte	I
-	I
induced	I
maturation	I
protein	I
1	I
by	O
OT	B
-	I
I	I
cells	O
in	O
the	O
presence	O
of	O
20	O
ng	O
/	O
mL	O
IL	B
-	I
2	I
,	O
providing	O
a	O
mechanism	O
for	O
the	O
role	O
of	O
T	B
-	I
bet	I
in	O
driving	O
terminal	O
differentiation	O
in	O
concert	O
with	O
a	O
high	O
level	O
of	O
IL	B
-	I
2	I
receptor	I
signalling	O
.	O

TGF	B
-	I
β	I
signaling	O
is	O
required	O
for	O
maintenance	O
of	O
retinal	O
ganglion	O
cell	O
differentiation	O
and	O
survival	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
role	O
of	O
TGF	B
-	I
β1	I
in	O
the	O
maintenance	O
of	O
retinal	O
ganglion	O
cell	O
line	O
(	O
RGC	O
-	O
5	O
)	O
differentiation	O
and	O
integrity	O
.	O

METHODS	O
:	O
RGC	O
-	O
5	O
cells	O
were	O
differentiated	O
in	O
media	O
conditioned	O
by	O
human	O
non	O
-	O
pigmented	O
ciliary	O
epithelial	O
cells	O
(	O
HNPE	O
)	O
for	O
4	O
days	O
before	O
treatment	O
with	O
TGF	B
-	I
β1	I
for	O
24	O
h	O
.	O
Cells	O
were	O
examined	O
for	O
morphological	O
changes	O
and	O
harvested	O
for	O
western	O
blot	O
and	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

For	O
study	O
of	O
apoptosis	O
,	O
differentiated	O
RGC	O
-	O
5	O
cells	O
were	O
grown	O
in	O
serum	O
-	O
free	O
medium	O
for	O
24	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
TGF	B
-	I
β1	I
and	O
collected	O
for	O
Annexin	B
V	I
/	O
Propidium	B
iodide	I
FACs	O
analysis	O
.	O

The	O
role	O
of	O
MAPK	B
pathways	O
in	O
TGF	B
-	I
β1	I
-	O
dependent	O
signaling	O
was	O
determined	O
by	O
treatment	O
with	O
specific	O
inhibitors	O
of	O
ERK	B
,	O
JNK	B
and	O
p38	B
.	O

RESULTS	O
:	O
Differentiation	O
of	O
RGC	O
-	O
5	O
cells	O
in	O
HNPE	O
-	O
conditioned	O
media	O
(	O
CM	O
)	O
increased	O
the	O
neural	O
cell	O
markers	O
,	O
Brn	B
-	I
3c	I
,	O
NF	B
-	I
160	I
,	O
Thy1	B
.	I
2	I
,	O
Tau	B
and	O
PGP9	B
.	I
5	I
.	O

Treatment	O
with	O
TGF	B
-	I
β1	I
significantly	O
increased	O
the	O
length	O
of	O
neurites	O
extended	O
by	O
differentiated	O
RGC	O
-	O
5s	O
,	O
concomitant	O
with	O
increased	O
expression	O
of	O
NF	B
-	I
160	I
and	O
PGP9	B
.	I
5	I
,	O
but	O
not	O
Brn	B
-	I
3c	I
,	O
Thy1	B
.	I
2	I
or	O
Tau	B
.	O

TGF	B
-	I
β1	I
also	O
decreased	O
RGC	O
-	O
5	O
cell	O
apoptosis	O
in	O
serum	O
-	O
free	O
medium	O
.	O

p38	B
phosphorylation	O
,	O
but	O
not	O
smad2	B
/	I
3	I
,	O
JNK	B
or	O
ERK	B
phosphorylation	O
,	O
was	O
increased	O
in	O
TGF	B
-	I
β1	I
treated	O
cells	O
.	O

Specific	O
inhibition	O
of	O
p38	B
signaling	O
reversed	O
TGF	B
-	I
β1	I
induced	O
neurite	O
growth	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
the	O
induction	O
of	O
RGC	O
-	O
5	O
cell	O
differentiation	O
by	O
HNPE	O
-	O
derived	O
CM	O
and	O
illustrate	O
a	O
role	O
for	O
TGF	B
-	I
β1	I
in	O
maintaining	O
RGC	O
-	O
5	O
cell	O
survival	O
and	O
promoting	O
neurite	O
outgrowth	O
through	O
p38	B
MAPK	O
.	O

Aberrant	O
expression	O
of	O
genes	O
necessary	O
for	O
neuronal	O
development	O
and	O
Notch	B
signaling	O
in	O
an	O
epileptic	O
mind	B
bomb	I
zebrafish	O
.	O

Mutation	O
within	O
an	O
ubiquitin	B
E3	I
ligase	I
gene	I
can	O
lead	O
to	O
a	O
failure	O
in	O
Notch	B
signaling	O
,	O
excessive	O
neurons	O
,	O
and	O
depletion	O
of	O
neural	O
progenitor	O
cells	O
in	O
mind	O
bomb	O
mutants	O
.	O

Using	O
mib	B
(	O
hi904	B
)	O
zebrafish	O
,	O
we	O
reported	O
seizures	O
and	O
a	O
down	O
-	O
regulation	O
of	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
signaling	O
pathway	O
genes	O
.	O

A	O
transcriptome	O
analysis	O
also	O
identified	O
differential	O
expression	O
pattern	O
of	O
genes	O
related	O
to	O
Notch	B
signaling	O
and	O
neurodevelopment	O
.	O

Here	O
,	O
we	O
selected	O
nine	O
of	O
these	O
genes	O
(	O
her4	B
.	I
2	I
,	O
hes5	B
,	O
bhlhb5	B
,	O
hoxa5a	B
,	O
hoxb5b	B
,	O
dmbx1a	B
,	O
dbx1a	B
,	O
nxph1	B
,	O
and	O
plxnd1	B
)	O
and	O
performed	O
a	O
more	O
thorough	O
analysis	O
of	O
expression	O
using	O
conventional	O
polymerase	O
chain	O
reaction	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
in	O
situ	O
hybridization	O
.	O

Transgenic	O
reporter	O
fish	O
(	O
Gfap	B
:	O
GFP	B
and	O
Dlx5a	B
-	I
6a	I
:	O
GFP	B
)	O
were	O
used	O
to	O
assess	O
early	O
brain	O
morphology	O
in	O
vivo	O
.	O

Down	O
-	O
regulation	O
of	O
many	O
of	O
these	O
genes	O
was	O
prominent	O
throughout	O
key	O
structures	O
of	O
the	O
developing	O
mib	B
(	O
hi904	O
)	O
zebrafish	O
brain	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
the	O
pallium	O
,	O
ventral	O
thalamus	O
,	O
and	O
optic	O
tectum	O
.	O

Brain	O
expression	O
of	O
Dlx5a	B
-	I
6a	I
and	O
Gfap	B
was	O
also	O
reduced	O
.	O

In	O
conclusion	O
,	O
these	O
expression	O
studies	O
indicate	O
a	O
general	O
down	O
-	O
regulation	O
of	O
Notch	B
signaling	O
genes	O
necessary	O
for	O
proper	O
brain	O
development	O
and	O
suggest	O
that	O
these	O
mutant	O
fish	O
could	O
provide	O
valuable	O
insights	O
into	O
neurological	O
conditions	O
,	O
such	O
as	O
Angelman	O
syndrome	O
,	O
associated	O
with	O
ubiquitin	B
E3	I
ligase	I
mutation	O
.	O

Atlas	O
of	O
Wnt	B
and	O
R	B
-	I
spondin	I
gene	O
expression	O
in	O
the	O
developing	O
male	O
mouse	O
lower	O
urogenital	O
tract	O
.	O

Prostate	O
development	O
is	O
influenced	O
by	O
β	B
-	I
catenin	I
signaling	O
,	O
but	O
it	O
is	O
unclear	O
which	O
β	B
-	I
catenin	I
activators	O
are	O
involved	O
,	O
where	O
they	O
are	O
synthesized	O
,	O
and	O
whether	O
their	O
mRNA	O
abundance	O
is	O
influenced	O
by	O
androgens	O
.	O

We	O
identified	O
WNT	B
/	O
β	B
-	I
catenin	I
-	O
responsive	O
β	B
-	I
galactosidase	I
activity	O
in	O
the	O
lower	O
urogenital	O
tract	O
(	O
LUT	O
)	O
of	O
transgenic	O
reporter	O
mice	O
,	O
but	O
β	B
-	I
galactosidase	I
activity	O
differed	O
among	O
the	O
four	O
mouse	O
strains	O
we	O
examined	O
.	O

We	O
used	O
in	O
situ	O
hybridization	O
to	O
compare	O
patterns	O
of	O
Wnts	B
,	O
r	B
-	I
spondins	I
(	O
Rspo	B
<	O
/	O
m	O
Rspos	B
,	O
co	O
-	O
activators	O
of	O
β	B
-	I
catenin	I
signaling	O
)	O
,	O
β	B
-	I
catenin	I
-	O
responsive	O
mRNAs	O
,	O
and	O
an	O
androgen	B
receptor	I
-	O
responsive	O
mRNA	O
in	O
wild	O
type	O
fetal	O
male	O
,	O
fetal	O
female	O
,	O
and	O
neonatal	O
male	O
LUT	O
.	O

Most	O
Wnt	B
and	O
Rspo	B
mRNAs	I
were	O
present	O
in	O
LUT	O
during	O
prostate	O
development	O
.	O

Sexually	O
dimorphic	O
expression	O
patterns	O
were	O
observed	O
for	O
WNT	B
/	O
β	B
-	I
catenin	I
-	O
responsive	O
genes	O
,	O
and	O
for	O
Wnt2b	B
,	O
Wnt4	B
,	O
Wnt7a	B
,	O
Wnt9b	B
,	O
Wnt10b	B
,	O
Wnt11	B
,	O
Wnt16	B
,	O
and	O
Rspo3	B
mRNAs	I
.	O

These	O
results	O
reveal	O
sexual	O
differences	O
in	O
WNT	B
/	O
β	B
-	I
catenin	I
signaling	O
in	O
fetal	O
LUT	O
,	O
supporting	O
the	O
idea	O
that	O
this	O
pathway	O
may	O
be	O
directly	O
or	O
indirectly	O
responsive	O
to	O
androgens	O
during	O
prostate	O
ductal	O
development	O
.	O

Recombinant	B
Brugia	I
malayi	I
pepsin	I
inhibitor	I
(	O
r	B
Bm33	I
)	O
induced	O
monocyte	O
function	O
and	O
absence	O
of	O
apoptotic	O
cell	O
death	O
:	O
an	O
in	O
vitro	O
study	O
.	O

The	O
effect	O
of	O
recombinant	O
Brugia	O
malayi	O
pepsin	B
inhibitor	O
(	O
r	B
Bm33	I
)	O
on	O
human	O
monocytes	O
/	O
macrophages	O
has	O
been	O
examined	O
using	O
THP	O
-	O
1	O
cells	O
.	O

THP	O
-	O
1	O
cells	O
stimulated	O
with	O
r	B
Bm33	I
showed	O
enhanced	O
levels	O
of	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
IL	B
-	I
1beta	I
,	O
TNF	B
-	I
alpha	I
,	O
IL	B
-	I
6	I
)	O
and	O
diminished	O
levels	O
of	O
IL	B
-	I
12	I
,	O
iNOS	B
and	O
anti	O
-	O
inflammatory	O
cytokine	O
(	O
IL	B
-	I
10	I
)	O
expression	O
suggesting	O
the	O
predominant	O
features	O
of	O
Th1	O
response	O
.	O

Phorbol	O
-	O
12	O
-	O
myristate	O
-	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
treated	O
THP	O
-	O
1	O
cells	O
stimulated	O
with	O
r	B
Bm33	I
and	O
subsequent	O
incubation	O
with	O
GFP	B
expressing	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
for	O
2	O
h	O
enhanced	O
the	O
uptake	O
of	O
E	O
.	O
coli	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
levels	O
measured	O
in	O
the	O
supernatants	O
of	O
these	O
cultures	O
did	O
not	O
show	O
significant	O
changes	O
.	O

Apoptotic	O
studies	O
with	O
Peripheral	O
Blood	O
Mononuclear	O
Cells	O
(	O
PBMCs	O
)	O
from	O
normal	O
individuals	O
stimulated	O
with	O
r	B
Bm33	I
did	O
not	O
induce	O
apoptosis	O
of	O
monocytes	O
or	O
lymphocytes	O
.	O

These	O
observations	O
suggest	O
that	O
r	B
Bm33	I
stimulates	O
macrophages	O
to	O
induce	O
Th1	O
response	O
and	O
does	O
not	O
promote	O
apoptosis	O
.	O

Knockdown	O
of	O
cathepsin	B
B	I
and	O
uPAR	B
inhibits	O
CD151	B
and	O
α3β1	B
integrin	I
-	O
mediated	O
cell	O
adhesion	O
and	O
invasion	O
in	O
glioma	O
.	O

Glioma	O
is	O
a	O
highly	O
complex	O
brain	O
tumor	O
characterized	O
by	O
the	O
dysregulation	O
of	O
proteins	O
and	O
genes	O
that	O
leads	O
to	O
tumor	O
metastasis	O
.	O

Cathepsin	B
B	I
and	O
uPAR	B
are	O
overexpressed	O
in	O
gliomas	O
and	O
they	O
are	O
postulated	O
to	O
play	O
central	O
roles	O
in	O
glioma	O
metastasis	O
.	O

In	O
this	O
study	O
,	O
efficient	O
downregulation	O
of	O
cathepsin	B
B	I
and	O
uPAR	B
by	O
siRNA	O
treatments	O
significantly	O
reduced	O
glioma	O
cell	O
adhesion	O
to	O
laminin	B
as	O
compared	O
to	O
vitronectin	B
,	O
fibronectin	B
,	O
or	O
collagen	B
I	I
in	O
U251	O
and	O
4910	O
glioma	O
cell	O
lines	O
.	O

Brain	O
glioma	O
tissue	O
array	O
analysis	O
showed	O
high	O
expression	O
of	O
CD151	B
in	O
clinical	O
samples	O
when	O
compared	O
with	O
normal	O
brain	O
tissue	O
.	O

Cathepsin	B
B	I
and	O
uPAR	B
siRNA	O
treatment	O
led	O
to	O
the	O
downregulation	O
of	O
CD151	B
and	O
laminin	B
laminin	I
-	I
binding	I
integri	I
integrins	I
α3	I
and	O
β1	B
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
downregulation	O
of	O
cathepsin	B
B	I
and	O
uPAR	B
decreased	O
the	O
interaction	O
of	O
CD151	B
with	O
uPAR	B
cathepsin	B
B	I
,	O
and	O
α3β1	B
integrin	I
.	O

Studies	O
on	O
the	O
downstream	O
signaling	O
cascade	O
of	O
uPAR	B
/	O
CD151	B
/	O
α3β1	B
integrin	I
have	O
shown	O
that	O
phosphorylation	O
of	O
FAK	B
,	O
SRC	B
,	O
paxillin	B
,	O
and	O
expression	O
of	O
adaptor	O
cytoskeletal	O
proteins	O
talin	B
and	O
vinculin	B
were	O
reduced	O
with	O
knockdown	O
of	O
cathepsin	B
B	I
,	O
uPAR	B
,	O
and	O
CD151	B
.	O

Treatment	O
with	O
the	O
bicistronic	O
construct	O
reduced	O
interactions	O
between	O
uPAR	B
and	O
CD151	B
as	O
well	O
as	O
lowering	O
α3β1	B
integrin	I
,	O
talin	B
,	O
and	O
vinculin	B
expression	O
levels	O
in	O
pre	O
-	O
established	O
glioma	O
tumors	O
of	O
nude	O
mice	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
downregulation	O
of	O
cathepsin	B
B	I
and	O
uPAR	B
alone	O
and	O
in	O
combination	O
inhibit	O
glioma	O
cell	O
adhesion	O
by	O
downregulating	O
CD151	B
and	O
its	O
associated	O
signaling	O
molecules	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
show	O
that	O
targeting	O
the	O
uPAR	B
-	O
cathepsin	B
B	I
system	O
has	O
possible	O
therapeutic	O
potential	O
.	O

Epididymal	B
protein	I
Rnase10	I
is	O
required	O
for	O
post	O
-	O
testicular	O
sperm	O
maturation	O
and	O
male	O
fertility	O
.	O

Eutherian	O
spermatozoa	O
are	O
dependent	O
on	O
the	O
environment	O
of	O
the	O
proximal	O
epididymis	O
to	O
complete	O
their	O
maturation	O
;	O
however	O
,	O
no	O
specific	O
epididymal	O
factors	O
that	O
mediate	O
this	O
process	O
have	O
so	O
far	O
been	O
identified	O
.	O

Here	O
,	O
we	O
show	O
that	O
targeted	O
disruption	O
of	O
the	O
novel	O
gene	O
Rnase10	B
encoding	O
a	O
secreted	O
proximal	O
epididymal	O
protein	O
in	O
the	O
mouse	O
results	O
in	O
a	O
binding	O
defect	O
in	O
spermatozoa	O
and	O
their	O
inability	O
to	O
pass	O
through	O
the	O
uterotubal	O
junction	O
in	O
the	O
female	O
.	O

The	O
failure	O
to	O
gain	O
the	O
site	O
of	O
fertilization	O
in	O
the	O
knockout	O
spermatozoa	O
is	O
associated	O
with	O
a	O
gradual	O
loss	O
of	O
ADAM3	B
and	O
ADAM6	B
proteins	I
during	O
epididymal	O
transit	O
.	O

In	O
the	O
distal	O
epididymis	O
,	O
these	O
spermatozoa	O
appear	O
to	O
lack	O
calcium	O
-	O
dependent	O
associations	O
with	O
the	O
immobilizing	O
glutinous	O
extracellular	O
material	O
and	O
are	O
released	O
as	O
single	O
,	O
vigorously	O
motile	O
cells	O
that	O
display	O
no	O
tendency	O
for	O
head	O
-	O
to	O
-	O
head	O
agglutination	O
and	O
lack	O
affinity	O
to	O
the	O
oviductal	O
epithelium	O
.	O

In	O
sperm	O
-	O
egg	O
binding	O
assay	O
,	O
they	O
are	O
unable	O
to	O
establish	O
a	O
tenacious	O
association	O
with	O
the	O
zona	O
pellucida	O
,	O
yet	O
they	O
are	O
capable	O
of	O
fertilization	O
.	O

Furthermore	O
,	O
these	O
sperm	O
show	O
accelerated	O
capacitation	O
resulting	O
in	O
an	O
overall	O
in	O
vitro	O
fertilizing	O
ability	O
superior	O
to	O
that	O
of	O
wild	O
-	O
type	O
sperm	O
.	O

We	O
conclude	O
that	O
the	O
physiological	O
role	O
of	O
sperm	O
adhesiveness	O
is	O
in	O
the	O
mechanism	O
of	O
restricted	O
sperm	O
entry	O
into	O
the	O
oviduct	O
rather	O
than	O
in	O
sperm	O
-	O
egg	O
interaction	O
.	O

Gene	O
profile	O
of	O
chemokines	O
on	O
hepatic	O
stellate	O
cells	O
of	O
schistosome	O
-	O
infected	O
mice	O
and	O
antifibrotic	O
roles	O
of	O
CXCL9	B
/	I
10	I
on	O
liver	O
non	O
-	O
parenchymal	O
cells	O
.	O

Hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
liver	O
fibrosis	O
caused	O
by	O
schistosomiasis	O
.	O

Chemokines	O
were	O
widely	O
expressed	O
and	O
involved	O
in	O
cellular	O
activation	O
,	O
proliferation	O
and	O
migration	O
in	O
inflammatory	O
and	O
infectious	O
diseases	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
expressions	O
of	O
chemokines	O
on	O
HSCs	O
in	O
the	O
schistosoma	O
infection	O
.	O

In	O
addition	O
,	O
the	O
roles	O
of	O
chemokines	O
in	O
pathogenesis	O
of	O
liver	O
fibrosis	O
are	O
not	O
totally	O
clear	O
.	O

In	O
our	O
study	O
,	O
we	O
used	O
microarray	O
to	O
analyze	O
the	O
temporal	O
gene	O
expressions	O
of	O
primary	O
HSCs	O
isolated	O
from	O
mice	O
with	O
both	O
acute	O
and	O
chronic	O
schistosomiasis	O
.	O

Our	O
microarray	O
data	O
showed	O
that	O
most	O
of	O
the	O
chemokines	O
expressed	O
on	O
HSCs	O
were	O
upregulated	O
at	O
3	O
weeks	O
post	O
-	O
infection	O
(	O
p	O
.	O
i	O
)	O
when	O
the	O
egg	O
granulomatous	O
response	O
was	O
not	O
obviously	O
evoked	O
in	O
the	O
liver	O
.	O

However	O
,	O
some	O
of	O
them	O
like	O
CXCL9	B
,	O
CXCL10	B
and	O
CXCL11	B
were	O
subsequently	O
decreased	O
at	O
6	O
weeks	O
p	O
.	O
i	O
when	O
the	O
granulomatous	O
response	O
reached	O
the	O
peak	O
.	O

In	O
the	O
chronic	O
stage	O
,	O
most	O
of	O
the	O
differentially	O
expressed	O
chemokines	O
maintained	O
persistent	O
high	O
-	O
abundances	O
.	O

Furthermore	O
,	O
several	O
chemokines	O
including	O
CCR2	B
,	O
CCR5	B
,	O
CCR7	B
,	O
CXCR3	B
,	O
CXCR4	B
,	O
CCL2	B
,	O
CCL5	B
,	O
CCL21	B
,	O
CXCL9	B
and	O
CXCL10	B
were	O
expressed	O
by	O
HCSs	O
and	O
the	O
abundances	O
of	O
them	O
were	O
changed	O
following	O
the	O
praziquantel	O
treatment	O
in	O
the	O
chronic	O
stage	O
,	O
indicating	O
that	O
chemokines	O
were	O
possibly	O
necessary	O
for	O
the	O
persistence	O
of	O
the	O
chronic	O
stage	O
.	O

In	O
vitro	O
experiments	O
,	O
hepatic	O
non	O
-	O
parenchymal	O
cells	O
,	O
primary	O
HSCs	O
and	O
human	O
HSCs	O
line	O
LX	O
-	O
2	O
were	O
stimulated	O
by	O
chemokines	O
.	O

The	O
results	O
showed	O
that	O
CXCL9	B
and	O
CXCL10	B
,	O
but	O
not	O
CXCL11	B
or	O
CXCL4	B
,	O
significantly	O
inhibited	O
the	O
gene	O
expressions	O
of	O
Col1α1	B
,	O
Col3α1	B
and	O
α	B
-	I
SMA	I
,	O
indicating	O
the	O
potential	O
anti	O
-	O
fibrosis	O
effect	O
of	O
CXCL9	B
and	O
CXCL10	B
in	O
schistosomiasis	O
.	O

More	O
interestingly	O
,	O
soluble	O
egg	O
antigen	O
(	O
SEA	O
)	O
of	O
Schistosoma	O
japonicum	O
was	O
able	O
to	O
inhibit	O
transcriptional	O
expressions	O
of	O
some	O
chemokines	B
by	O
LX	O
-	O
2	O
cells	O
,	O
suggesting	O
that	O
SEA	O
was	O
capable	O
of	O
regulating	O
the	O
expression	O
pattern	O
of	O
chemokine	B
family	O
and	O
modulating	O
the	O
hepatic	O
immune	O
microenvironment	O
in	O
schistosomiasis	O
.	O

Altered	O
AKT1	B
and	O
MAPK1	B
gene	I
expression	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
correlation	O
with	O
T	B
-	I
helper	I
-	I
transcription	I
factors	I
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O

Kinases	O
have	O
been	O
implicated	O
in	O
the	O
immunopathological	O
mechanisms	O
of	O
Systemic	O
Lupus	O
Erythematosus	O
(	O
SLE	O
)	O
.	O

v	B
-	I
akt	I
murine	I
-	I
thymoma	I
viral	I
-	I
oncogene	I
-	I
homolog	I
1	I
(	O
AKT1	B
)	O
and	O
mitogen	B
-	I
activated	I
-	I
protein	I
-	I
kinase	I
1	I
(	O
MAPK1	B
)	O
gene	O
expressions	O
in	O
peripheral	O
mononuclear	O
cells	O
from	O
thirteen	O
SLE	O
patients	O
with	O
inactive	O
or	O
mild	O
disease	O
were	O
evaluated	O
using	O
quantitative	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
-	O
chain	O
-	O
reaction	O
and	O
analyzed	O
whether	O
there	O
was	O
any	O
correlation	O
with	O
T	O
-	O
helper	O
(	O
Th	O
)	O
transcription	O
factors	O
(	O
TF	O
)	O
gene	O
expression	O
,	O
cytokines	B
,	O
and	O
S100A8	B
/	O
S100A9	B
-	O
(	O
Calprotectin	B
)	O
.	O

Age	O
-	O
and	O
gender	O
-	O
matched	O
thirteen	O
healthy	O
controls	O
were	O
examined	O
.	O

AKT1	B
and	O
MAPK1	B
expressions	O
were	O
upregulated	O
in	O
SLE	O
patients	O
and	O
correlated	O
with	O
Th17	O
-	O
(	O
Retinoic	O
acid	O
-	O
related	O
orphan	O
receptor	O
(	O
ROR	O
)	O
-	O
C	O
)	O
,	O
T	O
-	O
regulatory	O
-	O
(	O
Treg	O
)	O
-	O
(	O
Transforming	B
Growth	I
Factor	I
Beta	I
(	I
TGFB	I
)	I
-	I
2	I
)	O
,	O
and	O
Th2	O
-	O
(	O
interleukin	B
(	I
IL	I
)	I
-	I
5	I
)	O
-	O
related	O
genes	O
.	O

MAPK1	B
expression	O
correlated	O
with	O
Th1	O
-	O
(	O
IL	B
-	I
12A	I
,	O
T	B
-	I
box	I
TF	I
-	I
(	I
T	I
-	I
bet	I
)	I
)	O
,	O
Th2	O
-	O
(	O
GATA	B
binding	I
protein	I
-	I
(	I
GATA	I
)	I
-	I
3	I
)	O
,	O
and	O
IL	B
-	I
10	I
expressions	O
.	O

IL	B
-	I
10	I
expression	O
was	O
increased	O
and	O
correlated	O
with	O
plasma	O
Tumor	B
Necrosis	I
Factor	I
(	I
TNF	I
)	I
-	I
alpha	I
and	O
Th0	O
-	O
(	O
IL	B
-	I
2	I
)	O
,	O
Th1	O
-	O
(	O
IL	B
-	I
12A	I
,	O
T	B
-	I
bet	I
)	O
,	O
GATA3	B
,	O
Treg	O
-	O
(	O
Forkhead	B
/	I
winged	I
-	I
helix	I
transcription	I
factor	I
-	O
(	B
FOXP	I
)	I
-	I
3	I
)	I
,	O
and	O
IL	B
-	I
6	I
expressions	O
.	O

FOXP3	B
expression	O
,	O
FOXP3	B
/	O
RORC	B
,	O
and	O
FOXP3	B
/	O
GATA3	B
expression	O
ratios	O
were	O
increased	O
.	O

Plasma	O
IL	B
-	I
1beta	I
,	O
IL	B
-	I
12	I
(	I
p70	I
)	I
,	O
Interferon	B
-	I
(	I
IFN	I
)	I
-	I
gamma	I
,	O
and	O
IL	B
-	I
6	I
cytokines	I
were	O
augmented	O
.	O

Plasma	O
IL	B
-	I
1beta	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
2	I
,	O
IFN	B
-	I
gamma	I
,	O
TNF	B
-	I
alpha	I
,	O
IL	B
-	I
10	I
,	O
and	O
IL	B
-	I
13	I
correlated	O
with	O
C	B
-	I
reactive	I
protein	I
,	O
respectively	O
.	O

Increased	O
Calprotectin	B
correlated	O
with	O
neutrophils	O
.	O

Conclusion	O
,	O
SLE	O
patients	O
presented	O
a	O
systemic	O
immunoinflammatory	O
activity	O
,	O
augmented	O
AKT1	B
and	O
MAPK1	B
expressions	O
,	O
proinflammatory	O
cytokines	O
,	O
and	O
Calprotectin	O
,	O
together	O
with	O
increased	O
expression	O
of	O
Treg	O
-	O
related	O
genes	O
,	O
suggesting	O
a	O
regulatory	O
feedback	O
opposing	O
the	O
inflammatory	O
activity	O
.	O

MyD88	B
is	O
crucial	O
for	O
the	O
development	O
of	O
a	O
protective	O
CNS	O
immune	O
response	O
to	O
Toxoplasma	O
gondii	O
infection	O
.	O

BACKGROUND	O
:	O
Toxoplasmosis	O
is	O
one	O
of	O
the	O
most	O
common	O
parasitic	O
infections	O
in	O
humans	O
.	O

It	O
can	O
establish	O
chronic	O
infection	O
and	O
is	O
characterized	O
by	O
the	O
formation	O
of	O
tissue	O
cysts	O
in	O
the	O
brain	O
.	O

The	O
cysts	O
remain	O
largely	O
quiescent	O
for	O
the	O
life	O
of	O
the	O
host	O
,	O
but	O
can	O
reactivate	O
and	O
cause	O
life	O
-	O
threatening	O
toxoplasmic	O
encephalitis	O
in	O
immunocompromised	O
patients	O
,	O
such	O
as	O
those	O
with	O
AIDS	O
,	O
neoplastic	O
diseases	O
and	O
organ	O
transplants	O
.	O

Toll	B
-	I
like	I
receptor	I
(	O
TLR	B
)	O
adaptor	O
MyD88	B
activation	O
is	O
required	O
for	O
the	O
innate	O
sensing	O
of	O
Toxoplasma	O
gondii	O
.	O

Mice	O
deficient	O
in	O
MyD88	B
have	O
defective	O
IL	B
-	I
12	I
and	O
Th1	O
effector	O
responses	O
,	O
and	O
are	O
highly	O
susceptible	O
to	O
the	O
acute	O
phase	O
of	O
T	O
.	O
gondii	O
infection	O
.	O

However	O
,	O
the	O
role	O
of	O
this	O
signaling	O
pathway	O
during	O
cerebral	O
infection	O
is	O
poorly	O
understood	O
and	O
requires	O
examination	O
.	O

METHOD	O
:	O
MyD88	B
-	O
deficient	O
mice	O
and	O
control	O
mice	O
were	O
orally	O
infected	O
with	O
T	O
.	O
gondii	O
cysts	O
.	O

Cellular	O
and	O
parasite	O
infiltration	O
in	O
the	O
peripheral	O
organs	O
and	O
in	O
the	O
brain	O
were	O
determined	O
by	O
histology	O
and	O
immunohistochemistry	O
.	O

Cytokine	O
levels	O
were	O
determined	O
by	O
ELISA	O
and	O
chemokine	O
mRNA	O
levels	O
were	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
.	O

RESULTS	O
:	O
Thirteen	O
days	O
after	O
infection	O
,	O
a	O
higher	O
parasite	O
burden	O
was	O
observed	O
but	O
there	O
was	O
no	O
histological	O
change	O
in	O
the	O
liver	O
,	O
heart	O
,	O
lungs	O
and	O
small	O
intestine	O
of	O
MyD88	B
⁻	I
/	I
⁻	I
and	O
MyD88	B
⁺	I
/	I
⁺	I
mice	I
.	O

However	O
,	O
MyD88	B
⁻	O
/	O
⁻	O
mice	O
compared	O
to	O
MyD88	B
⁺	O
/	O
⁺	O
mice	O
were	O
highly	O
susceptible	O
to	O
cerebral	O
infection	O
,	O
displayed	O
high	O
parasite	O
migration	O
to	O
the	O
brain	O
,	O
severe	O
neuropathological	O
signs	O
of	O
encephalitis	O
and	O
succumbed	O
within	O
2	O
weeks	O
of	O
oral	O
infection	O
.	O

Susceptibility	O
was	O
primarily	O
associated	O
with	O
lower	O
expression	O
of	O
Th1	B
cytokin	I
cytokines	I
,	O
especially	O
IL	B
-	I
12	I
,	O
IFN	B
-	I
γ	I
and	O
TNF	B
-	I
α	I
,	O
significant	O
decrease	O
in	O
the	O
expression	O
of	O
CCL3	B
,	O
CCL5	B
,	O
CCL7	B
and	O
CCL19	B
chemokines	I
,	O
marked	O
defect	O
of	O
CD8	O
⁺	O
T	O
cells	O
,	O
and	O
infiltration	O
of	O
CD11b	O
⁺	O
and	O
F4	B
/	I
80	I
⁺	I
cells	O
in	O
the	O
brain	O
.	O

CONCLUSION	O
:	O
MyD88	B
is	O
essential	O
for	O
the	O
protection	O
of	O
mice	O
during	O
the	O
cerebral	O
installation	O
of	O
T	O
.	O
gondii	O
infection	O
.	O

These	O
results	O
establish	O
a	O
role	O
for	O
MyD88	B
in	O
T	O
cell	O
-	O
mediated	O
control	O
of	O
T	O
.	O
gondii	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Network	O
of	O
brain	O
protein	O
level	O
changes	O
in	O
glutaminase	B
deficient	O
fetal	O
mice	O
.	O

Glutaminase	B
is	O
a	O
multifunctional	O
enzyme	O
encoded	O
by	O
gene	B
Gls	I
involved	O
in	O
energy	O
metabolism	O
,	O
ammonia	O
trafficking	O
and	O
regeneration	O
of	O
neurotransmitter	O
glutamate	O
.	O

To	O
address	O
the	O
proteomic	O
basis	O
for	O
the	O
neurophenotypes	O
of	O
glutaminase	B
-	O
deficient	O
mice	O
,	O
brain	O
proteins	O
from	O
late	O
gestation	O
wild	O
type	O
,	O
Gls	B
+	O
/	O
-	O
and	O
Gls	B
-	O
/	O
-	O
male	O
mice	O
were	O
subjected	O
to	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
,	O
with	O
subsequent	O
identification	O
by	O
mass	O
spectrometry	O
using	O
nano	O
-	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
.	O

Protein	O
spots	O
that	O
showed	O
differential	O
genotypic	O
variation	O
were	O
quantified	O
by	O
immunoblotting	O
.	O

Differentially	O
expressed	O
proteins	O
unambiguously	O
identified	O
by	O
MS	O
/	O
MS	O
included	O
neurocalcin	B
delta	I
,	O
retinol	B
binding	I
protein	I
-	I
1	I
,	O
reticulocalbin	B
-	I
3	I
,	O
cytoskeleton	B
proteins	I
fascin	B
and	O
tropomyosin	B
alpha	I
-	I
4	I
-	I
chain	I
,	O
dihydropyrimidinase	B
-	I
related	I
protein	I
-	I
5	I
,	O
apolipoprotein	B
IV	I
and	O
proteins	O
from	O
protein	O
metabolism	O
proteasome	B
subunits	I
alpha	I
type	I
2	I
,	I
type	I
7	I
,	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
C1	O
/	O
C2	O
and	O
H	O
,	O
voltage	O
-	O
gated	O
anion	O
-	O
selective	O
channel	O
proteins	O
1	O
and	O
2	O
,	O
ATP	B
synthase	I
subunit	I
beta	I
and	O
transitional	B
endoplasmic	I
reticulum	I
ATPase	I
.	O

An	O
interaction	O
network	O
determined	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
revealed	O
a	O
link	O
between	O
glutaminase	B
and	O
calcium	O
,	O
Akt	B
and	O
retinol	O
signaling	O
,	O
cytoskeletal	O
elements	O
,	O
ATPases	B
,	O
ion	O
channels	O
,	O
protein	O
synthesis	O
and	O
the	O
proteasome	O
system	O
,	O
intermediary	O
,	O
nucleic	O
acid	O
and	O
lipid	O
metabolism	O
,	O
huntingtin	B
,	O
guidance	O
cues	O
,	O
transforming	B
growth	I
factor	I
beta	I
-	I
1	I
and	O
hepatocyte	B
nuclear	I
factor	I
4	I
-	I
alpha	I
.	O

The	O
network	O
identified	O
involves	O
(	O
a	O
)	O
cellular	O
assembly	O
and	O
organization	O
and	O
(	O
b	O
)	O
cell	O
signaling	O
and	O
cell	O
cycle	O
,	O
suggesting	O
that	O
Gls	B
is	O
crucial	O
for	O
neuronal	O
maturation	O
.	O

An	O
angiogenic	O
role	O
for	O
adrenomedullin	B
in	O
choroidal	O
neovascularization	O
.	O

PURPOSE	O
:	O
Adrenomedullin	B
(	O
ADM	B
)	O
has	O
been	O
shown	O
to	O
take	O
part	O
in	O
physiological	O
and	O
pathological	O
angiogenesis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
ADM	B
signaling	O
is	O
involved	O
in	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
using	O
a	O
mouse	O
model	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
CNV	O
was	O
induced	O
by	O
laser	O
photocoagulation	O
in	O
8	O
-	O
week	O
-	O
old	O
C57BL	O
/	O
6	O
mice	O
.	O

ADM	B
mRNA	I
expression	O
significantly	O
increased	O
following	O
treatment	O
,	O
peaking	O
4	O
days	O
thereafter	O
.	O

The	O
expression	O
of	O
ADM	B
receptor	I
(	O
ADM	B
-	I
R	I
)	O
components	O
(	O
CRLR	B
,	O
RAMP2	B
and	O
RAMP	B
3	I
)	O
was	O
higher	O
in	O
CD31	B
(	O
+	O
)	O
CD45	B
(	O
-	O
)	O
endothelial	O
cells	O
(	O
ECs	O
)	O
than	O
CD31	B
(	O
-	O
)	O
CD45	B
(	O
-	O
)	O
non	O
-	O
ECs	O
.	O

Inflammatory	O
stimulation	O
upregulated	O
the	O
expression	O
of	O
ADM	B
not	O
only	O
in	O
cell	O
lines	O
but	O
also	O
in	O
cells	O
in	O
primary	O
cultures	O
of	O
the	O
choroid	O
/	O
retinal	O
pigment	O
epithelium	O
complex	O
.	O

Supernatants	O
from	O
TNFα	B
-	O
treated	O
macrophage	O
cell	O
lines	O
potentiated	O
the	O
proliferation	O
of	O
ECs	O
and	O
this	O
was	O
partially	O
suppressed	O
by	O
an	O
ADM	O
antagonist	O
,	O
ADM	O
(	O
22	O
-	O
52	O
)	O
.	O

Intravitreous	O
injection	O
of	O
ADM	B
(	O
22	O
-	O
52	O
)	O
or	O
ADM	B
neutralizing	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
after	O
laser	O
treatment	O
significantly	O
reduced	O
the	O
size	O
of	O
CNV	O
compared	O
with	O
vehicle	O
-	O
treated	O
controls	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
ADM	B
signaling	O
is	O
involved	O
in	O
laser	O
-	O
induced	O
CNV	O
formation	O
,	O
because	O
both	O
an	O
ADM	B
antagonist	O
and	O
ADM	B
mAb	I
significantly	O
inhibited	O
it	O
.	O

Suppression	O
of	O
ADM	B
signaling	O
might	O
be	O
a	O
valuable	O
alternative	O
treatment	O
for	O
CNV	O
associated	O
with	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

The	O
LIM	B
-	O
Homeodomain	B
transcription	O
factor	O
Islet	B
-	I
1	I
is	O
required	O
for	O
the	O
development	O
of	O
sympathetic	O
neurons	O
and	O
adrenal	O
chromaffin	O
cells	O
.	O

Islet	B
-	I
1	I
is	O
a	O
LIM	B
-	O
Homeodomain	B
transcription	O
factor	O
with	O
important	O
functions	O
for	O
the	O
development	O
of	O
distinct	O
neuronal	O
and	O
non	O
-	O
neuronal	O
cell	O
populations	O
.	O

We	O
show	O
here	O
that	O
Islet	B
-	I
1	I
acts	O
genetically	O
downstream	O
of	O
Phox2B	B
in	O
cells	O
of	O
the	O
sympathoadrenal	O
cell	O
lineage	O
and	O
that	O
the	O
development	O
of	O
sympathetic	O
neurons	O
and	O
chromaffin	O
cells	O
is	O
impaired	O
in	O
mouse	O
embryos	O
with	O
a	O
conditional	O
deletion	O
of	O
Islet	B
-	I
1	I
controlled	O
by	O
the	O
wnt1	B
promotor	I
.	O

Islet	B
-	I
1	I
is	O
not	O
essential	O
for	O
the	O
initial	O
differentiation	O
of	O
sympathoadrenal	O
cells	O
,	O
as	O
indicated	O
by	O
the	O
correct	O
expression	O
of	O
pan	O
-	O
neuronal	O
and	O
catecholaminergic	O
subtype	O
specific	O
genes	O
in	O
primary	O
sympathetic	O
ganglia	O
of	O
Islet	B
-	I
1	I
deficient	O
mouse	O
embryos	O
.	O

However	O
,	O
our	O
data	O
indicate	O
that	O
the	O
subsequent	O
survival	O
of	O
sympathetic	O
neuron	O
precursors	O
and	O
their	O
differentiation	O
towards	O
TrkA	B
expressing	O
neurons	O
depends	O
on	O
Islet	B
-	I
1	I
function	O
.	O

In	O
contrast	O
to	O
spinal	O
sensory	O
neurons	O
,	O
sympathetic	O
neurons	O
of	O
Islet	B
-	I
1	I
deficient	O
mice	O
did	O
not	O
display	O
ectopic	O
expression	O
of	O
genes	O
normally	O
present	O
in	O
the	O
CNS	O
.	O

In	O
Islet	B
-	I
1	I
deficient	O
mouse	O
embryos	O
the	O
numbers	O
of	O
chromaffin	O
cells	O
were	O
only	O
mildly	O
reduced	O
,	O
in	O
contrast	O
to	O
that	O
of	O
sympathetic	O
neurons	O
,	O
but	O
the	O
initiation	O
of	O
the	O
adrenaline	O
synthesizing	O
enzyme	O
PNMT	B
was	O
abrogated	O
and	O
the	O
expression	O
level	O
of	O
chromogranin	B
A	I
was	O
diminished	O
.	O

Microarray	O
analysis	O
revealed	O
that	O
developing	O
chromaffin	O
cells	O
of	O
Islet	B
-	I
1	I
deficient	O
mice	O
displayed	O
normal	O
expression	O
levels	O
of	O
TH	B
,	O
DBH	B
and	O
the	O
transcription	O
factors	O
Phox2B	B
,	O
Mash	B
-	I
1	I
,	O
Hand2	B
,	O
Gata3	B
and	O
Insm1	B
,	O
but	O
the	O
expression	O
levels	O
of	O
the	O
transcription	O
factors	O
Gata2	B
and	O
Hand1	B
,	O
and	O
AP	B
-	I
2b	I
were	O
significantly	O
reduced	O
.	O

Together	O
our	O
data	O
indicate	O
that	O
Islet	B
-	I
1	I
is	O
not	O
essentially	O
required	O
for	O
the	O
initial	O
differentiation	O
of	O
sympathoadrenal	O
cells	O
,	O
but	O
has	O
an	O
important	O
function	O
for	O
the	O
correct	O
subsequent	O
development	O
of	O
sympathetic	O
neurons	O
and	O
chromaffin	O
cells	O
.	O

MiR	B
-	I
155	I
has	O
a	O
protective	O
role	O
in	O
the	O
development	O
of	O
non	O
-	O
alcoholic	O
hepatosteatosis	O
in	O
mice	O
.	O

Hepatic	O
steatosis	O
is	O
a	O
global	O
epidemic	O
that	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

MicroRNAs	O
(	O
miRs	O
)	O
are	O
regulators	O
that	O
can	O
functionally	O
integrate	O
a	O
range	O
of	O
metabolic	O
and	O
inflammatory	O
pathways	O
in	O
liver	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
functional	O
role	O
of	O
miR	B
-	I
155	I
in	O
hepatic	O
steatosis	O
.	O

Male	O
C57BL	O
/	O
6	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
miR	B
-	I
155	I
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
fed	O
either	O
normal	O
chow	O
or	O
high	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
6	O
months	O
then	O
lipid	O
levels	O
,	O
metabolic	O
and	O
inflammatory	O
parameters	O
were	O
assessed	O
in	O
livers	O
and	O
serum	O
of	O
the	O
mice	O
.	O

Mice	O
lacking	O
endogenous	O
miR	B
-	I
155	I
that	O
were	O
fed	O
HFD	O
for	O
6	O
months	O
developed	O
increased	O
hepatic	O
steatosis	O
compared	O
to	O
WT	O
controls	O
.	O

This	O
was	O
associated	O
with	O
increased	O
liver	O
weight	O
and	O
serum	O
VLDL	B
/	I
LDL	I
cholesterol	I
and	O
alanine	B
transaminase	I
(	O
ALT	B
)	O
levels	O
,	O
as	O
well	O
as	O
increased	O
hepatic	O
expression	O
of	O
genes	O
involved	O
in	O
glucose	O
regulation	O
(	O
Pck1	B
,	O
Cebpa	B
)	O
,	O
fatty	O
acid	O
uptake	O
(	O
Cd36	B
)	O
and	O
lipid	O
metabolism	O
(	O
Fasn	B
,	O
Fabp4	B
,	O
Lpl	B
,	O
Abcd2	B
,	O
Pla2g7	B
)	O
.	O

Using	O
miRNA	O
target	O
prediction	O
algorithms	O
and	O
the	O
microarray	O
transcriptomic	O
profile	O
of	O
miR	O
-	O
155	O
(	O
-	O
/	O
-	O
)	O
livers	O
,	O
we	O
identified	O
and	O
validated	O
that	O
Nr1h3	B
(	O
LXRα	B
)	O
as	O
a	O
direct	O
miR	B
-	I
155	I
target	O
gene	O
that	O
is	O
potentially	O
responsible	O
for	O
the	O
liver	O
phenotype	O
of	O
miR	B
-	I
155	I
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Together	O
these	O
data	O
indicate	O
that	O
miR	B
-	I
155	I
plays	O
a	O
pivotal	O
role	O
regulating	O
lipid	O
metabolism	O
in	O
liver	O
and	O
that	O
its	O
deregulation	O
may	O
lead	O
to	O
hepatic	O
steatosis	O
in	O
patients	O
with	O
diabetes	O
.	O

A	O
homozygous	O
mutation	O
in	O
LYRM7	B
/	O
MZM1L	B
associated	O
with	O
early	O
onset	O
encephalopathy	O
,	O
lactic	O
acidosis	O
,	O
and	O
severe	O
reduction	O
of	O
mitochondrial	B
complex	I
III	I
activity	O
.	O

Mutations	O
in	O
nuclear	O
genes	O
associated	O
with	O
defective	O
complex	O
III	O
(	O
cIII	O
)	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
are	O
rare	O
,	O
having	O
been	O
found	O
in	O
only	O
two	O
cIII	O
assembly	O
factors	O
and	O
,	O
as	O
private	O
changes	O
in	O
single	O
families	O
,	O
three	O
cIII	O
structural	O
subunits	O
.	O

Recently	O
,	O
human	B
LYRM7	I
/	O
MZM1L	B
,	O
the	O
ortholog	O
of	O
yeast	O
MZM1	B
,	O
has	O
been	O
identified	O
as	O
a	O
new	O
assembly	O
factor	O
for	O
cIII	B
.	O

In	O
a	O
baby	O
patient	O
with	O
early	O
onset	O
,	O
severe	O
encephalopathy	O
,	O
lactic	O
acidosis	O
and	O
profound	O
,	O
isolated	O
cIII	O
deficiency	O
in	O
skeletal	O
muscle	O
,	O
we	O
identified	O
a	O
disease	O
-	O
segregating	O
homozygous	O
mutation	O
(	O
c	O
.	O
73G	O
>	O
A	O
)	O
in	O
LYRM7	B
/	O
MZM1L	B
,	O
predicting	O
a	O
drastic	O
change	O
in	O
a	O
highly	O
conserved	O
amino	O
-	O
acid	O
residue	O
(	O
p	O
.	O
Asp25Asn	O
)	O
.	O

In	O
a	O
mzm1	B
Δ	I
yeast	O
strain	O
,	O
the	O
expression	O
of	O
a	O
mzm1	B
(	I
D25N	I
)	I
mutant	I
allele	I
caused	O
temperature	O
-	O
sensitive	O
respiratory	O
growth	O
defect	O
,	O
decreased	O
oxygen	O
consumption	O
,	O
impaired	O
maturation	O
/	O
stabilization	O
of	O
the	O
Rieske	B
Fe	I
-	I
S	I
protein	I
,	O
and	O
reduced	O
complex	O
III	O
activity	O
and	O
amount	O
.	O

LYRM7	B
/	O
MZM1L	B
is	O
a	O
novel	O
disease	O
gene	O
,	O
causing	O
cIII	O
-	O
defective	O
,	O
early	O
onset	O
,	O
severe	O
mitochondrial	O
encephalopathy	O
.	O

Secreted	B
protein	I
acidic	I
and	I
rich	I
in	I
cysteine	I
(	O
SPARC	B
)	O
exacerbates	O
colonic	O
inflammatory	O
symptoms	O
in	O
dextran	O
sodium	O
sulphate	O
-	O
induced	O
murine	O
colitis	O
.	O

BACKGROUND	O
:	O
Secreted	B
Protein	I
Acidic	I
and	I
Rich	I
in	I
Cysteine	I
(	O
SPARC	B
)	O
is	O
expressed	O
during	O
tissue	O
repair	O
and	O
regulates	O
cellular	O
proliferation	O
,	O
migration	O
and	O
cytokine	O
expression	O
.	O

The	O
aim	O
was	O
to	O
determine	O
if	O
SPARC	B
modifies	O
intestinal	O
inflammation	O
.	O

METHODS	O
:	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
SPARC	B
-	O
null	O
(	O
KO	O
)	O
mice	O
received	O
3	O
%	O
dextran	O
sodium	O
sulphate	O
(	O
DSS	O
)	O
for	O
7	O
days	O
.	O

Inflammation	O
was	O
assessed	O
endoscopically	O
,	O
clinically	O
and	O
histologically	O
.	O

IL	B
-	I
1beta	I
,	O
IL	B
-	I
4	I
,	O
IL	B
-	I
5	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
10	I
,	O
IL	B
-	I
13	I
,	O
IL	B
-	I
17A	I
,	O
IL	B
-	I
12	I
/	I
IL23p40	I
,	O
TNF	B
-	I
alpha	I
,	O
IFN	B
-	I
gamma	I
,	O
RANTES	B
,	O
MCP	B
-	I
1	I
,	O
MIP	B
-	I
1alpha	I
,	O
MIP	B
-	I
1beta	I
,	O
MIG	B
and	O
TGF	B
-	I
beta1	I
levels	O
were	O
measured	O
by	O
ELISA	O
and	O
cytometric	O
bead	O
array	O
.	O

Inflammatory	O
cells	O
were	O
characterised	O
by	O
CD68	B
,	O
Ly6G	B
,	O
F4	B
/	I
80	I
and	O
CD11b	B
immunofluorescence	O
staining	O
and	O
regulatory	O
T	O
cells	O
from	O
spleen	O
and	O
mesenteric	O
lymph	O
nodes	O
were	O
assessed	O
by	O
flow	O
cytometry	O
.	O

RESULTS	O
:	O
KO	O
mice	O
had	O
less	O
weight	O
loss	O
and	O
diarrhoea	O
with	O
less	O
endoscopic	O
and	O
histological	O
inflammation	O
than	O
WT	O
animals	O
.	O

By	O
day	O
35	O
,	O
all	O
(	O
n	O
=	O
13	O
)	O
KO	O
animals	O
completely	O
resolved	O
the	O
inflammation	O
compared	O
to	O
7	O
of	O
14	O
WT	O
mice	O
(	O
p	O
&	O
lt	O
;	O
0	O
.	O
01	O
)	O
.	O

Compared	O
to	O
WTs	O
,	O
KO	O
animals	O
at	O
day	O
7	O
had	O
less	O
IL1beta	B
(	O
p	O
=	O
0	O
.	O
025	O
)	O
and	O
MIG	B
(	O
p	O
=	O
0	O
.	O
031	O
)	O
with	O
higher	O
TGFbeta1	B
(	O
p	O
=	O
0	O
.	O
017	O
)	O
expression	O
and	O
a	O
greater	O
percentage	O
of	O
FoxP3	B
+	O
regulatory	O
T	O
cells	O
in	O
the	O
spleen	O
and	O
draining	O
lymph	O
nodes	O
of	O
KO	O
animals	O
(	O
p	O
&	O
lt	O
;	O
0	O
.	O
01	O
)	O
.	O

KO	O
mice	O
also	O
had	O
fewer	O
CD68	B
+	O
and	O
F4	B
/	I
80	I
+	O
macrophages	O
,	O
Ly6G	B
+	O
neutrophils	O
and	O
CD11b	B
+	O
cells	O
infiltrating	O
the	O
inflamed	O
colon	O
.	O

CONCLUSIONS	O
:	O
Compared	O
to	O
WT	O
,	O
SPARC	B
KO	O
mice	O
had	O
less	O
inflammation	O
with	O
fewer	O
inflammatory	O
cells	O
and	O
more	O
regulatory	O
T	O
cells	O
.	O

Together	O
,	O
with	O
increased	O
TGF	B
-	I
beta1	I
levels	O
,	O
this	O
could	O
aid	O
in	O
the	O
more	O
rapid	O
resolution	O
of	O
inflammation	O
and	O
restoration	O
of	O
the	O
intestinal	O
mucosa	O
suggesting	O
that	O
the	O
presence	O
of	O
SPARC	B
increases	O
intestinal	O
inflammation	O
.	O

Association	O
of	O
a	O
FGFR	B
-	I
4	I
gene	I
polymorphism	O
with	O
bronchopulmonary	O
dysplasia	O
and	O
neonatal	O
respiratory	O
distress	O
.	O

BACKGROUND	O
:	O
Bronchopulmonary	O
dysplasia	O
(	O
BPD	O
)	O
is	O
the	O
most	O
common	O
chronic	O
lung	O
disease	O
of	O
premature	O
birth	O
,	O
characterized	O
by	O
impaired	O
alveolar	O
development	O
and	O
inflammation	O
.	O

Pathomechanisms	O
contributing	O
to	O
BPD	O
are	O
poorly	O
understood	O
.	O

However	O
,	O
it	O
is	O
assumed	O
that	O
genetic	O
factors	O
predispose	O
to	O
BPD	O
and	O
other	O
pulmonary	O
diseases	O
of	O
preterm	O
neonates	O
,	O
such	O
as	O
neonatal	O
respiratory	O
distress	O
syndrome	O
(	O
RDS	O
)	O
.	O

For	O
association	O
studies	O
,	O
genes	O
upregulated	O
during	O
alveolarization	O
are	O
major	O
candidates	O
for	O
genetic	O
analysis	O
,	O
for	O
example	O
,	O
matrix	O
metalloproteinases	O
(	O
MMPs	B
)	O
and	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	B
)	O
and	O
their	O
receptors	O
(	O
FGFR	B
)	O
.	O

OBJECTIVE	O
:	O
Determining	O
genetic	O
risk	O
variants	O
in	O
a	O
Caucasian	O
population	O
of	O
premature	O
neonates	O
with	O
BPD	O
and	O
RDS	O
.	O

Methods	O
.	O

We	O
genotyped	O
27	O
polymorphisms	O
within	O
14	O
candidate	O
genes	O
via	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
:	O
MMP	B
-	I
1	I
,	I
-	I
2	I
,	I
-	I
9	I
,	I
and	I
-	I
12	I
,	I
-	I
16	I
,	O
FGF	B
receptors	I
2	I
and	I
4	I
,	O
FGF	B
-	I
2	I
,	I
-	I
3	I
,	I
-	I
4	I
,	I
-	I
7	I
,	I
and	I
-	I
18	I
,	O
Signal	B
-	I
Regulatory	I
Protein	I
α	I
(	O
SIRPA	B
)	O
and	O
Thyroid	B
Transcription	I
Factor	I
-	I
1	I
(	O
TTF	B
-	I
1	I
)	O
.	O

RESULTS	O
:	O
Five	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
MMP	B
-	I
9	I
,	O
MMP	B
-	I
12	I
,	O
FGFR	B
-	I
4	I
,	O
FGF	B
-	I
3	I
,	O
and	O
FGF	B
-	I
7	I
are	O
associated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
RDS	O
,	O
defined	O
as	O
surfactant	O
application	O
within	O
the	O
first	O
24	O
hours	O
after	O
birth	O
.	O

One	O
of	O
them	O
,	O
in	O
FGFR	B
-	I
4	I
(	O
rs1966265	O
)	O
,	O
is	O
associated	O
with	O
both	O
RDS	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
BPD	O
(	O
P	O
=	O
0	O
.	O
023	O
)	O
.	O

CONCLUSION	O
:	O
rs1966265	O
in	O
FGF	B
receptor	I
4	I
is	O
a	O
possible	O
genetic	O
key	O
variant	O
in	O
alveolar	O
diseases	O
of	O
preterm	O
newborns	O
.	O

Miz1	B
deficiency	O
in	O
the	O
mammary	O
gland	O
causes	O
a	O
lactation	O
defect	O
by	O
attenuated	O
Stat5	B
expression	O
and	O
phosphorylation	O
.	O

Miz1	B
is	O
a	O
zinc	B
finger	I
transcription	I
factor	I
with	O
an	O
N	O
-	O
terminal	O
POZ	O
domain	O
.	O

Complexes	O
with	O
Myc	B
,	O
Bcl	B
-	I
6	I
or	O
Gfi	B
-	I
1	I
repress	O
expression	O
of	O
genes	O
like	O
Cdkn2b	B
(	O
p15	B
(	O
Ink4	B
)	O
)	O
or	O
Cdkn1a	B
(	O
p21	B
(	O
Cip	B
p21	O
(	O
Cip1	B
)	O
)	O
.	O

The	O
role	O
of	O
Miz1	B
in	O
normal	O
mammary	O
gland	O
development	O
has	O
not	O
been	O
addressed	O
so	O
far	O
.	O

Conditional	O
knockout	O
of	O
the	O
Miz1	B
POZ	I
domain	I
in	O
luminal	O
cells	O
during	O
pregnancy	O
caused	O
a	O
lactation	O
defect	O
with	O
a	O
transient	O
reduction	O
of	O
glandular	O
tissue	O
,	O
reduced	O
proliferation	O
and	O
attenuated	O
differentiation	O
.	O

This	O
was	O
recapitulated	O
in	O
vitro	O
using	O
mouse	O
mammary	O
gland	O
derived	O
HC11	O
cells	O
.	O

Further	O
analysis	O
revealed	O
decreased	O
Stat5	B
activity	O
in	O
Miz1	B
ΔPOZ	I
mammary	O
glands	O
and	O
an	O
attenuated	O
expression	O
of	O
Stat5	B
targets	I
.	O

Gene	O
expression	O
of	O
the	O
Prolactin	B
receptor	I
(	O
PrlR	B
)	O
and	O
ErbB4	B
,	O
both	O
critical	O
for	O
Stat5	B
phosphorylation	O
(	O
pStat5	B
<	O
/	O
Stat5	B
)	O
or	O
pStat5	B
<	O
/	O
Stat5	B
nuclear	O
translocation	O
,	O
was	O
decreased	O
in	O
Miz1	B
ΔPOZ	I
females	O
.	O

Microarray	O
,	O
ChIP	O
-	O
Seq	O
and	O
gene	O
set	O
enrichment	O
analysis	O
revealed	O
a	O
down	O
-	O
regulation	O
of	O
Miz1	B
target	I
genes	I
being	O
involved	O
in	O
vesicular	O
transport	O
processes	O
.	O

Our	O
data	O
suggest	O
that	O
deranged	O
intracellular	O
transport	O
and	O
localization	O
of	O
PrlR	B
and	O
ErbB4	B
disrupt	O
the	O
Stat5	B
signalling	I
pathway	I
in	O
mutant	O
glands	O
and	O
cause	O
the	O
observed	O
lactation	O
phenotype	O
.	O

High	O
STAT1	B
mRNA	I
levels	O
but	O
not	O
its	O
tyrosine	O
phosphorylation	O
are	O
associated	O
with	O
macrophage	O
infiltration	O
and	O
bad	O
prognosis	O
in	O
breast	O
cancer	O
.	O

BACKGROUND	O
:	O
STAT1	B
has	O
been	O
attributed	O
a	O
function	O
as	O
tumor	B
suppressor	I
.	O

However	O
,	O
in	O
breast	O
cancer	O
data	O
from	O
microarray	O
analysis	O
indicated	O
a	O
predictive	O
value	O
of	O
high	O
mRNA	O
expression	O
levels	O
of	O
STAT1	B
and	O
STAT1	B
target	O
genes	O
belonging	O
to	O
the	O
interferon	B
-	O
related	O
signature	O
for	O
a	O
poor	O
response	O
to	O
therapy	O
.	O

To	O
clarify	O
this	O
issue	O
we	O
have	O
determined	O
STAT1	B
expression	O
levels	O
and	O
activation	O
by	O
different	O
methods	O
,	O
and	O
investigated	O
their	O
association	O
with	O
tumor	O
infiltration	O
by	O
immune	O
cells	O
.	O

Additionally	O
,	O
we	O
evaluated	O
the	O
interrelationship	O
of	O
these	O
parameters	O
and	O
their	O
significance	O
for	O
predicting	O
disease	O
outcome	O
.	O

METHODS	O
:	O
Expression	O
of	O
STAT1	B
,	O
its	O
target	O
genes	O
SOCS1	B
,	O
IRF1	B
,	O
CXCL9	B
,	O
CXCL10	B
,	O
CXCL11	B
,	O
IFIT1	B
,	O
IFITM1	B
,	O
MX1	B
and	O
genes	O
characteristic	O
for	O
immune	O
cell	O
infiltration	O
(	O
CD68	B
,	O
CD163	B
,	O
PD	B
-	I
L1	I
,	O
PD	B
-	I
L2	I
,	O
PD	B
-	I
1	I
,	O
CD45	B
,	O
IFN	B
-	I
gamma	I
,	O
FOXP3	B
)	O
was	O
determined	O
by	O
RT	O
-	O
PCR	O
in	O
two	O
independent	O
cohorts	O
comprising	O
132	O
breast	O
cancer	O
patients	O
.	O

For	O
a	O
subset	O
of	O
patients	O
,	O
protein	O
levels	O
of	O
total	O
as	O
well	O
as	O
serine	O
and	O
tyrosine	O
-	O
phosphorylated	O
STAT1	B
were	O
ascertained	O
by	O
immunohistochemistry	O
or	O
immunoblotting	O
and	O
protein	O
levels	O
of	O
CXCL10	B
by	O
ELISA	O
.	O

RESULTS	O
:	O
mRNA	O
expression	O
levels	O
of	O
STAT1	B
and	O
STAT1	B
target	O
genes	O
,	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
serine	O
-	O
phosphorylated	O
STAT1	B
correlated	O
with	O
each	O
other	O
in	O
neoplastic	O
tissue	O
.	O

However	O
,	O
there	O
was	O
no	O
association	O
between	O
tumor	O
levels	O
of	O
STAT1	B
mRNA	I
and	O
tyrosine	B
-	I
phosphorylated	I
STAT1	I
and	O
between	O
CXCL10	B
serum	O
levels	O
and	O
CXCL10	B
expression	O
in	O
the	O
tumor	O
.	O

Tumors	O
with	O
increased	O
STAT1	B
mRNA	I
amounts	O
exhibited	O
elevated	O
expression	O
of	O
genes	O
characteristic	O
for	O
tumor	O
-	O
associated	O
macrophages	O
and	O
immunosuppressive	O
T	O
lymphocytes	O
.	O

Survival	O
analysis	O
revealed	O
an	O
association	O
of	O
high	O
STAT1	B
mRNA	I
levels	O
and	O
bad	O
prognosis	O
in	O
both	O
cohorts	O
.	O

A	O
similar	O
prognostically	O
relevant	O
correlation	O
with	O
unfavorable	O
outcome	O
was	O
evident	O
for	O
CXCL10	B
,	O
MX1	B
,	O
CD68	B
,	O
CD163	B
,	O
IFN	B
-	I
gamma	I
,	O
and	O
PD	B
-	I
L2	I
expression	O
in	O
at	O
least	O
one	O
collective	O
.	O

By	O
contrast	O
,	O
activation	O
of	O
STAT1	B
as	O
assessed	O
by	O
the	O
level	O
of	O
STAT1	B
-	O
Y701	O
phosphorylation	O
was	O
linked	O
to	O
positive	O
outcome	O
.	O

In	O
multivariate	O
Cox	O
regression	O
,	O
the	O
predictive	O
power	O
of	O
STAT1	B
mRNA	I
expression	O
was	O
lost	O
when	O
including	O
expression	O
of	O
CXCL10	B
,	O
MX1	B
and	O
CD68	B
as	O
confounders	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
confirms	O
distinct	O
prognostic	O
relevance	O
of	O
STAT1	B
expression	O
levels	O
and	O
STAT1	B
tyrosine	O
phosphorylation	O
in	O
breast	O
cancer	O
patients	O
and	O
identifies	O
an	O
association	O
of	O
high	O
STAT1	B
levels	O
with	O
elevated	O
expression	O
of	O
STAT1	B
target	O
genes	O
and	O
markers	O
for	O
infiltrating	O
immune	O
cells	O
.	O

Essential	O
roles	O
of	O
epithelial	O
bone	B
morphogenetic	I
protein	I
signaling	O
during	O
prostatic	O
development	O
.	O

Prostate	O
is	O
a	O
male	O
sex	O
-	O
accessory	O
organ	O
.	O

The	O
prostatic	O
epithelia	O
consist	O
primarily	O
of	O
basal	O
and	O
luminal	O
cells	O
that	O
differentiate	O
from	O
embryonic	O
urogenital	O
sinus	O
epithelia	O
.	O

Prostate	O
tumors	O
are	O
believed	O
to	O
originate	O
in	O
the	O
basal	O
and	O
luminal	O
cells	O
.	O

However	O
,	O
factors	O
that	O
promote	O
normal	O
epithelial	O
differentiation	O
have	O
not	O
been	O
well	O
elucidated	O
,	O
particularly	O
for	O
bone	B
morphogenetic	I
protein	I
(	O
Bmp	B
)	O
signaling	O
.	O

This	O
study	O
shows	O
that	O
Bmp	B
signaling	O
prominently	O
increases	O
during	O
prostatic	O
differentiation	O
in	O
the	O
luminal	O
epithelia	O
,	O
which	O
is	O
monitored	O
by	O
the	O
expression	O
of	O
phosphorylated	O
Smad1	B
/	I
5	I
/	I
8	I
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
epithelial	O
differentiation	O
and	O
the	O
function	O
of	O
Bmp	B
signaling	O
during	O
prostatic	O
development	O
,	O
conditional	O
male	O
mutant	O
mouse	O
analysis	O
for	O
the	O
epithelial	O
-	O
specific	O
Bmp	B
receptor	I
1a	I
(	O
Bmpr1a	B
)	O
was	O
performed	O
.	O

We	O
demonstrate	O
that	O
Bmp	B
signaling	O
is	O
indispensable	O
for	O
luminal	O
cell	O
maturation	O
,	O
which	O
regulates	O
basal	O
cell	O
proliferation	O
.	O

Expression	O
of	O
the	O
prostatic	O
epithelial	O
regulatory	O
gene	B
Nkx3	I
.	I
1	I
was	O
significantly	O
reduced	O
in	O
the	O
Bmpr1a	B
mutants	I
.	O

These	O
results	O
indicate	O
that	O
Bmp	B
signaling	O
is	O
a	O
key	O
factor	O
for	O
prostatic	O
epithelial	O
differentiation	O
,	O
possibly	O
by	O
controlling	O
the	O
prostatic	O
regulatory	O
gene	O
Nkx3	B
.	I
1	I
.	O

Crucial	O
role	O
of	O
calbindin	B
-	I
D28k	I
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
'	O
s	O
disease	O
mouse	O
model	O
.	O

Calbindin	B
-	I
D28k	I
(	O
CB	B
)	O
,	O
one	O
of	O
the	O
major	O
calcium	O
-	O
binding	O
and	O
buffering	O
proteins	O
,	O
has	O
a	O
critical	O
role	O
in	O
preventing	O
a	O
neuronal	O
death	O
as	O
well	O
as	O
maintaining	O
calcium	O
homeostasis	O
.	O

Although	O
marked	O
reductions	O
of	O
CB	O
expression	O
have	O
been	O
observed	O
in	O
the	O
brains	O
of	O
mice	O
and	O
humans	O
with	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
,	O
it	O
is	O
unknown	O
whether	O
these	O
changes	O
contribute	O
to	O
AD	O
-	O
related	O
dysfunction	O
.	O

To	O
determine	O
the	O
pathogenic	O
importance	O
of	O
CB	O
depletions	O
in	O
AD	O
models	O
,	O
we	O
crossed	O
5	O
familial	O
AD	O
mutations	O
(	O
5XFAD	O
;	O
Tg	O
)	O
mice	O
with	O
CB	O
knock	O
-	O
out	O
(	O
CBKO	O
)	O
mice	O
and	O
generated	O
a	O
novel	O
line	O
CBKO	O
·	O
5XFAD	O
(	O
CBKOTg	O
)	O
mice	O
.	O

We	O
first	O
identified	O
the	O
change	O
of	O
signaling	O
pathways	O
and	O
differentially	O
expressed	O
proteins	O
globally	O
by	O
removing	O
CB	O
in	O
Tg	O
mice	O
using	O
mass	O
spectrometry	O
and	O
antibody	O
microarray	O
.	O

Immunohistochemistry	O
showed	O
that	O
CBKOTg	O
mice	O
had	O
significant	O
neuronal	O
loss	O
in	O
the	O
subiculum	O
area	O
without	O
changing	O
the	O
magnitude	O
(	O
number	O
)	O
of	O
amyloid	O
β	O
-	O
peptide	O
(	O
Aβ	O
)	O
plaques	O
deposition	O
and	O
elicited	O
significant	O
apoptotic	O
features	O
and	O
mitochondrial	O
dysfunction	O
compared	O
with	O
Tg	O
mice	O
.	O

Moreover	O
,	O
CBKOTg	O
mice	O
reduced	O
levels	O
of	O
phosphorylated	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
)	I
1	I
/	I
2	I
and	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
at	O
Ser	O
-	O
133	O
and	O
synaptic	O
molecules	O
such	O
as	O
N	B
-	I
methyl	I
-	I
D	I
-	I
aspartate	I
receptor	I
1	I
(	O
NMDA	B
receptor	I
1	I
)	O
,	O
NMDA	B
receptor	I
2A	I
,	O
PSD	B
-	I
95	I
and	O
synaptophysin	B
in	O
the	O
subiculum	O
compared	O
with	O
Tg	O
mice	O
.	O

Importantly	O
,	O
this	O
is	O
the	O
first	O
experimental	O
evidence	O
that	O
removal	O
of	O
CB	O
from	O
amyloid	B
precursor	I
protein	I
/	O
presenilin	B
transgenic	O
mice	O
aggravates	O
AD	O
pathogenesis	O
,	O
suggesting	O
that	O
CB	O
has	O
a	O
critical	O
role	O
in	O
AD	O
pathogenesis	O
.	O

Elongated	B
TCR	I
alpha	I
chain	I
CDR3	I
favors	O
an	O
altered	O
CD4	B
cytokine	I
profile	I
.	O

BACKGROUND	O
:	O
CD4	B
T	O
lymphocyte	O
activation	O
requires	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
engagement	O
by	O
peptide	O
/	O
MHC	B
(	O
major	B
histocompatibility	I
complex	I
)	O
(	O
p	O
MHC	B
)	O
.	O

The	O
TCR	B
complementarity	B
-	I
determining	I
region	I
3	I
(	O
CDR3	B
)	O
contains	O
variable	O
α	O
and	O
β	O
loops	O
critical	O
for	O
p	O
MHC	B
recognition	O
.	O

During	O
any	O
immune	O
response	O
,	O
tuning	O
of	O
TCR	B
usage	O
through	O
progressive	O
clonal	O
selection	O
occurs	O
.	O

Th1	O
and	O
Th2	O
cells	O
operate	O
at	O
different	O
avidities	O
for	O
activation	O
and	O
display	O
distinct	O
transcriptional	O
programs	O
,	O
although	O
polarization	O
may	O
be	O
plastic	O
,	O
influenced	O
by	O
pathogens	O
and	O
cytokines	O
.	O

We	O
therefore	O
hypothesized	O
that	O
CDR3αβ	B
sequence	I
features	I
may	O
intrinsically	O
influence	O
CD4	B
phenotype	O
during	O
progression	O
of	O
a	O
response	O
.	O

RESULTS	O
:	O
We	O
show	O
that	O
CD4	B
polarization	O
involves	O
distinct	O
CDR3α	B
usage	O
:	O
Th1	O
and	O
Th17	O
cells	O
favored	O
short	O
TCR	B
CDR3α	B
sequences	O
of	O
12	O
and	O
11	O
amino	O
acids	O
,	O
respectively	O
,	O
while	O
Th2	O
cells	O
favored	O
elongated	O
CDR3α	B
loops	O
of	O
14	O
amino	O
acids	O
,	O
with	O
lower	O
predicted	O
affinity	O
.	O

The	O
dominant	O
Th2	O
-	O
and	O
Th1	O
-	O
derived	O
TCRα	B
sequences	O
with	O
14	O
amino	O
acid	O
CDR3	B
loops	O
and	O
12	O
amino	O
acid	O
CDR3	B
loops	O
,	O
respectively	O
,	O
were	O
expressed	O
in	O
TCR	B
transgenics	O
.	O

The	O
functional	O
impact	O
of	O
these	O
TCRα	B
transgenes	O
was	O
assessed	O
after	O
in	O
vivo	O
priming	O
with	O
a	O
peptide	O
/	O
adjuvant	O
.	O

The	O
short	O
,	O
Th1	O
-	O
derived	O
receptor	O
transgenic	O
T	O
cell	O
lines	O
made	O
IFNγ	B
,	O
but	O
not	O
IL	B
-	I
4	I
,	O
5	O
or	O
13	O
,	O
while	O
the	O
elongated	O
,	O
Th2	O
-	O
derived	O
receptor	O
transgenic	O
T	O
cell	O
lines	O
made	O
little	O
or	O
no	O
IFNγ	B
,	O
but	O
increased	O
IL	B
-	I
4	I
,	O
5	O
and	O
13	O
with	O
progressive	O
re	O
-	O
stimulations	O
,	O
mirrored	O
by	O
GATA	B
-	I
3	I
up	O
-	O
regulation	O
.	O

T	O
cells	O
from	O
primed	O
Th2	O
TCRα	B
transgenics	O
selected	O
dominant	O
TCR	B
Vβ	I
expansions	O
,	O
allowing	O
us	O
to	O
generate	O
TCRαβ	B
transgenics	O
carrying	O
the	O
favored	O
,	O
Th2	O
-	O
derived	O
receptor	O
heterodimer	O
.	O

Primed	O
T	O
cells	O
from	O
TCRαβ	B
transgenics	O
made	O
little	O
or	O
no	O
IL	B
-	I
17	I
or	O
IFNγ	B
,	O
but	O
favored	O
IL	B
-	I
9	I
after	O
priming	O
with	O
Complete	O
Freund	O
'	O
s	O
adjuvant	O
and	O
IL	B
-	I
4	I
,	I
5	I
,	I
9	I
,	I
10	I
and	I
13	I
after	O
priming	O
with	O
incomplete	O
Freund	O
'	O
s	O
.	O

In	O
tetramer	O
-	O
binding	O
studies	O
,	O
this	O
transgenic	O
receptor	O
showed	O
low	O
binding	O
avidity	O
for	O
pMHC	O
and	O
polarized	O
T	O
cell	O
lines	O
show	O
TCR	B
avidity	O
for	O
Th17	O
>	O
Th1	O
>	O
Th2	O
.	O

While	O
transgenic	O
expression	O
of	O
a	O
Th2	O
-	O
derived	O
,	O
'	O
elongated	O
'	O
TCR	B
-	O
CDR3α	B
and	O
the	O
TCRαβ	B
pair	O
,	O
clearly	O
generated	O
a	O
program	O
shifted	O
away	O
from	O
Th1	O
immunity	O
and	O
with	O
low	O
binding	O
avidity	O
,	O
cytokine	B
-	O
skewing	O
could	O
be	O
over	O
-	O
ridden	O
by	O
altering	O
peptide	O
challenge	O
dose	O
.	O

CONCLUSION	O
:	O
We	O
propose	O
that	O
selection	O
from	O
responding	O
clones	O
with	O
distinctive	O
TCR	B
s	I
on	O
the	O
basis	O
of	O
functional	O
avidity	O
can	O
direct	O
a	O
preference	O
away	O
from	O
Th1	O
effector	O
responses	O
,	O
favoring	O
Th2	O
cytokines	O
.	O

Seed	O
dormancy	O
cycling	O
in	O
Arabidopsis	O
:	O
chromatin	O
remodelling	O
and	O
regulation	O
of	O
DOG1	B
in	O
response	O
to	O
seasonal	O
environmental	O
signals	O
.	O

The	O
involvement	O
of	O
chromatin	O
remodelling	O
in	O
dormancy	O
cycling	O
in	O
the	O
soil	O
seed	O
bank	O
(	O
SSB	O
)	O
is	O
poorly	O
understood	O
.	O

Natural	O
variation	O
between	O
the	O
winter	O
and	O
summer	O
annual	O
Arabidopsis	O
ecotypes	O
Cvi	O
and	O
Bur	O
was	O
exploited	O
to	O
investigate	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
chromatin	O
remodelling	O
via	O
histone	B
2B	I
(	O
H2B	B
)	O
ubiquitination	O
/	O
de	O
-	O
ubiquitination	O
and	O
histone	O
acetylation	O
/	O
deacetylation	O
,	O
the	O
repressive	O
histone	B
methyl	I
transferases	I
CURLY	B
LEAF	I
(	O
CLF	B
)	O
and	O
SWINGER	B
(	O
SWN	B
)	O
,	O
and	O
the	O
gene	O
silencing	O
repressor	O
ROS1	B
(	O
REPRESSOR	B
OF	I
SILENCING1	I
)	O
and	O
promoter	O
of	O
silencing	O
KYP	B
/	O
SUVH4	B
(	O
KRYPTONITE	B
)	O
,	O
during	O
dormancy	O
cycling	O
in	O
the	O
SSB	O
.	O

ROS1	B
expression	O
was	O
positively	O
correlated	O
with	O
dormancy	O
while	O
the	O
reverse	O
was	O
observed	O
for	O
CLF	B
and	O
KYP	B
/	O
SUVH4	B
.	O

We	O
propose	O
ROS1	B
dependent	O
repression	O
of	O
silencing	O
and	O
a	O
sequential	O
requirement	O
of	O
CLF	B
and	O
KYP	B
/	O
SUVH4	B
dependent	O
gene	O
repression	O
and	O
silencing	O
for	O
the	O
maintenance	O
and	O
suppression	O
of	O
dormancy	O
during	O
dormancy	O
cycling	O
.	O

Seasonal	O
expression	O
of	O
H2B	B
modifying	I
genes	I
was	O
correlated	O
negatively	O
with	O
temperature	O
and	O
positively	O
with	O
DOG1	B
expression	O
,	O
as	O
were	O
histone	B
acetyltransferase	I
genes	I
,	O
with	O
histone	B
deacetylases	I
positively	O
correlated	O
with	O
temperature	O
.	O

Changes	O
in	O
the	O
histone	B
marks	O
H3	B
K4me3	I
and	O
H3	B
K27me3	I
were	O
seen	O
on	O
DOG1	B
(	O
DELAY	B
OF	I
GERMINATION1	I
)	O
in	O
Cvi	O
during	O
dormancy	O
cycling	O
.	O

H3	B
K4me3	O
activating	O
marks	O
remained	O
stable	O
along	O
DOG1	B
.	O

During	O
relief	O
of	O
dormancy	O
,	O
H3	B
K27me3	O
repressive	O
marks	O
slowly	O
accumulated	O
and	O
accelerated	O
on	O
exposure	O
to	O
light	O
completing	O
dormancy	O
loss	O
.	O

We	O
propose	O
that	O
these	O
marks	O
on	O
DOG1	B
serve	O
as	O
a	O
thermal	O
sensing	O
mechanism	O
during	O
dormancy	O
cycling	O
in	O
preparation	O
for	O
light	O
repression	O
of	O
dormancy	O
.	O

Overall	O
,	O
chromatin	O
remodelling	O
plays	O
a	O
vital	O
role	O
in	O
temporal	O
sensing	O
through	O
regulation	O
of	O
gene	O
expression	O
.	O

AF10	B
regulates	O
progressive	O
H3	B
K79	O
methylation	O
and	O
HOX	B
gene	I
expression	O
in	O
diverse	O
AML	O
subtypes	O
.	O

Homeotic	B
(	O
HOX	B
)	O
ge	O
HOX	B
<	O
/	O
mark	O
>	O
are	O
dysregulated	O
in	O
multiple	O
malignancies	O
,	O
including	O
several	O
AML	O
subtypes	O
.	O

We	O
demonstrate	O
that	O
H3	B
K79	I
dimethylation	O
(	O
H3	B
K79me2	I
)	O
is	O
converted	O
to	O
monomethylation	O
(	O
H3	B
K79me1	I
)	O
at	O
HOX	B
loci	I
as	O
hematopoietic	O
cells	O
mature	O
,	O
thus	O
coinciding	O
with	O
a	O
decrease	O
in	O
HOX	B
gene	I
expression	O
.	O

We	O
show	O
that	O
H3	B
K79	O
methyltransferase	O
activity	O
as	O
well	O
as	O
H3	B
K79me1	O
-	O
to	O
-	O
H3	B
K79me2	O
conversion	O
is	O
regulated	O
by	O
the	O
DOT1L	B
cofactor	I
AF10	I
.	O

AF10	B
inactivation	O
reverses	O
leukemia	O
-	O
associated	O
epigenetic	O
profiles	O
,	O
precludes	O
abnormal	O
HOXA	B
gene	I
expression	O
,	O
and	O
impairs	O
the	O
transforming	O
ability	O
of	O
MLL	B
-	O
AF9	B
,	O
MLL	B
-	O
AF6	B
,	O
and	O
NUP98	B
-	O
NSD1	B
fusions	O
-	O
mechanistically	O
distinct	O
HOX	B
-	I
activating	I
oncogenes	I
.	O

Furthermore	O
,	O
NUP98	B
-	O
NSD1	B
-	O
transformed	O
cells	O
are	O
sensitive	O
to	O
small	O
-	O
molecule	O
inhibition	O
of	O
DOT1L	B
.	O

Our	O
findings	O
demonstrate	O
that	O
pharmacological	O
inhibition	O
of	O
the	O
DOT1L	B
/	O
AF10	B
complex	O
may	O
provide	O
therapeutic	O
benefits	O
in	O
an	O
array	O
of	O
malignancies	O
with	O
abnormal	O
HOXA	B
gene	O
expression	O
.	O

Mesenchymal	O
stem	O
cells	O
promote	O
liver	O
regeneration	O
and	O
prolong	O
survival	O
in	O
small	O
-	O
for	O
-	O
size	O
liver	O
grafts	O
:	O
involvement	O
of	O
C	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
cyclin	B
D1	I
,	O
and	O
NF	B
-	I
kappaB	I
.	O

BACKGROUND	O
:	O
The	O
therapeutic	O
potential	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
has	O
been	O
highlighted	O
recently	O
for	O
treatment	O
of	O
acute	O
or	O
chronic	O
liver	O
injury	O
,	O
by	O
possibly	O
differentiating	O
into	O
hepatocyte	O
-	O
like	O
cells	O
,	O
reducing	O
inflammation	O
,	O
and	O
enhancing	O
tissue	O
repair	O
.	O

Despite	O
recent	O
progress	O
,	O
exact	O
mechanisms	O
of	O
action	O
are	O
not	O
clearly	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
we	O
attempted	O
to	O
explore	O
whether	O
and	O
how	O
MSCs	O
protected	O
hepatocytes	O
and	O
stimulated	O
allograft	O
regeneration	O
in	O
small	O
-	O
for	O
-	O
size	O
liver	O
transplantation	O
(	O
SFSLT	O
)	O
.	O

METHODS	O
:	O
SFSLT	O
model	O
was	O
established	O
with	O
a	O
30	O
%	O
partial	O
liver	O
transplantation	O
(	O
30PLT	O
)	O
in	O
rats	O
.	O

The	O
differentiation	O
potential	O
and	O
characteristics	O
of	O
bone	O
marrow	O
derived	O
MSCs	O
were	O
explored	O
in	O
vitro	O
.	O

MSCs	O
were	O
infused	O
transvenously	O
immediately	O
after	O
graft	O
implantation	O
in	O
therapy	O
group	O
.	O

Expressions	O
of	O
apoptosis	O
-	O
,	O
inflammatory	O
-	O
,	O
anti	O
-	O
inflammatory	O
-	O
,	O
and	O
growth	O
factor	O
-	O
related	O
genes	O
were	O
measured	O
by	O
RT	O
-	O
PCR	O
,	O
activities	O
of	O
transcription	O
factors	O
AP	B
-	I
1	I
and	O
NF	B
-	I
kappaB	I
were	O
analyzed	O
by	O
EMSA	O
,	O
and	O
proliferative	O
responses	O
of	O
the	O
hepatic	O
graft	O
were	O
evaluated	O
by	O
immunohistochemistry	O
and	O
western	O
blot	O
.	O

RESULTS	O
:	O
MSCs	O
were	O
successfully	O
induced	O
into	O
hepatocyte	O
-	O
like	O
cells	O
,	O
osteoblasts	O
and	O
adipocytes	O
in	O
vitro	O
.	O

MSCs	O
therapy	O
could	O
not	O
only	O
alleviate	O
ischemia	O
reperfusion	O
injury	O
and	O
acute	O
inflammation	O
to	O
promote	O
liver	O
regeneration	O
,	O
but	O
also	O
profoundly	O
improve	O
one	O
week	O
survival	O
rate	O
.	O

It	O
markedly	O
up	O
-	O
regulated	O
the	O
mRNA	O
expressions	O
of	O
HGF	B
,	O
Bcl	B
-	I
2	I
,	O
Bcl	B
-	I
XL	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
10	I
,	O
IP	B
-	I
10	I
,	O
and	O
CXCR2	B
,	O
however	O
,	O
down	O
-	O
regulated	O
TNF	B
-	I
alpha	I
.	O

Increased	O
activities	O
of	O
AP	B
-	I
1	I
and	O
NF	B
-	I
kappaB	I
,	O
as	O
well	O
as	O
elevated	O
expressions	O
of	O
p	B
-	I
c	I
-	I
Jun	I
,	O
cyclin	B
D1	I
,	O
and	O
proliferating	B
cell	I
nuclear	I
antigen	I
(	O
PCNA	B
)	O
,	O
were	O
also	O
found	O
in	O
MSCs	O
therapy	O
group	O
.	O

CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
MSCs	O
therapy	O
promotes	O
hepatocyte	O
proliferation	O
and	O
prolongs	O
survival	O
in	O
SFSLT	O
by	O
reducing	O
ischemia	O
reperfusion	O
injury	O
and	O
acute	O
inflammation	O
,	O
and	O
sustaining	O
early	O
increased	O
expressions	O
of	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
Kinase	I
,	O
Cyclin	B
D1	I
,	O
and	O
NF	B
-	I
kappaB	I
.	O

Multipotent	O
caudal	O
neural	O
progenitors	O
derived	O
from	O
human	O
pluripotent	O
stem	O
cells	O
that	O
give	O
rise	O
to	O
lineages	O
of	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

The	O
caudal	O
neural	O
plate	O
is	O
a	O
distinct	O
region	O
of	O
the	O
embryo	O
that	O
gives	O
rise	O
to	O
major	O
progenitor	O
lineages	O
of	O
the	O
developing	O
central	O
and	O
peripheral	O
nervous	O
system	O
,	O
including	O
neural	O
crest	O
and	O
floor	O
plate	O
cells	O
.	O

We	O
show	O
that	O
dual	O
inhibition	O
of	O
the	O
glycogen	B
synthase	I
kinase	I
3β	I
and	O
activin	B
/	O
nodal	B
pathways	O
by	O
small	O
molecules	O
differentiate	O
human	O
pluripotent	O
stem	O
cells	O
(	O
hPSCs	O
)	O
directly	O
into	O
a	O
preneuroepithelial	O
progenitor	O
population	O
we	O
named	O
"	O
caudal	O
neural	O
progenitors	O
"	O
(	O
CNPs	O
)	O
.	O

CNPs	O
coexpress	O
caudal	O
neural	O
plate	O
and	O
mesoderm	O
markers	O
,	O
and	O
,	O
share	O
high	O
similarities	O
to	O
embryonic	O
caudal	O
neural	O
plate	O
cells	O
in	O
their	O
lineage	O
differentiation	O
potential	O
.	O

Exposure	O
of	O
CNPs	O
to	O
BMP2	B
/	I
4	I
,	O
sonic	B
hedgehog	I
,	O
or	O
FGF2	B
signaling	O
efficiently	O
directs	O
their	O
fate	O
to	O
neural	O
crest	O
/	O
roof	O
plate	O
cells	O
,	O
floor	O
plate	O
cells	O
,	O
and	O
caudally	O
specified	O
neuroepithelial	O
cells	O
,	O
respectively	O
.	O

Neural	O
crest	O
derived	O
from	O
CNPs	O
differentiated	O
to	O
neural	O
crest	O
derivatives	O
and	O
demonstrated	O
extensive	O
migratory	O
properties	O
in	O
vivo	O
.	O

Importantly	O
,	O
we	O
also	O
determined	O
the	O
key	O
extrinsic	O
factors	O
specifying	O
CNPs	O
from	O
human	O
embryonic	O
stem	O
cell	O
include	O
FGF8	B
,	O
canonical	O
WNT	B
,	O
and	O
IGF1	B
.	O

Our	O
studies	O
are	O
the	O
first	O
to	O
identify	O
a	O
multipotent	O
neural	O
progenitor	O
derived	O
from	O
hPSCs	O
,	O
that	O
is	O
the	O
precursor	O
for	O
major	O
neural	O
lineages	O
of	O
the	O
embryonic	O
caudal	O
neural	O
tube	O
.	O

Extracellular	B
superoxide	I
dismutase	I
regulates	O
the	O
expression	O
of	O
small	B
gtpase	I
regulatory	I
proteins	I
GEFs	B
,	O
GAPs	B
,	O
and	O
GDI	B
.	O

Extracellular	B
superoxide	I
dismutase	I
(	O
SOD3	B
)	O
,	O
which	O
catalyzes	O
the	O
dismutation	O
of	O
superoxide	O
anions	O
to	O
hydrogen	O
peroxide	O
at	O
the	O
cell	O
membranes	O
,	O
regulates	O
the	O
cellular	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

This	O
enzyme	O
induces	O
primary	O
cell	O
proliferation	O
and	O
immortalization	O
at	O
low	O
expression	O
levels	O
whereas	O
it	O
activates	O
cancer	O
barrier	O
signaling	O
through	O
the	O
p53	B
-	O
p21	B
pathway	O
at	O
high	O
expression	O
levels	O
,	O
causing	O
growth	O
arrest	O
,	O
senescence	O
,	O
and	O
apoptosis	O
.	O

Because	O
previous	O
reports	O
suggested	O
that	O
the	O
SOD3	B
-	O
induced	O
reduction	O
in	O
the	O
rates	O
of	O
cellular	O
growth	O
and	O
migration	O
also	O
occurred	O
in	O
the	O
absence	O
of	O
functional	O
p53	B
signaling	O
,	O
in	O
the	O
current	O
study	O
we	O
investigated	O
the	O
SOD3	B
-	O
induced	O
growth	O
-	O
suppressive	O
mechanisms	O
in	O
anaplastic	O
thyroid	O
cancer	O
cells	O
.	O

Based	O
on	O
our	O
data	O
,	O
the	O
robust	O
over	O
-	O
expression	O
of	O
SOD3	B
increased	O
the	O
level	O
of	O
phosphorylation	O
of	O
the	O
EGFR	B
,	O
ERBB2	B
,	O
RYK	B
,	O
ALK	B
,	O
FLT3	B
,	O
and	O
EPHA10	B
receptor	O
tyrosine	B
kinases	I
with	O
the	O
consequent	O
downstream	O
activation	O
of	O
the	O
SRC	B
,	O
FYN	B
,	O
YES	B
,	O
HCK	B
,	O
and	O
LYN	B
kinases	I
.	O

However	O
,	O
pull	O
-	O
down	O
experiments	O
focusing	O
on	O
the	O
small	B
GTPase	I
RAS	I
,	O
RAC	B
,	O
CDC42	B
,	O
and	O
RHO	B
revealed	O
a	O
reduced	O
level	O
of	O
growth	O
and	O
migration	O
signal	O
transduction	O
,	O
such	O
as	O
the	O
lack	O
of	O
stimulation	O
of	O
the	O
mitogen	O
pathway	O
,	O
in	O
the	O
SOD3	B
over	O
-	O
expressing	O
cells	O
,	O
which	O
was	O
confirmed	O
by	O
MEK1	B
/	I
2	I
and	O
ERK1	B
/	I
2	I
Western	O
blotting	O
analysis	O
.	O

Interestingly	O
,	O
the	O
mRNA	O
expression	O
analyses	O
indicated	O
that	O
SOD3	B
regulated	O
the	O
expression	O
of	O
guanine	B
nucleotide	I
-	I
exchange	I
factors	I
(	O
RHO	B
GEF16	I
,	O
RAL	B
GEF	I
RGL1	I
)	O
,	O
GTPase	B
-	I
activating	I
proteins	I
(	O
ARFGAP	B
ADAP2	I
,	O
RAS	B
GAP	I
RASAL1	I
,	O
RGS4	B
)	O
,	O
and	O
a	O
Rho	B
guanine	I
nucleotide	I
-	I
disassociation	I
inhibitor	I
(	O
RHO	B
GDI	I
2	I
)	O
in	O
a	O
dose	O
dependent	O
manner	O
,	O
thus	O
controlling	O
signaling	O
through	O
the	O
small	B
G	I
protein	I
GTPases	I
.	O

Therefore	O
,	O
our	O
current	O
data	O
may	O
suggest	O
the	O
occurrence	O
of	O
dose	O
-	O
dependent	O
SOD3	B
-	O
driven	O
control	O
of	O
the	O
GTP	O
loading	O
of	O
small	B
G	I
proteins	I
indicating	O
a	O
novel	O
growth	O
regulatory	O
mechanism	O
of	O
this	O
enzyme	O
.	O

Regulation	O
of	O
IL	B
-	I
17A	I
responses	O
in	O
human	O
airway	O
smooth	O
muscle	O
cells	O
by	O
Oncostatin	B
M	I
.	O

BACKGROUND	O
:	O
Regulation	O
of	O
human	O
airway	O
smooth	O
muscle	O
cells	O
(	O
HASMC	O
)	O
by	O
cytokines	O
contributes	O
to	O
chemotactic	O
factor	O
levels	O
and	O
thus	O
to	O
inflammatory	O
cell	O
accumulation	O
in	O
lung	O
diseases	O
.	O

Cytokines	O
such	O
as	O
the	O
gp130	B
family	I
member	I
Oncostatin	I
M	I
(	O
OSM	B
)	O
can	O
act	O
synergistically	O
with	O
Th2	O
cytokin	O
cytokines	O
(	O
IL	B
-	I
4	I
and	O
IL	B
-	I
13	I
)	O
to	O
modulate	O
lung	O
cells	O
,	O
however	O
whether	O
IL	B
-	I
17A	I
responses	O
by	O
HASMC	O
can	O
be	O
altered	O
is	O
not	O
known	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
recombinant	B
OSM	I
,	O
or	O
other	O
gp130	B
c	I
gp130	I
n	I
cytokines	I
(	O
LIF	B
,	O
IL	B
-	I
31	I
,	O
and	O
IL	B
-	I
6	I
)	O
in	O
regulating	O
HASMC	O
responses	O
to	O
IL	B
-	I
17A	I
,	O
assessing	O
MCP	B
-	I
1	I
/	O
C	B
MCP	I
-	I
1	I
m	O
CCL2	B
and	O
IL	B
-	I
6	I
expression	O
and	O
cell	O
signaling	O
pathways	O
.	O

METHODS	O
:	O
Cell	O
responses	O
of	O
primary	O
HASMC	O
cultures	O
were	O
measured	O
by	O
the	O
assessment	O
of	O
protein	O
levels	O
in	O
supernatants	O
(	O
ELISA	O
)	O
and	O
mRNA	O
levels	O
(	O
qRT	O
-	O
PCR	O
)	O
in	O
cell	O
extracts	O
.	O

Activation	O
of	O
STAT	B
,	O
MAPK	B
<	I
/	I
m	I
MAPK	B
(	I
p38	I
)	I
<	I
/	I
m	I
p38	B
>	I
and	I
Akt	B
pathways	I
were	I
measured	I
by	I
immunoblot	I
.	I

Pharmacological	O
agents	O
were	O
used	O
to	O
assess	O
the	O
effects	O
of	O
inhibition	O
of	O
these	O
pathways	O
.	O

RESULTS	O
:	O
OSM	B
but	O
not	O
LIF	B
,	O
IL	B
-	I
31	I
or	O
IL	B
-	I
6	I
could	O
induce	O
detectable	O
responses	O
in	O
HASMC	O
,	O
elevating	O
MCP	B
-	I
1	I
/	I
C	I
MCP	B
-	I
1	I
m	O
CCL2	B
,	O
IL	B
-	I
6	I
levels	O
and	O
activation	O
of	O
STAT	B
-	I
1	I
,	I
3	I
,	I
5	I
,	O
p38	B
and	O
Akt	B
cell	O
signaling	O
pathways	O
.	O

OSM	B
induced	O
synergistic	O
action	O
with	O
IL	B
-	I
17A	I
enhancing	O
MCP	B
-	I
1	I
/	O
CCL	B
-	I
2	I
and	O
IL	B
-	I
6	I
mRNA	I
and	O
protein	O
expression	O
,	O
but	O
not	O
eotaxin	B
-	I
1	I
expression	O
,	O
while	O
OSM	B
in	O
combination	O
with	O
IL	B
-	I
4	I
or	O
IL	B
-	I
13	I
synergistically	O
induced	O
eotaxin	B
-	I
1	I
and	O
MCP	B
-	I
1	I
/	O
CCL2	B
.	O

OSM	B
elevated	O
steady	O
state	O
mRNA	O
levels	O
of	O
IL	B
-	I
4Rα	I
,	O
OSMRβ	B
and	O
gp130	B
,	O
but	O
not	O
IL	B
-	I
17RA	I
or	O
IL	B
-	I
17RC	I
.	O

Pharmacologic	O
inhibition	O
of	O
STAT3	B
activation	O
using	O
Stattic	O
down	O
-	O
regulated	O
OSM	B
,	O
OSM	B
/	O
IL	B
-	I
4	I
or	O
OSM	B
/	O
IL	B
-	I
13	I
,	O
and	O
OSM	B
/	O
IL	B
-	I
17A	I
synergistic	O
responses	O
of	O
MCP	B
-	I
1	I
/	O
CCL	B
-	I
2	I
induction	O
,	O
whereas	O
,	O
inhibitors	O
of	O
Akt	B
and	O
p38	B
MAPK	I
resulted	O
in	O
less	O
reduction	O
in	O
MCP	B
-	I
1	I
/	O
CCL2	B
levels	O
.	O

IL	B
-	I
6	I
expression	O
was	O
more	O
sensitive	O
to	O
inhibition	O
of	O
p38	B
(	O
using	O
SB203580	O
)	O
and	O
was	O
affected	O
by	O
Stattic	O
in	O
response	O
to	O
IL	B
-	I
17A	I
/	O
OSM	B
stimulation	O
.	O

CONCLUSIONS	O
:	O
Oncostatin	B
M	I
can	O
regulate	O
HASMC	O
responses	O
alone	O
or	O
in	O
synergy	O
with	O
IL	B
-	I
17A	I
.	O

OSM	B
/	O
IL	B
-	I
17A	I
combinations	O
enhance	O
MCP	B
-	I
1	I
/	O
CCL2	B
and	O
IL	B
-	I
6	I
but	O
not	O
eotaxin	B
-	I
1	I
.	O

Thus	O
,	O
OSM	B
through	O
STAT3	B
activation	O
of	O
HASMC	O
may	O
participate	O
in	O
inflammatory	O
cell	O
recruitment	O
in	O
inflammatory	O
airway	O
disease	O
.	O

ING5	B
suppresses	O
proliferation	O
,	O
apoptosis	O
,	O
migration	O
and	O
invasion	O
,	O
and	O
induces	O
autophagy	O
and	O
differentiation	O
of	O
gastric	O
cancer	O
cells	O
:	O
a	O
good	O
marker	O
for	O
carcinogenesis	O
and	O
subsequent	O
progression	O
.	O

Here	O
,	O
we	O
found	O
that	O
ING5	B
overexpression	O
increased	O
autophagy	O
,	O
differentiation	O
,	O
and	O
decreased	O
proliferation	O
,	O
apoptosis	O
,	O
migration	O
,	O
invasion	O
and	O
lamellipodia	O
formation	O
in	O
gastric	O
cancer	O
cells	O
,	O
while	O
ING5	B
knockdown	O
had	O
the	O
opposite	O
effects	O
.	O

In	O
SGC	O
-	O
7901	O
transfectants	O
,	O
ING5	B
overexpression	O
caused	O
G1	O
arrest	O
,	O
which	O
was	O
positively	O
associated	O
with	O
14	B
-	I
3	I
-	I
3	I
overexpression	O
,	O
Cdk4	B
and	O
c	B
-	I
jun	I
hypoexpression	O
.	O

The	O
induction	O
of	O
Bax	B
hypoexpression	O
,	O
Bcl	B
-	I
2	I
,	O
survivin	B
,	O
14	B
-	I
3	I
-	I
3	I
,	O
PI3K	B
,	O
p	B
-	I
Akt	I
and	O
p70S6K	B
overexpression	O
by	O
ING5	B
decreased	O
apoptosis	O
in	O
SGC	O
-	O
7901	O
cells	O
.	O

The	O
hypoexpression	O
of	O
MMP	B
-	I
9	I
,	O
MAP1B	B
and	O
flotillin	B
2	I
contributed	O
to	O
the	O
inhibitory	O
effects	O
of	O
ING5	B
on	O
migration	O
and	O
invasion	O
of	O
SGC	O
-	O
7901	O
cells	O
.	O

ING5	B
overexpression	O
might	O
activate	O
both	O
beta	B
-	I
catenin	I
and	O
NF	B
-	I
kappaB	I
pathways	O
in	O
SGC	O
-	O
7901	O
cells	O
,	O
and	O
promote	O
the	O
expression	O
of	O
down	O
-	O
stream	O
genes	O
(	O
c	B
-	I
myc	I
,	O
VEGF	B
,	O
Cyclin	B
D1	I
,	O
survivin	B
,	O
and	O
interleukins	B
)	O
.	O

Compared	O
with	O
the	O
control	O
,	O
ING5	B
transfectants	O
displayed	O
drug	O
resistance	O
to	O
triciribine	O
,	O
paclitaxel	O
,	O
cisplatin	O
,	O
SAHA	O
,	O
MG132	O
and	O
parthenolide	O
,	O
which	O
was	O
positively	O
related	O
to	O
their	O
apoptotic	O
induction	O
and	O
the	O
overexpression	O
of	O
chemoresistance	O
-	O
related	O
genes	O
(	O
MDR1	B
,	O
GRP78	B
,	O
GRP94	B
,	O
IRE	B
,	O
CD147	B
,	O
FBXW7	B
,	O
TOP1	B
,	O
TOP2	B
,	O
MLH1	B
,	O
MRP1	B
,	O
BRCP1	B
and	O
GST	B
-	I
pi	I
)	O
.	O

ING5	B
expression	O
was	O
higher	O
in	O
gastric	O
cancer	O
than	O
matched	O
mucosa	O
.	O

It	O
was	O
inversely	O
associated	O
with	O
tumor	O
size	O
,	O
dedifferentiation	O
,	O
lymph	O
node	O
metastasis	O
and	O
clinicopathological	O
staging	O
of	O
cancer	O
.	O

ING5	B
overexpression	O
suppressed	O
growth	O
,	O
blood	O
supply	O
and	O
lung	O
metastasis	O
of	O
SGC	O
-	O
7901	O
cells	O
by	O
inhibiting	O
proliferation	O
,	O
enhancing	O
autophagy	O
and	O
apoptosis	O
in	O
xenograft	O
models	O
.	O

It	O
was	O
suggested	O
that	O
ING5	B
expression	O
might	O
be	O
employed	O
as	O
a	O
good	O
marker	O
for	O
gastric	O
carcinogenesis	O
and	O
subsequent	O
progression	O
by	O
inhibiting	O
proliferation	O
,	O
growth	O
,	O
migration	O
,	O
invasion	O
and	O
metastasis	O
.	O

ING5	B
might	O
induce	O
apoptotic	O
and	O
chemotherapeutic	O
resistances	O
of	O
gastric	O
cancer	O
cells	O
by	O
activating	O
beta	B
-	I
catenin	I
,	O
NF	B
-	I
kappaB	I
and	O
Akt	B
pathways	O
.	O

Protein	O
-	O
Trap	O
Insertional	O
Mutagenesis	O
Uncovers	O
New	O
Genes	O
Involved	O
in	O
Zebrafish	O
Skin	O
Development	O
,	O
Including	O
a	O
Neuregulin	B
2a	I
-	O
Based	O
ErbB	B
Signaling	O
Pathway	O
Required	O
during	O
Median	O
Fin	O
Fold	O
Morphogenesis	O
.	O

Skin	O
disorders	O
are	O
widespread	O
,	O
but	O
available	O
treatments	O
are	O
limited	O
.	O

A	O
more	O
comprehensive	O
understanding	O
of	O
skin	O
development	O
mechanisms	O
will	O
drive	O
identification	O
of	O
new	O
treatment	O
targets	O
and	O
modalities	O
.	O

Here	O
we	O
report	O
the	O
Zebrafish	O
Integument	O
Project	O
(	O
ZIP	O
)	O
,	O
an	O
expression	O
-	O
driven	O
platform	O
for	O
identifying	O
new	O
skin	O
genes	O
and	O
phenotypes	O
in	O
the	O
vertebrate	O
model	O
Danio	O
rerio	O
(	O
zebrafish	O
)	O
.	O

In	O
vivo	O
selection	O
for	O
skin	O
-	O
specific	O
expression	O
of	O
gene	O
-	O
break	O
transposon	O
(	O
GBT	O
)	O
mutant	O
lines	O
identified	O
eleven	O
new	O
,	O
revertible	O
GBT	O
alleles	O
of	O
genes	O
involved	O
in	O
skin	O
development	O
.	O

Eight	O
genes	O
-	O
-	O
fras1	B
,	O
grip1	B
,	O
hmcn1	B
,	O
msxc	B
,	O
col4a4	B
,	O
ahnak	B
,	O
capn12	B
,	O
and	O
nrg2a	B
-	O
-	O
had	O
been	O
described	O
in	O
an	O
integumentary	O
context	O
to	O
varying	O
degrees	O
,	O
while	O
arhgef25b	B
,	O
fkbp10b	B
,	O
and	O
megf6a	B
emerged	O
as	O
novel	O
skin	O
genes	O
.	O

Embryos	O
homozygous	O
for	O
a	O
GBT	B
insertion	O
within	O
neuregulin	B
2a	I
(	O
nrg2a	B
)	O
revealed	O
a	O
novel	O
requirement	O
for	O
a	O
Neuregulin	B
2a	I
(	O
Nrg2a	B
)	O
-	O
ErbB2	B
/	O
3	O
-	O
AKT	B
signaling	O
pathway	O
governing	O
the	O
apicobasal	O
organization	O
of	O
a	O
subset	O
of	O
epidermal	O
cells	O
during	O
median	O
fin	O
fold	O
(	O
MFF	O
)	O
morphogenesis	O
.	O

In	O
nrg2a	B
mutant	I
larvae	I
,	O
the	O
basal	O
keratinocytes	O
within	O
the	O
apical	O
MFF	O
,	O
known	O
as	O
ridge	O
cells	O
,	O
displayed	O
reduced	O
p	B
AKT	I
levels	O
as	O
well	O
as	O
reduced	O
apical	O
domains	O
and	O
exaggerated	O
basolateral	O
domains	O
.	O

Those	O
defects	O
compromised	O
proper	O
ridge	O
cell	O
elongation	O
into	O
a	O
flattened	O
epithelial	O
morphology	O
,	O
resulting	O
in	O
thickened	O
MFF	O
edges	O
.	O

Pharmacological	O
inhibition	O
verified	O
that	O
Nrg2a	B
signals	O
through	O
the	O
ErbB	B
receptor	I
tyrosine	I
kinase	I
network	I
.	O

Moreover	O
,	O
knockdown	O
of	O
the	O
epithelial	O
polarity	O
regulator	O
and	O
tumor	B
suppressor	I
lgl2	I
ameliorated	O
the	O
nrg2a	B
mutant	I
phenotype	I
.	O

Identifying	O
Lgl2	B
as	O
an	O
antagonist	O
of	O
Nrg2a	B
-	O
ErbB	B
signaling	O
revealed	O
a	O
significantly	O
earlier	O
role	O
for	O
Lgl2	B
during	O
epidermal	O
morphogenesis	O
than	O
has	O
been	O
described	O
to	O
date	O
.	O

Furthermore	O
,	O
our	O
findings	O
demonstrated	O
that	O
successive	O
,	O
coordinated	O
ridge	O
cell	O
shape	O
changes	O
drive	O
apical	O
MFF	O
development	O
,	O
making	O
MFF	O
ridge	O
cells	O
a	O
valuable	O
model	O
for	O
investigating	O
how	O
the	O
coordinated	O
regulation	O
of	O
cell	O
polarity	O
and	O
cell	O
shape	O
changes	O
serves	O
as	O
a	O
crucial	O
mechanism	O
of	O
epithelial	O
morphogenesis	O
.	O

A	O
Transcriptome	O
-	O
Led	O
Exploration	O
of	O
Molecular	O
Mechanisms	O
Regulating	O
Somatostatin	B
-	O
Producing	O
D	O
-	O
Cells	O
in	O
the	O
Gastric	O
Epithelium	O
.	O

The	O
stomach	O
epithelium	O
contains	O
a	O
myriad	O
of	O
enteroendocrine	O
cells	O
that	O
modulate	O
a	O
range	O
of	O
physiological	O
functions	O
,	O
including	O
postprandial	O
secretion	O
of	O
regulatory	O
peptides	O
,	O
gastric	O
motility	O
,	O
and	O
nutrient	O
absorption	O
.	O

Somatostatin	B
(	O
SST	B
)	O
-	O
producing	O
D	O
-	O
cells	O
are	O
present	O
in	O
the	O
oxyntic	O
and	O
pyloric	O
regions	O
of	O
the	O
stomach	O
,	O
and	O
provide	O
a	O
tonic	O
inhibitory	O
tone	O
that	O
regulates	O
activity	O
of	O
neighboring	O
enteroendocrine	O
cells	O
and	O
gastric	O
acid	O
secretion	O
.	O

Cellular	O
mechanisms	O
underlying	O
the	O
effects	O
of	O
regulatory	O
factors	O
on	O
gastric	O
D	O
-	O
cells	O
are	O
poorly	O
defined	O
due	O
to	O
problems	O
in	O
identifying	O
primary	O
D	O
-	O
cells	O
,	O
and	O
uncertainty	O
remains	O
about	O
which	O
stimuli	O
influence	O
D	O
-	O
cells	O
directly	O
.	O

In	O
this	O
study	O
,	O
we	O
introduce	O
a	O
transgenic	O
mouse	O
line	O
,	O
SST	B
-	O
Cre	O
,	O
which	O
upon	O
crossing	O
with	O
Cre	O
reporter	O
strains	O
,	O
facilitates	O
the	O
identification	O
and	O
purification	O
of	O
gastric	O
D	O
-	O
cells	O
,	O
or	O
cell	O
-	O
specific	O
expression	O
of	O
genetically	O
encoded	O
calcium	O
indicators	O
.	O

Populations	O
of	O
D	O
-	O
cells	O
from	O
the	O
gastric	O
antrum	O
and	O
corpus	O
were	O
isolated	O
and	O
analyzed	O
by	O
RNA	O
sequencing	O
and	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
expression	O
of	O
hormones	O
,	O
hormone	O
receptors	O
,	O
neurotransmitter	O
receptors	O
,	O
and	O
nutrient	O
receptors	O
was	O
quantified	O
.	O

Pyy	B
,	O
Gipr	B
,	O
Chrm4	B
,	O
Calcrl	B
,	O
Taar1	B
,	O
and	O
Casr	B
were	O
identified	O
as	O
genes	O
that	O
are	O
highly	O
enriched	O
in	O
D	O
-	O
cells	O
compared	O
with	O
SST	B
-	O
negative	O
cells	O
.	O

Hormone	O
secretion	O
assays	O
performed	O
in	O
mixed	O
gastric	O
epithelial	O
cultures	O
confirmed	O
that	O
SST	B
secretion	O
is	O
regulated	O
by	O
incretin	O
hormones	O
,	O
cholecystokinin	B
,	O
acetylcholine	B
,	O
vasoactive	B
intestinal	I
polypeptide	I
,	O
calcitonin	B
gene	I
-	I
related	I
polypeptide	I
,	O
oligopetides	O
,	O
and	O
trace	O
amines	O
.	O

Cholecystokinin	B
and	O
oligopeptides	O
elicited	O
increases	O
in	O
intracellular	O
calcium	O
in	O
single	O
-	O
cell	O
imaging	O
experiments	O
performed	O
using	O
cultured	O
D	O
-	O
cells	O
.	O

Our	O
data	O
provide	O
the	O
first	O
transcriptomic	O
analysis	O
and	O
functional	O
characterization	O
of	O
gastric	O
D	O
-	O
cells	O
,	O
and	O
identify	O
regulatory	O
pathways	O
that	O
underlie	O
the	O
direct	O
detection	O
of	O
stimuli	O
by	O
this	O
cell	O
type	O
.	O

G	B
Protein	I
-	I
Coupled	I
Estrogen	I
Receptor	I
1	I
Mediates	O
Acute	O
Estrogen	O
-	O
Induced	O
Cardioprotection	O
via	O
MEK	B
/	O
ERK	B
/	O
GSK	B
-	I
3β	I
Pathway	O
after	O
Ischemia	O
/	O
Reperfusion	O
.	O

Three	O
types	O
of	O
estrogen	B
receptors	I
(	O
ER	B
)	O
exist	O
in	O
the	O
heart	O
,	O
Esr1	B
,	O
Esr2	B
and	O
the	O
G	B
protein	I
-	I
coupled	I
estrogen	I
receptor	I
1	I
,	O
Gper1	B
.	O

However	O
,	O
their	O
relative	O
importance	O
in	O
mediating	O
estrogen	O
protective	O
action	O
is	O
unknown	O
.	O

We	O
found	O
that	O
,	O
in	O
the	O
male	O
mouse	O
ventricle	O
,	O
Gper1	B
transcripts	I
are	O
three	O
-	O
and	O
seventeen	O
-	O
fold	O
more	O
abundant	O
than	O
Esr1	B
and	O
Esr2	B
mRNAs	I
,	O
respectively	O
.	O

Analysis	O
of	O
the	O
three	O
ER	O
knockouts	O
(	O
Esr1	B
-	O
/	O
-	O
,	O
Esr2	B
-	O
/	O
-	O
and	O
Gper1	B
-	O
/	O
-	O
)	O
showed	O
that	O
only	O
the	O
Gper1	B
-	O
/	O
-	O
hearts	O
lost	O
their	O
ability	O
to	O
be	O
protected	O
by	O
40	O
nM	O
estrogen	O
as	O
measured	O
by	O
heart	O
function	O
,	O
infarct	O
size	O
and	O
mitochondrial	O
Ca2	O
+	O
overload	O
,	O
an	O
index	O
of	O
mitochondrial	O
permeability	O
transition	O
pore	O
(	O
mPTP	O
)	O
activity	O
.	O

Analysis	O
of	O
Akt	B
,	O
ERK1	B
/	I
2	I
and	O
GSK	B
-	I
3β	I
salvage	O
kinases	O
uncovered	O
Akt	B
and	O
ERK1	B
/	I
2	I
transient	O
activation	O
by	O
estrogen	O
whose	O
phosphorylation	O
increased	O
during	O
the	O
first	O
5	O
min	O
of	O
non	O
-	O
ischemic	O
perfusion	O
.	O

All	O
these	O
increase	O
in	O
phosphorylation	O
effects	O
were	O
abrogated	O
in	O
Gper1	B
-	O
/	O
-	O
.	O

Inhibition	O
of	O
MEK1	B
/	I
2	I
/	O
ERK1	B
/	I
2	I
(	O
1	O
μM	O
U0126	O
)	O
and	O
PI	B
-	I
3K	I
/	O
Akt	B
(	O
10	O
μM	O
LY294002	O
)	O
signaling	O
showed	O
that	O
the	O
MEK1	B
/	I
2	I
/	O
ERK1	B
/	I
2	I
pathway	O
via	O
GSK	B
-	I
3β	I
exclusively	O
was	O
responsible	O
for	O
cardioprotection	O
as	O
an	O
addition	O
of	O
U0126	O
prevented	O
estrogen	O
-	O
induced	O
GSK	B
-	I
3β	I
increased	O
phosphorylation	O
,	O
resistance	O
to	O
mitochondrial	O
Ca2	O
+	O
-	O
overload	O
,	O
functional	O
recovery	O
and	O
protection	O
against	O
infarction	O
.	O

Further	O
,	O
inhibiting	O
PKC	B
translocation	O
(	O
1	O
μM	O
chelerythrin	O
-	O
chloride	O
)	O
abolished	O
estrogen	O
-	O
induced	O
cardioprotection	O
.	O

These	O
data	O
indicate	O
that	O
estrogen	O
-	O
Gper1	B
acute	O
coupling	O
plays	O
a	O
key	O
role	O
in	O
cardioprotection	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
male	O
mouse	O
via	O
a	O
cascade	O
involving	O
PKC	B
translocation	O
,	O
ERK1	B
/	I
2	I
/	O
GSK	B
-	I
3β	I
phosphorylation	O
leading	O
to	O
the	O
inhibition	O
of	O
the	O
mPTP	O
opening	O
.	O

Leptin	B
Matures	O
Aspects	O
of	O
Lung	O
Structure	O
and	O
Function	O
in	O
the	O
Ovine	O
Fetus	O
.	O

In	O
human	O
and	O
ovine	O
fetuses	O
,	O
glucocorticoids	O
stimulate	O
leptin	B
secretion	O
,	O
although	O
the	O
extent	O
to	O
which	O
leptin	B
mediates	O
the	O
maturational	O
effects	O
of	O
glucocorticoids	O
on	O
pulmonary	O
development	O
is	O
unclear	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
leptin	B
administration	O
on	O
indices	O
of	O
lung	O
structure	O
and	O
function	O
before	O
birth	O
.	O

Chronically	O
catheterized	O
singleton	O
sheep	O
fetuses	O
were	O
infused	O
iv	O
for	O
5	O
days	O
with	O
either	O
saline	O
or	O
recombinant	O
ovine	O
leptin	B
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
·	O
d	O
leptin	B
(	O
LEP	B
)	O
,	O
0	O
.	O
5	O
LEP	B
or	O
1	O
.	O
0	O
mg	O
/	O
kg	O
·	O
d	O
,	O
1	O
.	O
0	O
LEP	B
)	O
from	O
125	O
days	O
of	O
gestation	O
(	O
term	O
∼	O
145	O
d	O
)	O
.	O

Over	O
the	O
infusion	O
,	O
leptin	B
administration	O
increased	O
plasma	O
leptin	B
,	O
but	O
not	O
cortisol	O
,	O
concentrations	O
.	O

On	O
the	O
fifth	O
day	O
of	O
infusion	O
,	O
0	O
.	O
5	O
LEP	O
reduced	O
alveolar	O
wall	O
thickness	O
and	O
increased	O
the	O
volume	O
at	O
closing	O
pressure	O
of	O
the	O
pressure	O
-	O
volume	O
deflation	O
curve	O
,	O
interalveolar	O
septal	O
elastin	B
content	O
,	O
secondary	O
septal	O
crest	O
density	O
,	O
and	O
the	O
mRNA	O
abundance	O
of	O
the	O
leptin	B
receptor	I
(	O
Ob	B
-	I
R	I
)	O
and	O
surfactant	B
protein	I
(	I
SP	I
)	I
B	I
.	O

Neither	O
treatment	O
influenced	O
static	O
lung	O
compliance	O
,	O
maximal	O
lung	O
volume	O
at	O
40	O
cmH2O	O
,	O
lung	O
compartment	O
volumes	O
,	O
alveolar	O
surface	O
area	O
,	O
pulmonary	O
glycogen	O
,	O
protein	O
content	O
of	O
the	O
long	B
form	I
signaling	I
Ob	I
-	I
Rb	I
or	O
phosphorylated	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
-	I
3	I
,	O
or	O
mRNA	O
levels	O
of	O
SP	B
-	I
A	I
,	I
C	I
,	I
or	I
D	I
,	O
elastin	B
,	O
vascular	B
endothelial	I
growth	I
factor	I
-	I
A	I
,	O
the	O
vascular	B
endothelial	I
growth	I
factor	I
receptor	I
2	I
,	O
angiotensin	B
-	I
converting	I
enzyme	I
,	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
γ	I
,	O
or	O
parathyroid	B
hormone	I
-	I
related	I
peptide	I
.	O

Leptin	B
administration	O
in	O
the	O
ovine	O
fetus	O
during	O
late	O
gestation	O
promotes	O
aspects	O
of	O
lung	O
maturation	O
,	O
including	O
up	O
-	O
regulation	O
of	O
SP	B
-	I
B	I
.	O

Establishment	O
and	O
characterization	O
of	O
a	O
novel	O
MYC	B
/	O
BCL2	B
"	O
double	O
-	O
hit	O
"	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
cell	O
line	O
,	O
RC	O
.	O

BACKGROUND	O
:	O
Diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
the	O
most	O
common	O
type	O
of	O
lymphoid	O
malignancy	O
worldwide	O
.	O

Approximately	O
5	O
%	O
of	O
cases	O
of	O
DLBCL	O
are	O
so	O
-	O
called	O
double	O
-	O
hit	O
lymphomas	O
(	O
DHL	O
)	O
,	O
defined	O
by	O
a	O
chromosomal	O
translocation	O
or	O
rearrangement	O
involving	O
MYC	B
/	O
8q24	O
.	O
2	O
in	O
combination	O
with	O
another	O
recurrent	O
breakpoint	O
,	O
usually	O
BCL2	B
/	O
18q21	O
.	O
3	O
.	O

Patients	O
with	O
MYC	B
/	O
BCL2	B
DHL	O
are	O
resistant	O
to	O
standard	O
front	O
-	O
line	O
therapy	O
,	O
and	O
currently	O
,	O
there	O
is	O
no	O
consensus	O
for	O
a	O
therapeutic	O
strategy	O
to	O
treat	O
these	O
patients	O
.	O

Lack	O
of	O
clinically	O
relevant	O
or	O
validated	O
human	O
experimental	O
DHL	O
models	O
of	O
any	O
type	O
that	O
would	O
improve	O
our	O
understanding	O
of	O
the	O
biologic	O
basis	O
of	O
MYC	B
/	O
BCL2	B
DHL	O
pathophysiology	O
continues	O
to	O
hamper	O
identification	O
of	O
valid	O
therapeutic	O
targets	O
.	O

We	O
describe	O
a	O
unique	O
MYC	B
/	O
BCL2	B
DHL	O
cell	O
line	O
with	O
morphologic	O
features	O
of	O
DLBCL	O
that	O
we	O
have	O
established	O
,	O
designated	O
as	O
RC	O
.	O

METHODS	O
:	O
We	O
used	O
tissue	O
culture	O
techniques	O
to	O
establish	O
the	O
RC	O
cell	O
line	O
from	O
primary	O
DLBCL	O
cells	O
.	O

We	O
also	O
utilized	O
molecular	O
and	O
cellular	O
biological	O
techniques	O
including	O
flow	O
cytometry	O
,	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
DNA	O
fingerprinting	O
,	O
reverse	O
-	O
phase	O
protein	O
array	O
,	O
conventional	O
cytogenetics	O
,	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
to	O
characterize	O
the	O
RC	O
cell	O
line	O
.	O

NSG	O
-	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
were	O
utilized	O
as	O
a	O
model	O
for	O
xeno	O
-	O
transplantation	O
of	O
RC	O
cells	O
.	O

RESULTS	O
:	O
RC	O
cells	O
had	O
the	O
following	O
immunophenotype	O
:	O
positive	O
for	O
CD10	B
,	O
CD19	B
,	O
CD20	B
,	O
CD22	B
,	O
CD38	B
,	O
CD43	B
,	O
CD44	B
,	O
and	O
CD79b	B
and	O
negative	O
for	O
CD3	B
,	O
CD4	B
,	O
CD5	B
,	O
CD8	B
,	O
CD11c	B
,	O
CD14	B
,	O
CD30	B
,	O
CD56	B
,	O
and	O
CD200	B
,	O
which	O
was	O
identical	O
to	O
the	O
primary	O
tumor	O
cells	O
.	O

Conventional	O
cytogenetic	O
analysis	O
showed	O
a	O
t	O
(	O
2	O
;	O
8	O
)	O
(	O
p12	O
;	O
q24	O
.	O
2	O
)	O
and	O
t	O
(	O
14	O
;	O
18	O
)	O
(	O
q32	O
;	O
q21	O
.	O
3	O
)	O
,	O
corresponding	O
to	O
MYC	B
and	O
BCL2	B
gene	I
rearrangements	O
,	O
respectively	O
.	O

DNA	O
fingerprinting	O
authenticated	O
the	O
RC	O
cell	O
line	O
to	O
be	O
of	O
the	O
same	O
clone	O
as	O
the	O
primary	O
tumor	O
cells	O
.	O

In	O
addition	O
,	O
RC	O
cells	O
were	O
established	O
in	O
SCID	O
mice	O
as	O
an	O
in	O
vivo	O
model	O
for	O
translational	O
therapeutics	O
studies	O
.	O

Proteomic	O
analysis	O
showed	O
activation	O
of	O
the	O
mTOR	B
signaling	O
pathway	O
in	O
RC	O
cells	O
that	O
can	O
be	O
targeted	O
with	O
an	O
mTOR	B
inhibitor	O
.	O

CONCLUSION	O
:	O
The	O
data	O
presented	O
confirm	O
the	O
validity	O
of	O
the	O
RC	O
cell	O
line	O
as	O
a	O
representative	O
model	O
of	O
MYC	B
/	O
BCL2	B
DHL	O
that	O
will	O
be	O
useful	O
for	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
of	O
DHL	O
pathogenesis	O
and	O
therapeutics	O
.	O

The	O
mutational	O
landscape	O
of	O
cutaneous	O
T	O
cell	O
lymphoma	O
and	O
Sezary	O
syndrome	O
.	O

Sezary	O
syndrome	O
is	O
a	O
leukemic	O
and	O
aggressive	O
form	O
of	O
cutaneous	O
T	O
cell	O
lymphoma	O
(	O
CTCL	O
)	O
resulting	O
from	O
the	O
malignant	O
transformation	O
of	O
skin	O
-	O
homing	O
central	O
memory	O
CD4	B
(	I
+	I
)	I
T	I
cells	I
.	O

Here	O
we	O
performed	O
whole	O
-	O
exome	O
sequencing	O
of	O
tumor	O
-	O
normal	O
sample	O
pairs	O
from	O
25	O
patients	O
with	O
Sezary	O
syndrome	O
and	O
17	O
patients	O
with	O
other	O
CTCLs	O
.	O

These	O
analyses	O
identified	O
a	O
distinctive	O
pattern	O
of	O
somatic	O
copy	O
number	O
alterations	O
in	O
Sezary	O
syndrome	O
,	O
including	O
highly	O
prevalent	O
chromosomal	O
deletions	O
involving	O
the	O
TP53	B
,	O
RB1	B
,	O
PTEN	B
,	O
DNMT3A	B
and	O
CDKN1B	B
tumor	O
suppressors	O
.	O

Mutation	O
analysis	O
identified	O
a	O
broad	O
spectrum	O
of	O
somatic	O
mutations	O
in	O
key	O
genes	O
involved	O
in	O
epigenetic	O
regulation	O
(	O
TET2	B
,	O
CREBBP	B
,	O
KMT2D	B
(	O
MLL2	B
)	O
,	O
KMT2C	B
(	O
MLL3	B
)	O
,	O
BRD9	B
,	O
SMARCA4	B
and	O
CHD3	B
)	O
and	O
signaling	O
,	O
including	O
MAPK1	B
,	O
BRAF	B
,	O
CARD11	B
and	O
PRKG1	B
mutations	O
driving	O
increased	O
MAPK	B
,	O
NF	B
-	I
kappaB	I
and	O
NFAT	B
activity	O
upon	O
T	B
cell	I
receptor	I
stimulation	O
.	O

Collectively	O
,	O
our	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
genetics	O
of	O
Sezary	O
syndrome	O
and	O
CTCL	O
and	O
support	O
the	O
development	O
of	O
personalized	O
therapies	O
targeting	O
key	O
oncogenically	O
activated	O
signaling	O
pathways	O
for	O
the	O
treatment	O
of	O
these	O
diseases	O
.	O

A	O
-	O
kinase	O
anchor	O
protein	O
4	O
(	O
AKAP4	O
)	O
a	O
promising	O
therapeutic	O
target	O
of	O
colorectal	O
cancer	O
.	O

BACKGROUND	O
:	O
Colorectal	O
cancer	O
(	O
CRC	O
)	O
ranks	O
third	O
among	O
the	O
estimated	O
cancer	O
cases	O
and	O
cancer	O
related	O
mortalities	O
in	O
the	O
Western	O
world	O
.	O

Early	O
detection	O
and	O
efficient	O
therapy	O
of	O
CRC	O
remains	O
a	O
major	O
health	O
challenge	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
need	O
to	O
identify	O
novel	O
tumor	O
markers	O
for	O
early	O
diagnosis	O
and	O
treatment	O
of	O
CRC	O
.	O

METHODS	O
:	O
A	O
-	O
kinase	B
anchor	I
protein	I
4	I
(	O
AKAP4	B
)	O
gene	O
and	O
protein	O
expression	O
was	O
monitored	O
by	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
,	O
reverse	O
transcription	O
(	O
RT	O
)	O
-	O
PCR	O
and	O
Western	O
blotting	O
in	O
normal	O
colon	O
tissue	O
lysate	O
,	O
normal	O
colon	O
epithelial	O
cells	O
and	O
in	O
colon	O
cancer	O
cell	O
lines	O
viz	O
.	O
,	O
Caco	O
-	O
2	O
,	O
COLO205	O
,	O
COLO320DM	O
,	O
HCT	O
-	O
15	O
,	O
HCT116	O
,	O
HT	O
-	O
29	O
,	O
SW480	O
,	O
and	O
SW620	O
.	O

The	O
effect	O
of	O
AKAP4	B
on	O
cellular	O
growth	O
,	O
migration	O
and	O
invasion	O
abilities	O
was	O
studied	O
using	O
gene	O
silencing	O
approach	O
.	O

The	O
role	O
of	O
AKAP4	B
in	O
various	O
pathways	O
involved	O
in	O
cell	O
cycle	O
,	O
apoptosis	O
,	O
senescence	O
was	O
investigated	O
in	O
in	O
vitro	O
and	O
in	O
human	O
xenograft	O
mouse	O
model	O
.	O

RESULTS	O
:	O
Our	O
studies	O
showed	O
that	O
AKAP4	B
gene	I
and	O
protein	O
expression	O
was	O
expressed	O
in	O
all	O
colon	O
cancer	O
cells	O
while	O
no	O
expression	O
was	O
detectable	O
in	O
normal	O
colon	O
cells	O
.	O

Ablation	O
of	O
AKAP4	B
led	O
to	O
reduced	O
cellular	O
growth	O
,	O
migration	O
,	O
invasion	O
and	O
increased	O
apoptosis	O
and	O
senescence	O
of	O
CRC	O
cells	O
in	O
in	O
vitro	O
assays	O
and	O
tumor	O
growth	O
in	O
human	O
xenograft	O
mouse	O
.	O

Human	O
colon	O
xenograft	O
studies	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
cyclins	B
B1	I
,	I
D	I
and	I
E	I
and	O
cyclin	B
dependent	I
kinases	I
such	O
as	O
CDK1	B
,	O
CDK2	B
,	O
CDK4	B
and	O
CDK6	B
.	O

Interestingly	O
,	O
an	O
up	O
-	O
regulation	O
in	O
the	O
levels	O
of	O
p16	B
and	O
p21	B
was	O
also	O
observed	O
.	O

Besides	O
,	O
an	O
increase	O
in	O
the	O
levels	O
of	O
pro	O
-	O
apoptotic	O
molecules	O
AIF	B
,	O
APAF1	B
,	O
BAD	B
,	O
BID	B
,	O
BAK	B
,	O
BAX	B
,	O
PARP1	B
,	O
NOXA	B
,	O
PUMA	B
and	O
cyt	B
-	I
C	I
and	O
Caspase	B
3	I
,	I
7	I
,	I
8	I
and	I
9	I
was	O
also	O
found	O
in	O
cancer	O
cells	O
as	O
well	O
as	O
in	O
xenograft	O
tissue	O
sections	O
.	O

However	O
,	O
anti	O
-	O
apoptotic	O
molecules	O
BCL2	B
,	O
Bcl	B
-	I
xL	I
,	O
cIAP2	B
,	O
XIAP	B
,	O
Axin2	B
and	O
Survivin	B
were	O
down	O
regulated	O
in	O
these	O
samples	O
.	O

Our	O
data	O
also	O
revealed	O
elevated	O
expression	O
of	O
epithelial	O
marker	O
E	B
-	I
cadherin	I
and	O
down	O
regulation	O
of	O
EMT	B
markers	I
N	I
-	I
cadherin	I
,	O
P	B
-	I
cadherin	I
,	O
SLUG	B
,	O
α	B
-	I
SMA	I
,	O
SNAIL	B
,	O
TWIST	B
and	O
Vimentin	B
.	O

Further	O
ablation	O
of	O
AKAP4	B
resulted	O
in	O
the	O
down	O
regulation	O
of	O
invasion	O
molecules	O
matrix	B
metalloproteinase	I
MMP2	I
,	O
MMP3	B
and	O
MMP9	B
.	O

CONCLUSION	O
:	O
AKAP4	B
appears	O
to	O
be	O
a	O
novel	O
CRC	O
-	O
associated	O
antigen	O
with	O
a	O
potential	O
for	O
developing	O
as	O
a	O
new	O
clinical	O
therapeutic	O
target	O
.	O

DNA	B
-	I
damage	I
response	I
gene	I
GADD45A	I
induces	O
differentiation	O
in	O
hematopoietic	O
stem	O
cells	O
without	O
inhibiting	O
cell	O
cycle	O
or	O
survival	O
.	O

Hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
maintain	O
blood	O
cell	O
production	O
life	O
-	O
long	O
by	O
their	O
unique	O
abilities	O
of	O
self	O
-	O
renewal	O
and	O
differentiation	O
into	O
all	O
blood	O
cell	O
lineages	O
.	O

Growth	B
arrest	I
and	I
DNA	I
-	I
damage	I
-	I
inducible	I
45	I
alpha	I
(	O
GADD45A	B
)	O
is	O
induced	O
by	O
genotoxic	O
stress	O
in	O
HSCs	O
.	O

GADD45A	B
has	O
been	O
implicated	O
in	O
cell	O
cycle	O
control	O
,	O
cell	O
death	O
and	O
senescence	O
,	O
as	O
well	O
as	O
in	O
DNA	O
-	O
damage	O
repair	O
.	O

In	O
general	O
,	O
GADD45A	B
provides	O
cellular	O
stability	O
by	O
either	O
arresting	O
the	O
cell	O
cycle	O
progression	O
until	O
DNA	O
damage	O
is	O
repaired	O
or	O
,	O
in	O
cases	O
of	O
fatal	O
damage	O
,	O
by	O
inducing	O
apoptosis	O
.	O

However	O
,	O
the	O
function	O
of	O
GADD45A	B
in	O
hematopoiesis	O
remains	O
controversial	O
.	O

We	O
revealed	O
the	O
changes	O
in	O
murine	O
HSC	O
fate	O
control	O
orchestrated	O
by	O
the	O
expression	O
of	O
GADD45A	B
at	O
single	O
cell	O
resolution	O
.	O

In	O
contrast	O
to	O
other	O
cellular	O
systems	O
,	O
GADD45A	B
expression	O
did	O
not	O
cause	O
a	O
cell	O
cycle	O
arrest	O
or	O
an	O
alteration	O
in	O
the	O
decision	O
between	O
cell	O
survival	O
and	O
apoptosis	O
in	O
HSCs	O
.	O

Strikingly	O
,	O
GADD45A	B
strongly	O
induced	O
and	O
accelerated	O
the	O
differentiation	O
program	O
in	O
HSCs	O
.	O

Continuous	O
tracking	O
of	O
individual	O
HSCs	O
and	O
their	O
progeny	O
via	O
time	O
-	O
lapse	O
microscopy	O
elucidated	O
that	O
once	O
GADD45A	B
was	O
expressed	O
,	O
HSCs	O
differentiate	O
into	O
committed	O
progenitors	O
within	O
29	O
hours	O
.	O

GADD45A	B
-	O
expressing	O
HSCs	O
failed	O
to	O
long	O
-	O
term	O
reconstitute	O
the	O
blood	O
of	O
recipients	O
by	O
inducing	O
multilineage	O
differentiation	O
in	O
vivo	O
.	O

Importantly	O
,	O
γ	O
-	O
irradiation	O
of	O
HSCs	O
induced	O
their	O
differentiation	O
by	O
upregulating	O
endogenous	O
GADD45A	B
.	O

The	O
differentiation	O
induction	O
by	O
GADD45A	B
was	O
transmitted	O
by	O
activating	O
p38	B
Mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
signaling	O
and	O
allowed	O
the	O
generation	O
of	O
megakaryocytic	O
-	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
lineages	O
.	O

These	O
data	O
indicate	O
that	O
genotoxic	O
stress	O
-	O
induced	O
GADD45A	B
expression	O
in	O
HSCs	O
prevents	O
their	O
fatal	O
transformation	O
by	O
directing	O
them	O
into	O
differentiation	O
and	O
thereby	O
clearing	O
them	O
from	O
the	O
system	O
.	O

RNA	O
-	O
seq	O
analysis	O
of	O
impact	O
of	O
PNN	B
on	O
gene	O
expression	O
and	O
alternative	O
splicing	O
in	O
corneal	O
epithelial	O
cells	O
.	O

PURPOSE	O
:	O
The	O
specialized	O
corneal	O
epithelium	O
requires	O
differentiated	O
properties	O
,	O
specific	O
for	O
its	O
role	O
at	O
the	O
anterior	O
surface	O
of	O
the	O
eye	O
.	O

Thus	O
,	O
tight	O
maintenance	O
of	O
the	O
differentiated	O
qualities	O
of	O
the	O
corneal	O
epithelial	O
is	O
essential	O
.	O

Pinin	B
(	O
PNN	B
)	O
is	O
an	O
exon	O
junction	O
component	O
(	O
EJC	O
)	O
that	O
has	O
dramatic	O
implications	O
for	O
corneal	O
epithelial	O
cell	O
differentiation	O
and	O
may	O
act	O
as	O
a	O
stabilizer	O
of	O
the	O
corneal	O
epithelial	O
cell	O
phenotype	O
.	O

Our	O
studies	O
revealed	O
that	O
PNN	B
is	O
involved	O
in	O
transcriptional	O
repression	O
complexes	O
and	O
spliceosomal	O
complexes	O
,	O
placing	O
PNN	B
at	O
the	O
fulcrum	O
between	O
chromatin	O
and	O
mRNA	O
splicing	O
.	O

Transcriptome	O
analysis	O
of	O
PNN	B
-	O
knockdown	O
cells	O
revealed	O
clear	O
and	O
reproducible	O
alterations	O
in	O
transcript	O
profiles	O
and	O
splicing	O
patterns	O
of	O
a	O
subset	O
of	O
genes	O
that	O
would	O
significantly	O
impact	O
the	O
epithelial	O
cell	O
phenotype	O
.	O

We	O
further	O
investigated	O
PNN	O
'	O
s	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
alternative	O
splicing	O
(	O
AS	O
)	O
in	O
a	O
corneal	O
epithelial	O
context	O
.	O

METHODS	O
:	O
Human	O
corneal	O
epithelial	O
(	O
HCET	O
)	O
cells	O
that	O
carry	O
the	O
doxycycline	O
-	O
inducible	O
PNN	O
-	O
knockdown	O
shRNA	O
vector	O
were	O
used	O
to	O
perform	O
RNA	O
-	O
seq	O
to	O
determine	O
differential	O
gene	O
expression	O
and	O
differential	O
AS	O
events	O
.	O

RESULTS	O
:	O
Multiple	O
genes	O
and	O
AS	O
events	O
were	O
identified	O
as	O
differentially	O
expressed	O
between	O
PNN	O
-	O
knockdown	O
and	O
control	O
cells	O
.	O

Genes	O
upregulated	O
by	O
PNN	B
knockdown	O
included	O
a	O
large	O
proportion	O
of	O
genes	O
that	O
are	O
associated	O
with	O
enhanced	O
cell	O
migration	O
and	O
ECM	O
remodeling	O
processes	O
,	O
such	O
as	O
MMPs	B
,	O
ADAMs	B
,	O
HAS2	B
,	O
LAMA3	B
,	O
CXCR	B
s	I
,	O
and	O
UNC5C	B
.	O

Genes	O
downregulated	O
in	O
response	O
to	O
PNN	B
depletion	O
included	O
IGFBP5	B
,	O
FGD3	B
,	O
FGFR2	B
,	O
PAX6	B
,	O
RARG	B
,	O
and	O
SOX10	B
.	O

AS	O
events	O
in	O
PNN	B
-	O
knockdown	O
cells	O
compared	O
to	O
control	O
cells	O
were	O
also	O
more	O
likely	O
to	O
be	O
detected	O
,	O
and	O
upregulated	O
.	O

In	O
particular	O
,	O
60	O
%	O
of	O
exon	O
-	O
skipping	O
events	O
,	O
detected	O
in	O
only	O
one	O
condition	O
,	O
were	O
detected	O
in	O
PNN	O
-	O
knockdown	O
cells	O
and	O
of	O
the	O
shared	O
exon	O
-	O
skipping	O
events	O
,	O
92	O
%	O
of	O
those	O
differentially	O
expressed	O
were	O
more	O
frequent	O
in	O
the	O
PNN	B
knockdown	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
lowering	O
of	O
PNN	B
levels	O
in	O
epithelial	O
cells	O
results	O
in	O
dramatic	O
transformation	O
in	O
the	O
number	O
and	O
composition	O
of	O
splicing	O
variants	O
and	O
that	O
PNN	B
plays	O
a	O
crucial	O
role	O
in	O
the	O
selection	O
of	O
which	O
RNA	O
isoforms	O
differentiating	O
cells	O
produce	O
.	O

Many	O
of	O
the	O
genes	O
affected	O
by	O
PNN	B
knockdown	O
are	O
known	O
to	O
affect	O
the	O
epithelial	O
phenotype	O
.	O

This	O
window	O
into	O
the	O
complexity	O
of	O
RNA	O
splicing	O
in	O
the	O
corneal	O
epithelium	O
implies	O
that	O
PNN	B
exerts	O
broad	O
influence	O
over	O
the	O
regulation	O
and	O
maintenance	O
of	O
the	O
epithelial	O
cell	O
phenotype	O
.	O

Serum	B
Amyloid	I
A	I
Induces	O
Inflammation	O
,	O
Proliferation	O
and	O
Cell	O
Death	O
in	O
Activated	O
Hepatic	O
Stellate	O
Cells	O
.	O

Serum	B
amyloid	I
A	I
(	O
SAA	B
)	O
is	O
an	O
evolutionary	O
highly	O
conserved	O
acute	O
phase	O
protein	O
that	O
is	O
predominantly	O
secreted	O
by	O
hepatocytes	O
.	O

However	O
,	O
its	O
role	O
in	O
liver	O
injury	O
and	O
fibrogenesis	O
has	O
not	O
been	O
elucidated	O
so	O
far	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effects	O
of	O
SAA	B
on	O
hepatic	O
stellate	O
cells	O
(	O
HSCs	O
)	O
,	O
the	O
main	O
fibrogenic	O
cell	O
type	O
of	O
the	O
liver	O
.	O

Serum	B
amyloid	I
A	I
potently	O
activated	O
IkappaB	B
kinase	I
,	O
c	B
-	I
Jun	I
N	I
-	I
terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
Erk	B
and	O
Akt	B
and	O
enhanced	O
NF	B
-	I
kappaB	I
-	I
dependent	I
luciferase	I
activity	O
in	O
primary	O
human	O
and	O
rat	O
HSCs	O
.	O

Serum	B
amyloid	I
A	I
induced	O
the	O
transcription	O
of	O
MCP	B
-	I
1	I
,	O
RANTES	B
and	O
MMP9	B
in	O
an	O
NF	B
-	I
kappaB	I
-	O
and	O
JNK	B
-	O
dependent	O
manner	O
.	O

Blockade	O
of	O
NF	B
-	I
kappaB	I
revealed	O
cytotoxic	O
effects	O
of	O
SAA	B
in	O
primary	O
HSCs	O
with	O
signs	O
of	O
apoptosis	O
such	O
as	O
caspase	B
3	I
and	O
PARP	B
cleavage	O
and	O
Annexin	B
V	I
staining	O
.	O

Serum	B
amyloid	I
A	I
induced	O
HSC	O
proliferation	O
,	O
which	O
depended	O
on	O
JNK	B
,	O
Erk	B
and	O
Akt	B
activity	O
.	O

In	O
primary	O
hepatocytes	O
,	O
SAA	B
also	O
activated	O
MAP	B
kinases	I
,	O
but	O
did	O
not	O
induce	O
relevant	O
cell	O
death	O
after	O
NF	B
-	I
kappaB	I
inhibition	O
.	O

In	O
two	O
models	O
of	O
hepatic	O
fibrogenesis	O
,	O
CCl4	O
treatment	O
and	O
bile	O
duct	O
ligation	O
,	O
hepatic	O
mRNA	O
levels	O
of	O
SAA1	B
and	O
SAA3	B
were	O
strongly	O
increased	O
.	O

In	O
conclusion	O
,	O
SAA	B
may	O
modulate	O
fibrogenic	O
responses	O
in	O
the	O
liver	O
in	O
a	O
positive	O
and	O
negative	O
fashion	O
by	O
inducing	O
inflammation	O
,	O
proliferation	O
and	O
cell	O
death	O
in	O
HSCs	O
.	O

The	O
Innate	O
Immune	O
Receptor	O
NLRX1	B
Functions	O
as	O
a	O
Tumor	O
Suppressor	O
by	O
Reducing	O
Colon	O
Tumorigenesis	O
and	O
Key	O
Tumor	O
-	O
Promoting	O
Signals	O
.	O

NOD	B
-	I
like	I
receptor	I
(	O
NLR	B
)	O
proteins	O
are	O
intracellular	O
innate	O
immune	O
sensors	O
/	O
receptors	O
that	O
regulate	O
immunity	O
.	O

This	O
work	O
shows	O
that	O
NLRX1	B
serves	O
as	O
a	O
tumor	O
suppressor	O
in	O
colitis	O
-	O
associated	O
cancer	O
(	O
CAC	O
)	O
and	O
sporadic	O
colon	O
cancer	O
by	O
keeping	O
key	O
tumor	O
promoting	O
pathways	O
in	O
check	O
.	O

Nlrx1	B
(	I
-	I
/	I
-	I
)	I
mice	I
were	O
highly	O
susceptible	O
to	O
CAC	O
,	O
showing	O
increases	O
in	O
key	O
cancer	O
-	O
promoting	O
pathways	O
including	O
nuclear	B
factor	I
κB	I
(	O
NF	B
-	I
κB	I
)	O
,	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
,	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
,	O
and	O
interleukin	B
6	I
(	O
IL	B
-	I
6	I
)	O
.	O

The	O
tumor	O
-	O
suppressive	O
function	O
of	O
NLRX1	B
originated	O
primarily	O
from	O
the	O
non	O
-	O
hematopoietic	O
compartment	O
.	O

This	O
prompted	O
an	O
analysis	O
of	O
NLRX1	B
function	O
in	O
the	O
Apc	B
(	I
min	I
/	I
+	I
)	I
genetic	O
model	O
of	O
sporadic	O
gastrointestinal	O
cancer	O
.	O

NLRX1	B
attenuated	O
Apc	B
(	I
min	I
/	I
+	I
)	I
colon	O
tumorigenesis	O
,	O
cellular	O
proliferation	O
,	O
NF	B
-	I
κB	I
,	O
MAPK	B
,	O
STAT3	B
activation	O
,	O
and	O
IL	B
-	I
6	I
levels	O
.	O

Application	O
of	O
anti	B
-	I
interleukin	I
6	I
receptor	I
(	O
IL6R	B
)	O
antibody	O
therapy	O
reduced	O
tumor	O
burden	O
,	O
increased	O
survival	O
,	O
and	O
reduced	O
STAT3	B
activation	O
in	O
Nlrx1	B
(	I
-	I
/	I
-	I
)	I
Apc	I
(	I
min	I
/	I
+	I
)	I
mice	O
.	O

As	O
an	O
important	O
clinical	O
correlate	O
,	O
human	O
colon	O
cancer	O
samples	O
expressed	O
lower	O
levels	O
of	O
NLRX1	B
than	O
healthy	O
controls	O
in	O
multiple	O
patient	O
cohorts	O
.	O

These	O
data	O
implicate	O
anti	O
-	O
IL6R	B
as	O
a	O
potential	O
personalized	O
therapy	O
for	O
colon	O
cancers	O
with	O
reduced	O
NLRX1	B
.	O

Circulating	O
Fatty	B
Acid	I
Synthase	I
in	O
pregnant	O
women	O
:	O
Relationship	O
to	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
.	O

The	O
enzyme	O
FASN	B
(	O
fatty	B
acid	I
synthase	I
)	O
is	O
potentially	O
related	O
with	O
hypertension	O
and	O
metabolic	O
dysfunction	O
.	O

FASN	B
is	O
highly	O
expressed	O
in	O
the	O
human	O
placenta	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
relationship	O
circulating	O
FASN	B
has	O
with	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
in	O
healthy	O
pregnant	O
women	O
.	O

Circulating	O
FASN	B
was	O
assessed	O
in	O
115	O
asymptomatic	O
pregnant	O
women	O
in	O
the	O
second	O
trimester	O
of	O
gestation	O
along	O
with	O
C	B
-	I
peptide	I
,	O
fasting	O
glucose	O
and	O
insulin	B
,	O
post	O
-	O
load	O
glucose	O
lipids	O
,	O
HMW	B
-	I
adiponectin	I
and	O
blood	O
pressure	O
(	O
the	O
latter	O
was	O
assessed	O
in	O
each	O
trimester	O
of	O
gestation	O
)	O
.	O

At	O
birth	O
,	O
newborns	O
and	O
placentas	O
were	O
weighed	O
.	O

FASN	B
expression	O
was	O
also	O
able	O
to	O
be	O
assessed	O
in	O
80	O
placentas	O
.	O

Higher	O
circulating	O
FASN	B
was	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
with	O
a	O
more	O
favourable	O
metabolic	O
phenotype	O
(	O
lower	O
fasting	O
glucose	O
and	O
insulin	B
,	O
post	O
load	O
glucose	O
,	O
HbAc1	O
,	O
HOMA	O
-	O
IR	O
and	O
C	B
-	I
peptide	I
)	O
,	O
and	O
with	O
lower	O
placental	O
and	O
birth	O
weight	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
to	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Placental	B
FASN	I
expression	O
related	O
positively	O
to	O
circulating	O
FASN	B
(	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
negatively	O
to	O
placental	O
weight	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
observations	O
suggest	O
a	O
physiological	O
role	O
of	O
placental	O
FASN	B
in	O
human	O
pregnancy	O
.	O

Future	O
studies	O
will	O
clarify	O
whether	O
circulating	O
FASN	B
of	O
placental	O
origin	O
does	O
actually	O
regulate	O
placental	O
and	O
fetal	O
growth	O
,	O
and	O
(	O
thereby	O
)	O
has	O
a	O
favourable	O
influence	O
on	O
the	O
pregnant	O
mother	O
'	O
s	O
insulin	B
sensitivity	O
and	O
blood	O
pressure	O
.	O

High	B
Mobility	I
Group	I
Box	I
-	I
1	I
Promotes	O
Inflammation	O
-	O
Induced	O
Lymphangiogenesis	O
via	O
Toll	B
-	I
Like	I
Receptor	I
4	I
-	O
Dependent	O
Signalling	O
Pathway	O
.	O

Lymphangiogenesis	O
in	O
inflammation	O
has	O
received	O
considerable	O
attention	O
in	O
recent	O
years	O
.	O

Administration	O
of	O
modulating	O
lymphangiogenesis	O
provides	O
more	O
possibilities	O
of	O
treating	O
inflammation	O
-	O
associated	O
diseases	O
.	O

However	O
,	O
the	O
main	O
mediators	O
and	O
factors	O
governing	O
inflammation	O
-	O
induced	O
lymphangiogenesis	O
(	O
ILA	O
)	O
are	O
yet	O
to	O
be	O
defined	O
.	O

Here	O
,	O
we	O
explored	O
the	O
role	O
of	O
HMGB1	B
-	O
TLR4	B
signalling	O
pathway	O
in	O
modulating	O
inflammation	O
-	O
induced	O
lymphangiogenesis	O
and	O
its	O
underlying	O
mechanisms	O
using	O
an	O
ILA	O
mouse	O
model	O
and	O
2	O
cell	O
lines	O
.	O

Our	O
results	O
show	O
that	O
HMGB1	B
promoted	O
VEGF	B
-	I
C	I
-	O
induced	O
HDLECs	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
TLR4	B
mediates	O
HMGB1	B
-	O
induced	O
LECs	O
proliferation	O
and	O
tube	O
formation	O
in	O
vitro	O
.	O

And	O
in	O
vivo	O
,	O
r	B
HMGB1	I
treatment	O
significantly	O
promoted	O
ILA	O
,	O
and	O
the	O
promoting	O
effects	O
was	O
inhibited	O
notably	O
when	O
HMGB1	B
-	O
TLR4	B
was	O
blocked	O
.	O

HMGB1	B
-	O
associated	O
ILA	B
is	O
primarily	O
dependent	O
on	O
TLR4	B
but	O
not	O
on	O
TLR2	B
.	O

In	O
mechanisms	O
,	O
the	O
recruitment	O
and	O
activation	O
of	O
CD11b	B
+	O
cells	O
are	O
important	O
cellular	O
mechanisms	O
in	O
HMGB1	B
-	O
TLR4	B
associated	O
ILA	O
,	O
and	O
multiple	O
key	O
pro	O
-	O
lymphangiogenesis	O
molecules	O
mediates	O
HMGB1	B
-	O
TLR4	B
associated	O
ILA	O
,	O
including	O
VEGF	B
-	I
C	I
/	O
VEGFR3	B
,	O
inflammatory	O
factors	O
IL	B
-	I
1β	I
and	O
TNF	B
-	I
α	I
,	O
MMP	B
-	I
2	I
and	O
MMP	B
-	I
9	I
and	O
NF	B
-	I
κB	I
p65	I
<	O
/	O
ma	O
p65	O
.	O

In	O
conclusion	O
,	O
HMGB1	B
-	O
associated	O
ILA	O
is	O
primarily	O
dependent	O
on	O
TLR4	B
,	O
and	O
CD11b	B
+	O
cells	O
and	O
multiple	O
molecular	O
mechanisms	O
mediate	O
HMGB1	B
-	O
TLR4	B
associated	O
ILA	O
.	O

Furthermore	O
,	O
the	O
ILA	O
can	O
be	O
effectively	O
modulated	O
by	O
HMGB1	B
-	O
TLR4	B
signalling	O
.	O

Consequently	O
,	O
administration	O
of	O
modulating	O
ILA	O
through	O
HMGB1	B
-	O
TLR4	B
pathway	O
may	O
provide	O
us	O
more	O
possibilities	O
of	O
treating	O
inflammation	O
and	O
lymphangiogenesis	O
associated	O
diseases	O
.	O

Repurposing	O
an	O
orally	O
available	O
drug	O
for	O
the	O
treatment	O
of	O
geographic	O
atrophy	O
.	O

PURPOSE	O
:	O
Chronic	O
oxidative	O
stress	O
and	O
subacute	O
inflammation	O
have	O
been	O
implicated	O
as	O
causes	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
whether	O
an	O
orally	O
available	O
5	O
-	O
OH	O
-	O
tryptamine	B
(	O
5HT	B
)	O
1a	O
receptor	O
agonist	O
,	O
xaliproden	O
,	O
could	O
protect	O
against	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
cell	O
damage	O
in	O
culture	O
and	O
in	O
a	O
mouse	O
model	O
of	O
geographic	O
atrophy	O
.	O

METHODS	O
:	O
Paraquat	O
was	O
used	O
to	O
create	O
mitochondrial	O
oxidative	O
stress	O
in	O
ARPE	O
-	O
19	O
cells	O
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
a	I
(	O
TNF	B
-	I
a	I
)	O
was	O
used	O
to	O
stimulate	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
in	O
these	O
cells	O
.	O

The	O
production	O
of	O
antioxidant	O
proteins	O
,	O
metallothionein	B
,	O
and	O
inflammatory	O
cytokines	O
was	O
assayed	O
with	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Cell	O
survival	O
was	O
analyzed	O
with	O
microscopy	O
and	O
a	O
cell	O
titer	O
assay	O
.	O

Integrity	O
of	O
the	O
RPE	O
monolayer	O
was	O
determined	O
by	O
measuring	O
the	O
transepithelial	O
electrical	O
resistance	O
(	O
TEER	O
)	O
and	O
with	O
immunocytochemistry	O
with	O
zona	B
occludens	I
protein	I
1	I
(	O
ZO	B
-	I
1	I
)	O
antibody	O
.	O

RPE	O
atrophy	O
was	O
studied	O
in	O
mice	O
deleted	O
for	O
Sod2	B
(	O
the	O
gene	O
for	O
mitochondrial	B
superoxide	I
dismutase	I
)	O
specifically	O
in	O
the	O
RPE	O
.	O

The	O
mice	O
were	O
treated	O
orally	O
with	O
daily	O
doses	O
of	O
xaliproden	O
at	O
0	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
for	O
4	O
months	O
.	O

The	O
retinal	O
structure	O
was	O
analyzed	O
with	O
spectral	O
domain	O
optical	O
coherence	O
tomography	O
(	O
SD	O
-	O
OCT	O
)	O
and	O
with	O
light	O
and	O
electron	O
microscopy	O
.	O

Retinal	O
function	O
was	O
assessed	O
with	O
full	O
-	O
field	O
electroretinography	O
(	O
ERG	O
)	O
and	O
with	O
optokinetic	O
measurements	O
.	O

RESULTS	O
:	O
Xaliproden	O
led	O
to	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
cell	O
survival	O
following	O
treatment	O
with	O
paraquat	O
.	O

Synthesis	O
of	O
the	O
antioxidant	O
response	O
genes	O
NqO1	B
,	O
GSTM1	B
,	O
CAT	B
,	O
HO	B
-	I
1	I
,	O
and	O
Nrf2	B
was	O
increased	O
in	O
response	O
to	O
the	O
drug	O
,	O
as	O
was	O
the	O
zinc	O
chaperone	O
metallothionein	B
.	O

Treatment	O
of	O
cells	O
with	O
TNF	B
-	I
a	I
led	O
to	O
increased	O
production	O
of	O
IL	B
-	I
1b	I
,	O
IL	B
-	I
6	I
,	O
chemokine	B
(	I
C	I
-	I
C	I
motif	I
)	I
ligand	I
20	I
(	O
CCL20	B
)	O
,	O
and	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
by	O
ARPE	O
-	O
19	O
cells	O
,	O
and	O
this	O
response	O
was	O
attenuated	O
by	O
treatment	O
with	O
xaliproden	O
.	O

TNF	B
-	I
a	I
also	O
led	O
to	O
a	O
decrease	O
in	O
the	O
TEER	O
that	O
was	O
prevented	O
by	O
treatment	O
with	O
the	O
5HT1a	B
agonist	O
.	O

Daily	O
gavage	O
with	O
xaliproden	O
at	O
either	O
dose	O
induced	O
the	O
production	O
of	O
protective	O
enzymes	O
in	O
the	O
mouse	O
retina	O
,	O
and	O
treatment	O
of	O
the	O
Sod2	B
-	O
deleted	O
mice	O
with	O
the	O
drug	O
showed	O
improved	O
thickness	O
of	O
the	O
outer	O
nuclear	O
layer	O
and	O
improved	O
visual	O
acuity	O
relative	O
to	O
the	O
control	O
-	O
treated	O
mice	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
full	O
-	O
field	O
scotopic	O
ERG	O
among	O
the	O
treatment	O
groups	O
,	O
however	O
.	O

Vacuolization	O
of	O
the	O
RPE	O
and	O
disorganization	O
of	O
the	O
photoreceptor	O
outer	O
segments	O
were	O
reduced	O
at	O
both	O
dose	O
levels	O
of	O
xaliproden	O
.	O

CONCLUSIONS	O
:	O
Xaliproden	O
protected	O
RPE	O
cells	O
from	O
oxidative	O
and	O
inflammatory	O
insults	O
and	O
protected	O
the	O
mouse	O
RPE	O
and	O
retina	O
from	O
RPE	O
atrophy	O
in	O
the	O
face	O
of	O
excess	O
mitochondrial	O
oxidative	O
stress	O
.	O

These	O
results	O
suggest	O
that	O
this	O
drug	O
,	O
which	O
had	O
a	O
reasonable	O
safety	O
profile	O
in	O
clinical	O
trials	O
,	O
may	O
be	O
used	O
to	O
prevent	O
the	O
progression	O
of	O
geographic	O
atrophy	O
in	O
humans	O
.	O

Hsp90beta	B
is	O
involved	O
in	O
the	O
development	O
of	O
high	O
salt	O
-	O
diet	O
-	O
induced	O
nephropathy	O
via	O
interaction	O
with	O
various	O
signalling	O
proteins	O
.	O

A	O
high	O
-	O
salt	O
diet	O
often	O
leads	O
to	O
a	O
local	O
intrarenal	O
increase	O
in	O
renal	O
hypoxia	O
and	O
oxidative	O
stress	O
,	O
which	O
are	O
responsible	O
for	O
an	O
excess	O
production	O
of	O
pathogenic	O
substances	O
.	O

Here	O
,	O
Wistar	O
Kyoto	O
/	O
spontaneous	O
hypertensive	O
(	O
WKY	O
/	O
SHR	O
)	O
rats	O
fed	O
a	O
high	O
-	O
salt	O
diet	O
developed	O
severe	O
proteinuria	O
,	O
resulting	O
from	O
pronounced	O
renal	O
inflammation	O
,	O
fibrosis	O
and	O
tubular	O
epithelial	O
cell	O
apoptosis	O
.	O

All	O
these	O
were	O
mainly	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
.	O

Hsp90beta	B
,	O
TGF	B
-	I
beta	I
,	O
HIF	B
-	I
1alpha	I
,	O
TNF	B
-	I
alpha	I
,	O
IL	B
-	I
6	I
and	O
MCP	B
-	I
1	I
were	O
shown	O
to	O
be	O
highly	O
expressed	O
in	O
response	O
to	O
salt	O
loading	O
.	O

Next	O
,	O
we	O
found	O
that	O
Hsp90beta	B
might	O
play	O
the	O
key	O
role	O
in	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
of	O
salt	O
loading	O
through	O
a	O
series	O
of	O
cellular	O
signalling	O
events	O
,	O
including	O
the	O
NF	B
-	I
kappaB	I
,	O
p38	B
activation	O
and	O
Bcl	B
-	I
2	I
inactivation	O
.	O

Hsp90beta	B
was	O
previously	O
proven	O
to	O
regulate	O
the	O
upstream	O
mediators	O
in	O
multiple	O
cellular	O
signalling	O
cascades	O
through	O
stabilizing	O
and	O
maintaining	O
their	O
activities	O
.	O

In	O
our	O
study	O
,	O
17	O
-	O
dimethylaminoethylamino	O
-	O
17	O
-	O
demethoxygeldanamycin	O
(	O
17	O
-	O
DMAG	O
)	O
or	O
Hsp90beta	B
knockdown	O
dramatically	O
alleviated	O
the	O
high	O
-	O
salt	O
-	O
diet	O
-	O
induced	O
proteinuria	O
and	O
renal	O
damage	O
without	O
altering	O
blood	O
pressure	O
significantly	O
,	O
when	O
it	O
reversed	O
activations	O
of	O
NF	B
-	I
kappaB	I
,	O
mTOR	B
and	O
p38	B
signalling	O
cascades	O
.	O

Meanwhile	O
,	O
Co	O
-	O
IP	O
results	O
demonstrated	O
that	O
Hsp90beta	B
could	O
interact	O
with	O
and	O
stabilize	O
TAK1	B
,	O
AMPKalpha	B
,	O
IKKalpha	B
/	I
beta	I
,	O
HIF	B
-	I
1alpha	I
and	O
Raptor	B
,	O
whereas	O
Hsp90beta	B
inhibition	O
disrupted	O
this	O
process	O
.	O

In	O
addition	O
,	O
Hsp90beta	B
inhibition	O
-	O
mediated	O
renal	O
improvements	O
also	O
accompanied	O
the	O
reduction	O
of	O
renal	O
oxidative	O
stress	O
.	O

In	O
conclusion	O
,	O
salt	O
loading	O
indeed	O
exhibited	O
non	O
-	O
pressure	O
-	O
related	O
impacts	O
on	O
proteinuria	O
and	O
renal	O
dysfunction	O
in	O
WKY	O
/	O
SHR	O
rats	O
.	O

Hsp90beta	B
inhibition	O
caused	O
the	O
destabilization	O
of	O
upstream	O
mediators	O
in	O
various	O
pathogenic	O
signalling	O
events	O
,	O
thereby	O
effectively	O
ameliorating	O
this	O
nephropathy	O
owing	O
to	O
renal	O
hypoxia	O
and	O
oxidative	O
stress	O
.	O

Negative	O
Selection	O
and	O
Chromosome	O
Instability	O
Induced	O
by	O
Mad2	B
Overexpression	O
Delay	O
Breast	O
Cancer	O
but	O
Facilitate	O
Oncogene	O
-	O
Independent	O
Outgrowth	O
.	O

Chromosome	O
instability	O
(	O
CIN	O
)	O
is	O
associated	O
with	O
poor	O
survival	O
and	O
therapeutic	O
outcome	O
in	O
a	O
number	O
of	O
malignancies	O
.	O

Despite	O
this	O
correlation	O
,	O
CIN	O
can	O
also	O
lead	O
to	O
growth	O
disadvantages	O
.	O

Here	O
,	O
we	O
show	O
that	O
simultaneous	O
overexpression	O
of	O
the	O
mitotic	O
checkpoint	O
protein	O
Mad2	B
with	O
Kras	B
(	O
G12D	B
)	O
or	O
Her2	B
in	O
mammary	O
glands	O
of	O
adult	O
mice	O
results	O
in	O
mitotic	O
checkpoint	O
overactivation	O
and	O
a	O
delay	O
in	O
tumor	O
onset	O
.	O

Time	O
-	O
lapse	O
imaging	O
of	O
organotypic	O
cultures	O
and	O
pathologic	O
analysis	O
prior	O
to	O
tumor	O
establishment	O
reveals	O
error	O
-	O
prone	O
mitosis	O
,	O
mitotic	O
arrest	O
,	O
and	O
cell	O
death	O
.	O

Nonetheless	O
,	O
Mad2	B
expression	O
persists	O
and	O
increases	O
karyotype	O
complexity	O
in	O
Kras	B
tumors	I
.	O

Faced	O
with	O
the	O
selective	O
pressure	O
of	O
oncogene	O
withdrawal	O
,	O
Mad2	B
-	O
positive	O
tumors	O
have	O
a	O
higher	O
frequency	O
of	O
developing	O
persistent	O
subclones	O
that	O
avoid	O
remission	O
and	O
continue	O
to	O
grow	O
.	O

Deregulation	O
of	O
polycom	O
polycomb	O
repressor	O
complex	O
1	O
er	O
AUTS2	B
in	O
T	O
-	O
cell	O
leukemia	O
.	O

Recently	O
,	O
we	O
identified	O
deregulated	O
expression	O
of	O
the	O
B	O
-	O
cell	O
specific	O
transcription	O
factor	O
MEF2C	B
in	O
T	O
-	O
cell	O
acute	O
lymphoid	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

Here	O
,	O
we	O
performed	O
sequence	O
analysis	O
of	O
a	O
regulatory	O
upstream	O
section	O
of	O
MEF2C	B
in	O
T	O
-	O
ALL	O
cell	O
lines	O
which	O
,	O
however	O
,	O
proved	O
devoid	O
of	O
mutations	O
.	O

Unexpectedly	O
,	O
we	O
found	O
strong	O
conservation	O
between	O
the	O
regulatory	O
upstream	O
region	O
of	O
MEF2C	B
(	O
located	O
at	O
chromosomal	O
band	O
5q14	O
)	O
and	O
an	O
intergenic	O
stretch	O
at	O
7q11	O
located	O
between	O
STAG3L4	B
and	O
AUTS2	B
,	O
covering	O
nearly	O
20	O
kb	O
.	O

While	O
the	O
non	O
-	O
coding	O
gene	O
STAG3L4	B
was	O
inconspicuously	O
expressed	O
,	O
AUTS2	B
was	O
aberrantly	O
upregulated	O
in	O
6	O
%	O
of	O
T	O
-	O
ALL	O
patients	O
(	O
public	O
dataset	O
GSE42038	O
)	O
and	O
in	O
3	O
/	O
24	O
T	O
-	O
ALL	O
cell	O
lines	O
,	O
two	O
of	O
which	O
represented	O
very	O
immature	O
differentiation	O
stages	O
.	O

AUTS2	B
expression	O
was	O
higher	O
in	O
normal	O
B	O
-	O
cells	O
than	O
in	O
T	O
-	O
cells	O
,	O
indicating	O
lineage	O
-	O
specific	O
activity	O
in	O
lymphopoiesis	O
.	O

While	O
excluding	O
chromosomal	O
aberrations	O
,	O
examinations	O
of	O
AUTS2	B
transcriptional	O
regulation	O
in	O
T	O
-	O
ALL	O
cells	O
revealed	O
activation	O
by	O
IL7	B
-	O
IL7R	B
-	O
STAT5	B
-	O
signalling	O
and	O
MEF2C	B
.	O

AUTS2	B
protein	I
has	O
been	O
shown	O
to	O
interact	O
with	O
polycomb	B
repressor	I
complex	I
1	I
subtype	I
5	I
(	O
PRC1	B
.	I
5	I
)	O
,	O
transforming	O
this	O
particular	O
complex	O
into	O
an	O
activator	O
.	O

Accordingly	O
,	O
expression	O
profiling	O
and	O
functional	O
analyses	O
demonstrated	O
that	O
AUTS2	B
activated	O
while	O
PCGF5	B
repressed	O
transcription	O
of	O
NKL	B
homeobox	I
gene	I
MSX1	I
in	O
T	O
-	O
ALL	O
cells	O
.	O

Forced	O
expression	O
and	O
pharmacological	O
inhibition	O
of	O
EZH2	B
in	O
addition	O
to	O
H3K27me3	B
analysis	O
indicated	O
that	O
PRC2	B
repressed	O

MSX1	B
as	O
well	O
.	O

Taken	O
together	O
,	O
we	O
found	O
that	O
AUTS2	B
and	O
MEF2C	B
,	O
de	O
s	O
pite	O
lying	O
on	O
different	O
chromosomes	O
,	O
share	O
strikingly	O
similar	O
regulatory	O
upstream	O
regions	O
and	O
aberrant	O
expression	O
in	O
T	O
-	O
ALL	O
subsets	O
.	O

Our	O
data	O
implicate	O
chromatin	O
complexes	O
PRC1	B
/	O
AUTS2	B
and	O
PRC2	B
in	O
a	O
gene	O
network	O
in	O
T	O
-	O
ALL	O
regulating	O
early	O
lymphoid	O
differentiation	O
.	O

MiR	B
-	I
204	I
silencing	O
in	O
intraepithelial	O
to	O
invasive	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
progression	O
.	O

BACKGROUND	O
:	O
Cutaneous	O
squamous	O
cell	O
carcinoma	O
(	O
cSCC	O
)	O
is	O
the	O
second	O
most	O
common	O
skin	O
cancer	O
and	O
frequently	O
progresses	O
from	O
an	O
actinic	O
keratosis	O
(	O
AK	O
)	O
,	O
a	O
sun	O
-	O
induced	O
keratinocyte	O
intraepithelial	O
neoplasia	O
(	O
KIN	O
)	O
.	O

Epigenetic	O
mechanisms	O
involved	O
in	O
the	O
phenomenon	O
of	O
progression	O
from	O
AK	O
to	O
cSCC	O
remain	O
to	O
be	O
elicited	O
.	O

METHODS	O
:	O
Expression	O
of	O
microRNAs	O
in	O
sun	O
-	O
exposed	O
skin	O
,	O
AK	O
and	O
cSCC	O
was	O
analysed	O
by	O
Agilent	O
microarrays	O
.	O

DNA	O
methylation	O
of	O
miR	B
-	I
204	I
promoter	I
was	O
determined	O
by	O
bisulphite	O
treatment	O
and	O
pyrosequencing	O
.	O

Identification	O
of	O
miR	B
-	I
204	I
targets	I
and	O
pathways	O
was	O
accomplished	O
in	O
HaCat	O
cells	O
.	O

Immunofluorescence	O
and	O
immunohistochemistry	O
were	O
used	O
to	O
analyze	O
STAT3	B
activation	O
and	O
PTPN11	B
expression	O
in	O
human	O
biopsies	O
.	O

RESULTS	O
:	O
cSCCs	O
display	O
a	O
marked	O
downregulation	O
of	O
miR	B
-	I
204	I
expression	O
when	O
compared	O
to	O
AK	O
.	O

DNA	O
methylation	O
of	O
miR	B
-	I
204	I
promoter	I
was	O
identified	O
as	O
one	O
of	O
the	O
repressive	O
mechanisms	O
that	O
accounts	O
for	O
miR	B
-	I
204	I
silencing	O
in	O
cSCC	O
.	O

In	O
HaCaT	O
cells	O
miR	O
-	O
204	O
inhibits	O
STAT3	B
and	O
favours	O
the	O
MAPK	B
signaling	O
pathway	O
,	O
likely	O
acting	O
through	O
PTPN11	B
,	O
a	O
nuclear	O
tyrosine	B
phosphatase	I
that	O
is	O
a	O
direct	O
miR	O
-	O
204	O
target	O
.	O

In	O
non	O
-	O
peritumoral	O
AK	O
lesions	O
,	O
activated	O
STAT3	B
,	O
as	O
detected	O
by	O
pY705	B
-	O
STAT3	B
immunofluorescence	O
,	O
is	O
retained	O
in	O
the	O
membrane	O
and	O
cytoplasm	O
compartments	O
,	O
whereas	O
AK	O
lesions	O
adjacent	O
to	O
cSCCs	O
display	O
activated	O
STAT3	B
in	O
the	O
nuclei	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
miR	B
-	I
204	I
may	O
act	O
as	O
a	O
"	O
rheostat	O
"	O
that	O
controls	O
the	O
signalling	O
towards	O
the	O
MAPK	B
pathway	O
or	O
the	O
STAT3	B
pathway	O
in	O
the	O
progression	O
from	O
AK	O
to	O
cSCC	O
.	O

Gartanin	B
induces	O
cell	O
cycle	O
arrest	O
and	O
autophagy	O
and	O
suppresses	O
migration	O
involving	O
PI3K	B
/	O
Akt	B
/	O
mTOR	B
and	O
MAPK	B
signalling	O
pathway	O
in	O
human	O
glioma	O
cells	O
.	O

In	O
central	O
nervous	O
system	O
,	O
glioma	O
is	O
the	O
most	O
common	O
primary	O
brain	O
tumour	O
.	O

The	O
diffuse	O
migration	O
and	O
rapid	O
proliferation	O
are	O
main	O
obstacles	O
for	O
successful	O
treatment	O
.	O

Gartanin	O
,	O
a	O
natural	O
xanthone	O
of	O
mangosteen	O
,	O
suppressed	O
proliferation	O
,	O
migration	O
and	O
colony	O
formation	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
in	O
T98G	O
glioma	O
cells	O
but	O
not	O
in	O
mouse	O
normal	O
neuronal	O
HT22	O
cells	O
.	O

Gartanin	O
,	O
at	O
low	O
micromole	O
,	O
led	O
to	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
accompanied	O
by	O
inhibited	O
expression	O
level	O
of	O
G1	O
cell	O
cycle	O
regulatory	O
proteins	O
cyclin	B
D1	I
,	O
while	O
increased	O
expression	O
level	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
p27Kip1	I
.	O

In	O
addition	O
,	O
the	O
secretion	O
and	O
activity	O
of	O
matrix	B
metalloproteinases	I
2	I
/	I
9	I
(	O
MMP	B
-	I
2	I
/	I
-	I
9	I
)	O
were	O
significantly	O
suppressed	O
in	O
T98G	O
cells	O
treated	O
with	O
gartanin	O
,	O
and	O
it	O
might	O
result	O
from	O
modulating	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
(	O
MAPK	B
)	O
signalling	O
pathway	O
in	O
T98G	O
glioma	O
cells	O
.	O

Moreover	O
,	O
gartanin	O
significantly	O
induced	O
autophagy	O
in	O
T98G	O
cells	O
and	O
increased	O
GFP	B
-	O
LC3	B
punctate	O
fluorescence	O
accompanied	O
by	O
the	O
increased	O
expression	O
level	O
of	O
Beclin	B
1	I
and	O
LC3	B
-	I
II	I
,	O
while	O
suppressed	O
expression	O
level	O
of	O
p62	B
.	O

Gartanin	B
treatment	O
resulted	O
in	O
obvious	O
inhibition	O
of	O
PI3K	B
/	O
Akt	B
/	O
mTOR	B
signalling	O
pathway	O
,	O
which	O
is	O
important	O
in	O
modulating	O
autophagy	O
.	O

Notably	O
,	O
gartanin	O
-	O
mediated	O
anti	O
-	O
viability	O
was	O
significantly	O
abrogated	O
by	O
autophagy	O
inhibitors	O
including	O
3	O
-	O
methyladenine	O
(	O
3	O
-	O
MA	O
)	O
and	O
chloroquine	O
(	O
CQ	O
)	O
.	O

These	O
results	O
indicate	O
that	O
anti	O
-	O
proliferation	O
effect	O
of	O
gartanin	O
in	O
T98G	O
cells	O
is	O
most	O
likely	O
via	O
cell	O
cycle	O
arrest	O
modulated	O
by	O
autophagy	O
,	O
which	O
is	O
regulated	O
by	O
PI3K	B
/	I
Akt	I
/	I
mTOR	I
signalling	I
pathway	O
,	O
while	O
anti	O
-	O
migration	O
effect	O
is	O
most	O
likely	O
via	O
suppression	O
of	O
MMP	B
-	I
2	I
/	I
-	I
9	I
activity	O
which	O
is	O
involved	O
in	O
MAPK	B
signalling	I
pathway	O
.	O

DDA	O
suppresses	O
angiogenesis	O
and	O
tumor	O
growth	O
of	O
colorectal	O
cancer	O
in	O
vivo	O
through	O
decreasing	O
VEGFR2	B
signaling	O
.	O

As	O
angiogenesis	O
is	O
required	O
for	O
tumor	O
growth	O
and	O
metastasis	O
,	O
suppressing	O
angiogenesis	O
is	O
a	O
promising	O
strategy	O
in	O
limiting	O
tumor	O
progression	O
.	O

Vascular	B
endothelial	I
growth	I
factor	I
(	I
VEGF	I
)	I
-	I
A	I
,	O
a	O
critical	O
pro	O
-	O
angiogenic	O
factor	O
,	O
has	O
thus	O
become	O
an	O
attractive	O
target	O
for	O
therapeutic	O
interventions	O
in	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
underlying	O
mechanisms	O
of	O
a	O
novel	O
anthraquinone	O
derivative	O
DDA	O
in	O
suppressing	O
angiogenesis	O
.	O

DDA	B
inhibited	O
VEGF	B
-	I
A	I
-	O
induced	O
proliferation	O
,	O
migration	O
and	O
tube	O
formation	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

DDA	O
also	O
reduced	O
VEGF	B
-	I
A	I
-	O
induced	O
microvessel	O
sprouting	O
from	O
aortic	O
rings	O
ex	O
vivo	O
and	O
suppressed	O
neovascularization	O
in	O
vivo	O
.	O

VEGF	B
-	I
A	I
-	O
induced	O
VEGFR1	B
,	O
VEGFR2	B
,	O
FAK	B
,	O
Akt	B
,	O
ERK1	B
/	I
2	I
or	O
STAT3	B
phosphorylation	O
was	O
reduced	O
in	O
the	O
presence	O
of	O
DDA	O
.	O

In	O
addition	O
,	O
NRP	B
-	I
1	I
siRNA	O
reduced	O
VEGF	B
-	I
A	I
'	O
s	O
enhancing	O
effects	O
in	O
VEGFR2	B
,	O
FAK	B
and	O
Akt	B
phosphorylation	O
and	O
cell	O
proliferation	O
in	O
HUVECs	O
.	O

DDA	B
disrupted	O
VEGF	B
-	I
A	I
-	O
induced	O
complex	O
formation	O
between	O
NRP	B
-	I
1	I
and	O
VEGFR2	B
.	O

Furthermore	O
,	O
systemic	O
administration	O
of	O
DDA	O
was	O
shown	O
to	O
suppress	O
tumor	O
angiogenesis	O
and	O
growth	O
in	O
in	O
vivo	O
mouse	O
xenograft	O
models	O
.	O

Taken	O
together	O
,	O
we	O
demonstrated	O
in	O
this	O
study	O
that	O
DDA	O
exhibits	O
anti	O
-	O
angiogenic	O
properties	O
through	O
suppressing	O
VEGF	B
-	I
A	I
signaling	O
.	O

These	O
observations	O
also	O
suggest	O
that	O
DDA	O
might	O
be	O
a	O
potential	O
drug	O
candidate	O
for	O
developing	O
anti	O
-	O
angiogenic	O
agent	O
in	O
the	O
field	O
of	O
cancer	O
and	O
angiogenesis	O
-	O
related	O
diseases	O
.	O

MXRA5	B
is	O
a	O
TGF	B
-	I
b1	I
-	I
regulated	I
human	I
protein	I
with	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
properties	O
.	O

Current	O
therapy	O
for	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
is	O
unsatisfactory	O
because	O
of	O
an	O
insufficient	O
understanding	O
of	O
its	O
pathogenesis	O
.	O

Matrix	B
remodelling	I
-	I
associated	I
protein	I
5	I
(	O
MXRA5	B
,	O
adlican	B
)	O
is	O
a	O
human	O
protein	O
of	O
unknown	O
function	O
with	O
high	O
kidney	O
tissue	O
expression	O
,	O
not	O
present	O
in	O
rodents	O
.	O

Given	O
the	O
increased	O
expression	O
of	O
MXRA5	B
in	O
injured	O
tissues	O
,	O
including	O
the	O
kidneys	O
,	O
we	O
have	O
suggested	O
that	O
MXRA5	B
may	O
modulate	O
kidney	O
injury	O
.	O

MXRA5	B
immunoreactivity	O
was	O
observed	O
in	O
tubular	O
cells	O
in	O
human	O
renal	O
biopsies	O
and	O
in	O
urine	O
from	O
CKD	O
patients	O
.	O

We	O
then	O
explored	O
factors	O
regulating	O
MXRA5	B
expression	O
and	O
MXRA5	B
function	O
in	O
cultured	O
human	O
proximal	O
tubular	O
epithelial	O
cells	O
and	O
explored	O
MXRA5	B
expression	O
in	O
kidney	O
cancer	O
cells	O
and	O
kidney	O
tissue	O
.	O

The	O
fibrogenic	O
cytokine	O
transforming	B
growth	I
factor	I
-	I
β1	I
(	O
TGFb1	B
)	O
up	O
-	O
regulated	O
MXRA5	B
mRNA	I
and	O
protein	O
expression	O
.	O

TGFb1	B
-	O
induced	O
MXRA5	B
up	O
-	O
regulation	O
was	O
prevented	O
by	O
either	O
interference	O
with	O
TGFb1	B
activation	O
of	O
the	O
TGFb	B
receptor	I
1	I
(	O
TGFBR1	B
,	O
ALK5	B
)	O
or	O
by	O
the	O
vitamin	B
D	I
receptor	I
agonist	O
paricalcitol	O
.	O

By	O
contrast	O
,	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
TWEAK	B
did	O
not	O
modulate	O
MXRA5	B
expression	O
.	O

MXRA5	B
siRNA	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
constitutive	O
MXRA5	B
expression	O
resulted	O
in	O
higher	O
TWEAK	B
-	O
induced	O
expression	O
of	O
chemokines	O
.	O

In	O
addition	O
,	O
MXRA5	B
down	O
-	O
regulation	O
resulted	O
in	O
a	O
magnified	O
expression	O
of	O
genes	O
encoding	O
extracellular	O
matrix	O
proteins	O
in	O
response	O
to	O
TGFb1	B
.	O

Furthermore	O
,	O
in	O
clear	O
cell	O
renal	O
cancer	O
,	O
von	B
Hippel	I
-	I
Lindau	I
(	O
VHL	B
)	O
regulated	O
MXRA5	B
expression	O
.	O

In	O
conclusion	O
,	O
MXRA5	B
is	O
a	O
TGFb1	B
-	O
and	O
VHL	B
-	O
regulated	O
protein	O
and	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
identify	O
MXRA5	B
functions	O
as	O
an	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
fibrotic	O
molecule	O
.	O

This	O
information	O
may	O
yield	O
clues	O
to	O
design	O
novel	O
therapeutic	O
strategies	O
in	O
diseases	O
characterized	O
by	O
inflammation	O
and	O
fibrosis	O
.	O

Prognostic	O
and	O
therapeutic	O
value	O
of	O
mitochondrial	B
serine	I
hydroxyl	I
-	I
methyltransferase	I
2	I
as	O
a	O
breast	O
cancer	O
biomarker	O
.	O

Mitochondrial	O
serine	B
hydroxylmethyltransferase	I
2	I
(	O
SHMT2	B
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
serine	O
/	O
glycine	O
synthesis	O
pathway	O
.	O

SHMT2	B
has	O
been	O
implicated	O
as	O
a	O
critical	O
component	O
for	O
tumor	O
cell	O
survival	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
prognostic	O
value	O
and	O
efficiency	O
of	O
SHMT2	B
as	O
a	O
biomarker	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Individual	O
and	O
pooled	O
survival	O
analyses	O
were	O
performed	O
on	O
five	O
independent	O
breast	O
cancer	O
microarray	O
datasets	O
.	O

Gene	O
signatures	O
enriched	O
by	O
SHMT2	B
were	O
also	O
analyzed	O
in	O
these	O
datasets	O
.	O

SHMT2	B
protein	I
expression	O
was	O
detected	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
assay	O
in	O
128	O
breast	O
cancer	O
cases	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
revealed	O
that	O
SHMT2	B
was	O
significantly	O
associated	O
with	O
gene	O
signatures	O
of	O
mitochondrial	O
module	O
,	O
cancer	O
invasion	O
,	O
metastasis	O
and	O
poor	O
survival	O
among	O
breast	O
cancer	O
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
clinical	O
relevance	O
of	O
SHMT2	B
was	O
validated	O
on	O
IHC	O
data	O
.	O

The	O
mitochondrial	O
localization	O
of	O
SHMT2	B
protein	I
was	O
visualized	O
on	O
IHC	O
staining	O
.	O

Independent	O
and	O
pooled	O
analysis	O
confirmed	O
that	O
SHMT2	B
expression	O
was	O
associated	O
with	O
breast	O
cancer	O
tumor	O
aggressiveness	O
(	O
TNM	O
staging	O
and	O
Elson	O
grade	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
prognostic	O
performance	O
of	O
SHMT2	B
mRNA	I
was	O
comparable	O
to	O
other	O
gene	O
signatures	O
and	O
proved	O
superior	O
to	O
TNM	O
staging	O
.	O

Further	O
analysis	O
results	O
indicated	O
that	O
SHMT2	B
had	O
better	O
prognostic	O
value	O
for	O
estrogen	B
receptor	I
(	O
ER	B
)	O
-	O
negative	O
breast	O
cancer	O
patients	O
,	O
compared	O
to	O
ER	O
-	O
positive	O
patients	O
.	O

In	O
cases	O
involving	O
stage	O
IIb	O
breast	O
cancer	O
,	O
chemotherapy	O
significantly	O
extended	O
survival	O
time	O
among	O
patients	O
with	O
high	O
SHMT2	B
expression	O
.	O

These	O
results	O
indicate	O
that	O
SHMT2	B
may	O
be	O
a	O
valuable	O
prognostic	O
biomarker	O
in	O
ER	B
-	O
negative	O
breast	O
cancer	O
cases	O
.	O

Furthermore	O
,	O
SHMT2	B
may	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
treatment	O
and	O
drug	O
discovery	O
.	O

Regulation	O
of	O
GPCR	B
expression	O
through	O
an	O
interaction	O
with	O
CCT7	B
,	O
a	O
subunit	O
of	O
the	O
CCT	B
/	O
TRiC	B
complex	O
.	O

Mechanisms	O
that	O
prevent	O
aggregation	O
and	O
promote	O
folding	O
of	O
nascent	B
G	I
protein	I
-	I
coupled	I
receptors	I
(	O
GPCRs	B
)	O
remain	O
poorly	O
understood	O
.	O

We	O
identified	O
chaperonin	B
containing	I
TCP	I
-	I
1	I
subunit	I
eta	I
(	O
CCT7	B
)	O
as	O
an	O
interacting	O
partner	O
of	O
the	O
β	O
-	O
isoform	O
of	O
thrombo	B
thromboxane	I
A2	I
receptor	I
(	O
TPβ	B
)	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

CCT7	B
coimmunoprecipitated	O
with	O
overexpressed	O
TPβ	B
and	O
β2	B
-	I
adrenergic	I
receptor	I
(	O
β2AR	B
)	O
in	O
HEK	O
293	O
cells	O
,	O
but	O
also	O
with	O
endogenous	O
β2AR	B
.	O

CCT7	B
depletion	O
by	O
small	O
interfering	O
RNA	O
reduced	O
total	O
and	O
cell	O
-	O
surface	O
expression	O
of	O
both	O
receptors	O
and	O
caused	O
redistribution	O
of	O
the	O
receptors	O
to	O
juxtanuclear	O
aggresomes	O
,	O
significantly	O
more	O
so	O
for	O
TPβ	B
than	O
β2AR	B
.	O

Interestingly	O
,	O
Hsp90	B
coimmunoprecipitated	O
with	O
β2AR	B
but	O
virtually	O
not	O
with	O
TPβ	B
,	O
indicating	O
that	O
nascent	O
GPCRs	B
can	O
adopt	O
alternative	O
folding	O
pathways	O
.	O

In	O
vitro	O
pull	O
-	O
down	O
assays	O
showed	O
that	O
both	O
receptors	O
can	O
interact	O
directly	O
with	O
CCT7	B
through	O
their	O
third	O
intracellular	O
loops	O
and	O
C	O
-	O
termini	O
.	O

We	O
demonstrate	O
that	O
Trp	O
(	O
334	O
)	O
in	O
the	O
TPβ	B
C	O
-	O
terminus	O
is	O
critical	O
for	O
the	O
CCT7	B
interaction	O
and	O
plays	O
an	O
important	O
role	O
in	O
TPβ	B
maturation	O
and	O
cell	O
-	O
surface	O
expression	O
.	O

Of	O
note	O
,	O
introducing	O
a	O
tryptophan	O
in	O
the	O
corresponding	O
position	O
of	O
the	O
TPα	B
isoform	O
confers	O
the	O
CCT7	B
-	O
binding	O
and	O
maturation	O
properties	O
of	O
TPβ	B
.	O

We	O
show	O
that	O
an	O
interaction	O
with	O
a	O
subunit	O
of	O
the	O
CCT	B
/	O
TCP	B
-	I
1	I
ring	O
complex	O
(	O
TRiC	O
)	O
chaperonin	O
complex	O
is	O
involved	O
in	O
regulating	O
aggregation	O
of	O
nascent	O
GPCRs	B
and	O
in	O
promoting	O
their	O
proper	O
maturation	O
and	O
expression	O
.	O

Phosphatidylinositol	B
4	I
-	I
kinase	I
IIβ	I
negatively	O
regulates	O
invadopodia	O
formation	O
and	O
suppresses	O
an	O
invasive	O
cellular	O
phenotype	O
.	O

The	O
type	B
II	I
phosphatidylinositol	I
4	I
-	I
kinase	I
(	O
PI4KII	B
)	O
enzymes	B
synthesize	O
the	O
lipid	O
phosphatidylinositol	O
4	O
-	O
phosphate	O
(	O
PI	O
(	O
4	O
)	O
P	O
)	O
,	O
which	O
has	O
been	O
detected	O
at	O
the	O
Golgi	O
complex	O
and	O
endosomal	O
compartments	O
and	O
recruits	O
clathrin	B
adaptors	O
.	O

Despite	O
common	O
mechanistic	O
similarities	O
between	O
the	O
isoforms	O
,	O
the	O
extent	O
of	O
their	O
redundancy	O
is	O
unclear	O
.	O

We	O
found	O
that	O
depletion	O
of	O
PI4KIIα	B
and	O
PI4KIIβ	B
using	O
small	O
interfering	B
RNA	I
led	O
to	O
actin	B
remodeling	O
.	O

Depletion	O
of	O
PI4KIIβ	B
also	O
induced	O
the	O
formation	O
of	O
invadopodia	O
containing	O
membrane	B
type	I
I	I
matrix	I
metalloproteinase	I
(	O
MT1	B
-	I
MMP	I
)	O
.	O

Depletion	O
of	O
PI4KII	B
isoforms	O
also	O
differentially	O
affected	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
pools	O
of	O
PI	O
(	O
4	O
)	O
P	O
and	O
post	O
-	O
TGN	O
traffic	O
.	O

PI4KIIβ	B
depletion	O
caused	O
increased	O
MT1	B
-	I
MMP	I
trafficking	O
to	O
invasive	O
structures	O
at	O
the	O
plasma	O
membrane	O
and	O
was	O
accompanied	O
by	O
reduced	O
colocalization	O
of	O
MT1	B
-	I
MMP	I
with	O
membranes	O
containing	O
the	O
endosomal	O
markers	O
Rab5	B
and	O
Rab7	B
but	O
increased	O
localization	O
with	O
the	O
exocytic	O
Rab8	B
.	O

Depletion	O
of	O
PI4KIIβ	B
was	O
sufficient	O
to	O
confer	O
an	O
aggressive	O
invasive	O
phenotype	O
on	O
minimally	O
invasive	O
HeLa	O
and	O
MCF	O
-	O
7	O
cell	O
lines	O
.	O

Mining	O
oncogenomic	O
databases	O
revealed	O
that	O
loss	O
of	O
the	O
PI4K2B	B
allele	I
and	O
underexpression	O
of	O
PI4KIIβ	B
mRNA	I
are	O
associated	O
with	O
human	O
cancers	O
.	O

This	O
finding	O
supports	O
the	O
cell	O
data	O
and	O
suggests	O
that	O
PI4KIIβ	B
may	O
be	O
a	O
clinically	O
significant	O
suppressor	O
of	O
invasion	O
.	O

We	O
propose	O
that	O
PI4KIIβ	B
synthesizes	O
a	O
pool	O
of	O
PI	O
(	O
4	O
)	O
P	O
that	O
maintains	O
MT1	B
-	I
MMP	I
traffic	O
in	O
the	O
degradative	O
pathway	O
and	O
suppresses	O
the	O
formation	O
of	O
invadopodia	O
.	O

Sildenafil	O
attenuates	O
hypoxic	O
pulmonary	O
remodelling	O
by	O
inhibiting	O
bone	O
marrow	O
progenitor	O
cells	O
.	O

The	O
recruitment	O
of	O
bone	O
marrow	O
(	O
BM	O
)	O
-	O
derived	O
progenitor	O
cells	O
to	O
the	O
lung	O
is	O
related	O
to	O
pulmonary	O
remodelling	O
and	O
the	O
pathogenesis	O
of	O
pulmonary	O
hypertension	O
(	O
PH	O
)	O
.	O

Although	O
sildenafil	O
is	O
a	O
known	O
target	O
in	O
PH	O
treatment	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
still	O
elusive	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
the	O
therapeutic	O
effect	O
of	O
sildenafil	O
is	O
linked	O
to	O
the	O
reduced	O
recruitment	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
,	O
we	O
induced	O
pulmonary	O
remodelling	O
in	O
rats	O
by	O
two	O
-	O
week	O
exposure	O
to	O
chronic	O
hypoxia	O
(	O
CH	O
,	O
10	O
%	O
oxygen	O
)	O
,	O
a	O
trigger	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
.	O

Rats	O
were	O
treated	O
with	O
either	O
placebo	O
(	O
saline	O
)	O
or	O
sildenafil	O
(	O
1	O
.	O
4	O
mg	O
/	O
kg	O
/	O
day	O
ip	O
)	O
during	O
CH	O
.	O

Control	O
rats	O
were	O
kept	O
in	O
room	O
air	O
(	O
21	O
%	O
oxygen	O
)	O
with	O
no	O
treatment	O
.	O

As	O
expected	O
,	O
sildenafil	O
attenuated	O
the	O
CH	O
-	O
induced	O
increase	O
in	O
right	O
ventricular	O
systolic	O
pressure	O
and	O
right	O
ventricular	O
hypertrophy	O
.	O

However	O
,	O
sildenafil	O
suppressed	O
the	O
CH	O
-	O
induced	O
increase	O
in	O
c	B
-	I
kit	I
(	O
+	O
)	O
cells	O
in	O
the	O
adventitia	O
of	O
pulmonary	O
arteries	O
.	O

Moreover	O
,	O
sildenafil	O
reduced	O
the	O
number	O
of	O
c	B
-	I
kit	I
(	O
+	O
)	O
cells	O
that	O
colocalize	O
with	O
tyrosine	B
kinase	I
receptor	I
2	I
(	O
VEGF	B
-	I
R2	I
)	O
and	O
CD68	B
(	O
a	O
marker	O
for	O
macrophages	O
)	O
,	O
indicating	O
a	O
positive	O
effect	O
on	O
moderating	O
hypoxia	O
-	O
induced	O
smooth	O
muscle	O
cell	O
proliferation	O
and	O
inflammation	O
without	O
affecting	O
the	O
pulmonary	O
levels	O
of	O
hypoxia	B
-	I
inducible	I
factor	I
(	I
HIF	I
)	I
-	I
1α	I
.	O

Furthermore	O
,	O
sildenafil	O
depressed	O
the	O
number	O
of	O
CXCR4	O
(	O
+	O
)	O
cells	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
improvement	O
in	O
pulmonary	O
haemodynamic	O
by	O
sildenafil	O
is	O
linked	O
to	O
decreased	O
recruitment	O
of	O
BM	B
-	I
derived	I
c	I
-	I
kit	I
(	I
+	I
)	I
cells	O
in	O
the	O
pulmonary	O
tissue	O
.	O

The	O
attenuation	O
of	O
the	O
recruitment	O
of	O
BM	B
-	I
derived	I
c	I
-	I
kit	I
(	I
+	I
)	I
cells	I
by	O
sildenafil	O
may	O
provide	O
novel	O
therapeutic	O
insights	O
into	O
the	O
control	O
of	O
pulmonary	O
remodelling	O
.	O

Tryptophan	B
hydroxylase	I
1	I
and	O
5	B
-	I
HT7	I
receptor	I
preferentially	O
expressed	O
in	O
triple	O
-	O
negative	O
breast	O
cancer	O
promote	O
cancer	O
progression	O
through	O
autocrine	O
serotonin	O
signaling	O
.	O

BACKGROUND	O
:	O
Triple	O
-	O
negative	O
breast	O
cancer	O
(	O
TNBC	O
)	O
has	O
a	O
high	O
risk	O
of	O
relapse	O
and	O
there	O
are	O
few	O
chemotherapy	O
options	O
.	O

Although	O
5	O
-	O
hydroxytryptamine	O
(	O
5	O
-	O
HT	O
,	O
serotonin	O
)	O
signaling	O
pathways	O
have	O
been	O
suggested	O
as	O
potential	O
targets	O
for	O
anti	O
-	O
cancer	O
drug	O
development	O
,	O
the	O
mechanism	O
responsible	O
for	O
the	O
action	O
of	O
5	O
-	O
HT	O
in	O
TNBC	O
remains	O
unknown	O
.	O

METHODS	O
:	O
Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
and	O
Western	O
blotting	O
were	O
used	O
to	O
measure	O
mRNA	O
and	O
protein	O
levels	O
,	O
respectively	O
.	O

Cell	O
proliferation	O
was	O
measured	O
using	O
CellTiter	O
96	O
Aqueous	O
One	O
Solution	O
.	O

siRNA	O
transfection	O
was	O
used	O
to	O
assess	O
involvement	O
of	O
genes	O
in	O
cancer	O
invasion	O
,	O
which	O
were	O
identified	O
by	O
Matrigel	O
transwell	O
invasion	O
assay	O
.	O

Levels	O
of	O
5	O
-	O
HT	O
and	O
vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
were	O
measured	O
using	O
ELISA	O
kits	O
.	O

Chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
assay	O
and	O
mouse	O
tumor	O
model	O
were	O
used	O
to	O
investigate	O
the	O
in	O
vivo	O
effects	O
of	O
SB269970	O
,	O
a	O
5	B
-	I
HT7	I
receptor	I
antagonist	O
,	O
and	O
BJ	O
-	O
1113	O
,	O
a	O
novel	O
synthetic	O
compound	O
.	O

RESULTS	O
:	O
TNBC	O
cell	O
lines	O
(	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
HCC	O
-	O
1395	O
,	O
and	O
Hs578T	O
)	O
expressed	O
higher	O
levels	O
of	O
tryptophan	B
hydroxylase	I
1	I
(	O
TPH1	B
)	O
than	O
hormone	O
-	O
responsive	O
breast	O
cancer	O
cell	O
lines	O
(	O
MCF	O
-	O
7	O
and	O
T47D	O
)	O
.	O

In	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
5	O
-	O
HT	O
promoted	O
invasion	O
and	O
proliferation	O
via	O
5	B
-	I
HT7	I
receptor	I
,	O
and	O
interestingly	O
,	O
the	O
stimulatory	O
effect	O
of	O
5	O
-	O
HT	O
on	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
invasion	O
was	O
stronger	O
than	O
its	O
effect	O
on	O
proliferation	O
.	O

Likewise	O
,	O
downstream	O
signaling	O
pathways	O
of	O
5	B
-	I
HT7	I
differed	O
during	O
invasion	O
and	O
proliferation	O
,	O
that	O
is	O
,	O
Gα	B
-	O
activated	O
cAMP	O
and	O
Gβγ	B
-	O
activated	O
kinase	O
signaling	O
during	O
invasion	O
,	O
and	O
Gβγ	B
-	O
activated	O
PI3K	B
/	O
Akt	B
signaling	O
during	O
proliferation	O
.	O

Also	O
,	O
5	O
-	O
HT	O
increased	O
the	O
protein	O
expressions	O
of	O
TPH1	B
and	O
VEGF	B
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

These	O
results	O
provide	O
insight	O
of	O
the	O
stimulatory	O
effect	O
of	O
5	O
-	O
HT	O
on	O
breast	O
cancer	O
progression	O
;	O
5	O
-	O
HT	O
was	O
found	O
to	O
act	O
more	O
strongly	O
during	O
the	O
first	O
stage	O
of	O
metastasis	O
(	O
during	O
invasion	O
and	O
migration	O
)	O
than	O
during	O
the	O
later	O
proliferative	O
phase	O
after	O
local	O
invasion	O
.	O

Interestingly	O
,	O
these	O
actions	O
of	O
5	O
-	O
HT	O
were	O
inhibited	O
by	O
BJ	O
-	O
1113	O
,	O
a	O
6	O
-	O
amino	O
-	O
2	O
,	O
4	O
,	O
5	O
-	O
trimethylpyridin	O
-	O
3	O
-	O
ol	O
analog	O
.	O

BJ	O
-	O
1113	O
blocked	O
intracellular	O
signaling	O
pathways	O
initiated	O
by	O
5	B
-	I
HT7	I
receptor	I
activation	O
,	O
and	O
exhibited	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
invasive	O
activities	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

Furthermore	O
,	O
the	O
inhibitory	O
effect	O
of	O
BJ	O
-	O
1113	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
tumor	O
growth	O
was	O
greater	O
than	O
that	O
of	O
SB269970	O
,	O
a	O
5	B
-	I
HT7	I
receptor	I
antagonist	O
.	O

CONCLUSIONS	O
:	O
5	B
-	I
HT7	I
receptor	I
which	O
mediates	O
5	O
-	O
HT	O
-	O
induced	O
cancer	O
progression	O
is	O
a	O
potential	O
therapeutic	O
target	O
in	O
TNBC	O
,	O
and	O
BJ	O
-	O
1113	O
offers	O
a	O
novel	O
scaffold	O
for	O
the	O
development	O
of	O
anti	O
-	O
cancer	O
agents	O
against	O
TNBC	O
.	O

Voltage	B
-	I
Dependent	I
Anion	I
Channel	I
1	I
(	O
VDAC1	B
)	O
Participates	O
the	O
Apoptosis	O
of	O
the	O
Mitochondrial	O
Dysfunction	O
in	O
Desminopathy	O
.	O

Desminopathies	O
caused	O
by	O
the	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
desmin	O
are	O
genetically	O
protein	O
aggregation	O
myopathies	O
.	O

Mitochondrial	O
dysfunction	O
is	O
one	O
of	O
pathological	O
changes	O
in	O
the	O
desminopathies	O
at	O
the	O
earliest	O
stage	O
.	O

The	O
molecular	O
mechanisms	O
of	O
mitochondria	O
dysfunction	O
in	O
desminopathies	O
remain	O
exclusive	O
.	O

VDAC1	B
regulates	O
mitochondrial	O
uptake	O
across	O
the	O
outer	O
membrane	O
and	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
.	O

Relationships	O
between	O
desminopathies	O
and	O
Voltage	B
-	I
dependent	I
anion	I
channel	I
1	I
(	O
VDAC1	B
)	O
remain	O
unclear	O
.	O

Here	O
we	O
successfully	O
constructed	O
the	O
desminopathy	O
rat	O
model	O
,	O
evaluated	O
with	O
conventional	O
stains	O
,	O
containing	O
hematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
,	O
Gomori	O
Trichrome	O
(	O
MGT	O
)	O
,	O
(	O
PAS	O
)	O
,	O
red	O
oil	O
(	O
ORO	O
)	O
,	O
NADH	O
-	O
TR	O
,	O
SDH	O
staining	O
and	O
immunohistochemistry	O
.	O

Immunofluorescence	O
results	O
showed	O
that	O
VDAC1	B
was	O
accumulated	O
in	O
the	O
desmin	B
highly	O
stained	O
area	O
of	O
muscle	O
fibers	O
of	O
desminopathy	O
patients	O
or	O
desminopathy	O
rat	O
model	O
compared	O
to	O
the	O
normal	O
ones	O
.	O

Meanwhile	O
apoptosis	O
related	O
proteins	O
bax	B
and	O
ATF2	B
were	O
involved	O
in	O
desminopathy	O
patients	O
and	O
desminopathy	O
rat	O
model	O
,	O
but	O
not	O
bcl	B
-	I
2	I
,	O
bcl	B
-	I
xl	I
or	O
HK2	B
.	O
VDAC1	B
and	O
desmin	B
are	O
closely	O
relevant	O
in	O
the	O
tissue	O
splices	O
of	O
deminopathies	O
patients	O
and	O
rats	O
with	O
desminopathy	O
at	O
protein	O
lever	O
.	O

Moreover	O
,	O
apoptotic	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
desminopathies	O
,	O
like	O
bax	B
,	O
ATF2	B
,	O
but	O
not	O
bcl	B
-	I
2	I
,	O
bcl	B
-	I
xl	I
or	O
HK2	B
.	O

This	O
pathological	O
analysis	O
presents	O
the	O
correlation	O
between	O
VDAC1	B
and	O
desmin	B
,	O
and	O
apoptosis	B
related	I
proteins	I
are	O
correlated	O
in	O
the	O
desminopathy	O
.	O

Furthermore	O
,	O
we	O
provide	O
a	O
rat	O
model	O
of	O
desminopathy	O
for	O
the	O
investigation	O
of	O
desmin	B
related	O
myopathy	O
.	O

Bach1	B
siRNA	O
attenuates	O
bleomycin	O
-	O
induced	O
pulmonary	O
fibrosis	O
by	O
modulating	O
oxidative	O
stress	O
in	O
mice	O
.	O

Oxidative	O
stress	O
plays	O
an	O
essential	O
role	O
in	O
inflammation	O
and	O
fibrosis	O
.	O

Bach1	B
is	O
an	O
important	O
transcriptional	O
repressor	O
that	O
acts	O
by	O
modulating	O
oxidative	O
stress	O
and	O
represents	O
a	O
potential	O
target	O
in	O
the	O
treatment	O
of	O
pulmonary	O
fibrosis	O
(	O
PF	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
knocked	O
down	O
Bach1	B
using	O
adenovirus	O
-	O
mediated	O
small	O
interfering	B
RNA	I
(	O
siRNA	B
)	O
to	O
determine	O
whether	O
the	O
use	O
of	O
Bach1	B
siRNA	I
is	O
an	O
effective	O
therapeutic	O
strategy	O
in	O
mice	O
with	O
bleomycin	O
(	O
BLM	O
)	O
‑	O
induced	O
PF	O
.	O

Mouse	O
lung	O
fibroblasts	O
(	O
MLFs	O
)	O
were	O
incubated	O
with	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
β1	I
(	O
5	O
ng	O
/	O
ml	O
)	O
and	O
subsequently	O
infected	O
with	O
recombined	O
adenovirus	O
-	O
like	O
Bach1	B
siRNA1	O
and	O
Bach1	B
siRNA2	O
,	O
while	O
an	O
empty	O
adenovirus	O
vector	O
was	O
used	O
as	O
the	O
negative	O
control	O
.	O

The	O
selected	O
Bach1	B
siRNA	O
with	O
higher	O
interference	O
efficiency	O
was	O
used	O
for	O
the	O
animal	O
experiments	O
.	O

A	O
mouse	O
model	O
of	O
BLM	B
-	O
induced	O
PF	O
was	O
established	O
,	O
and	O
Bach1	B
siRNA	O
(	O
1x109	O
pfu	O
)	O
was	O
administered	O
to	O
the	O
mice	O
via	O
the	O
tail	O
vein	O
.	O

The	O
results	O
revealed	O
that	O
the	O
Bach1	B
mRNA	I
and	O
protein	O
levels	O
were	O
significantly	O
downregulated	O
by	O
Bach1	B
siRNA	O
.	O

Furthermore	O
,	O
the	O
MLFs	O
infected	O
with	O
Bach1	B
siRNA	O
exhibited	O
increased	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
heme	B
oxygenase	I
-	I
1	I
and	O
glutathione	B
peroxidase	I
1	I
,	O
but	O
decreased	O
levels	O
of	O
TGF	B
-	I
b1	I
and	O
interleukin	B
-	I
6	I
in	O
the	O
cell	O
supernatants	O
compared	O
with	O
the	O
cells	O
exposed	O
to	O
TGF	B
-	I
β1	I
alone	O
.	O

Bach1	B
knockdown	O
by	O
siRNA	O
also	O
enhanced	O
the	O
expression	O
of	O
antioxidant	O
factors	O
,	O
but	O
suppressed	O
that	O
of	O
fibrosis	O
‑	O
related	O
cytokines	O
in	O
mice	O
compared	O
with	O
the	O
BLM	O
group	O
.	O

Finally	O
,	O
the	O
inflammatory	O
infiltration	O
of	O
alveolar	O
and	O
interstitial	O
cells	O
and	O
the	O
destruction	O
of	O
lung	O
structure	O
were	O
significantly	O
attenuated	O
in	O
the	O
mide	O
administered	O
Bach1	B
siRNA	O
compared	O
with	O
those	O
in	O
the	O
BLM	O
group	O
.	O

On	O
the	O
whole	O
,	O
our	O
findings	O
demonstrate	O
that	O
Bach1	B
siRNA	O
exerts	O
protective	O
effects	O
against	O
BLM	O
-	O
induced	O
PF	O
in	O
mice	O
.	O

Our	O
data	O
may	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
novel	O
targeted	O
therapeutic	O
strategies	O
for	O
PF	O
.	O

Spirulina	O
lipopolysaccharides	O
inhibit	O
tumor	O
growth	O
in	O
a	O
Toll	B
-	I
like	I
receptor	I
4	I
-	O
dependent	O
manner	O
by	O
altering	O
the	O
cytokine	B
milieu	O
from	O
interleukin	B
-	I
17	I
/	O
interleukin	B
-	I
23	I
to	O
interferon	B
-	I
γ	I
.	O

Th17	O
cells	O
and	O
the	O
cytokine	O
they	O
produce	O
,	O
interleukin	B
(	I
IL	I
)	I
-	I
17	I
,	O
play	O
an	O
important	O
role	O
in	O
tumor	O
progression	O
in	O
humans	O
and	O
in	O
mice	O
.	O

IL	B
-	I
6	I
and	O
IL	B
-	I
23	I
are	O
critical	O
cytokines	O
for	O
the	O
differentiation	O
and	O
propagation	O
of	O
Th17	O
cells	O
,	O
respectively	O
.	O

Bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
are	O
known	O
to	O
stimulate	O
immune	O
cells	O
to	O
produce	O
such	O
inflammatory	O
cytokines	O
.	O

Contrary	O
to	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
LPS	O
,	O
LPS	O
from	O
Spirulina	O
has	O
low	O
toxicity	O
and	O
barely	O
induces	O
in	O
vivo	O
production	O
of	O
IL	B
-	I
6	I
and	O
IL	B
-	I
23	I
in	O
mice	O
.	O

We	O
examined	O
the	O
antitumor	O
effects	O
of	O
Spirulina	O
LPS	B
compared	O
to	O
E	B
.	I
coli	I
LPS	I
in	O
an	O
MH134	O
hepatoma	O
model	O
.	O

Administration	O
of	O
Spirulina	O
LPS	O
suppressed	O
tumor	O
growth	O
in	O
C3H	O
/	O
HeN	O
mice	O
,	O
but	O
not	O
in	O
Toll	B
-	I
like	I
receptor	I
4	I
(	O
TLR4	B
)	O
-	O
mutant	O
C3H	O
/	O
HeJ	O
mice	O
,	O
by	O
reducing	O
serum	O
levels	O
of	O
IL	B
-	I
17	I
and	O
IL	B
-	I
23	I
,	O
while	O
increasing	O
interferon	B
(	O
IFN	B
)	O
-	O
γ	B
levels	O
.	O

The	O
antitumor	O
activity	O
and	O
IFN	B
-	I
γ	I
production	O
were	O
mediated	O
by	O
T	O
cells	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
Spirulina	B
LPS	I
impaired	O
the	O
antigen	O
-	O
presenting	O
function	O
that	O
supports	O
the	O
generation	O
of	O
IL	B
-	I
17	I
-	O
producing	O
cells	O
in	O
a	O
toll	B
-	I
like	I
receptor	I
(	I
TLR	I
)	I
4	I
-	O
dependent	O
manner	O
.	O

Of	O
note	O
,	O
injection	O
of	O
anti	B
-	I
IL	I
-	I
17	I
antibody	I
in	O
tumor	O
-	O
bearing	O
C3H	O
/	O
HeN	O
mice	O
in	O
the	O
absence	O
of	O
Spirulina	O
LPS	O
markedly	O
suppressed	O
tumor	O
growth	O
and	O
augmented	O
IFN	B
-	I
γ	I
responses	O
.	O

Thus	O
,	O
our	O
results	O
support	O
the	O
notion	O
that	O
IFN	B
-	I
γ	I
and	O
IL	B
-	I
17	I
/	O
IL	B
-	I
23	I
mutually	O
regulate	O
Th17	O
and	O
Th1	O
responses	O
in	O
tumor	O
-	O
bearing	O
hosts	O
,	O
and	O
Spirulina	O
LPS	O
modulates	O
the	O
balance	O
of	O
the	O
IFN	B
-	I
γ	I
-	O
IL	B
-	I
17	I
/	O
IL	B
-	I
23	I
axis	O
towards	O
IFN	B
-	I
γ	I
production	O
,	O
which	O
leads	O
to	O
tumor	O
inhibition	O
.	O

Furthermore	O
,	O
Spirulina	O
LPS	O
effectively	O
inhibited	O
the	O
spontaneous	O
development	O
of	O
mammary	O
tumors	O
.	O

This	O
study	O
has	O
important	O
implications	O
for	O
the	O
exploitation	O
of	O
TLR	B
-	O
based	O
immunomodulators	O
for	O
cancer	O
immunotherapy	O
.	O

NEK2	B
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
hepatocellular	O
carcinoma	O
.	O

Never	B
in	I
mitosis	I
gene	I
A	I
(	I
NIMA	I
)	I
-	I
related	I
kinase	I
2	I
(	O
NEK2	B
)	O
is	O
a	O
microtubule	B
-	I
associated	I
protein	I
that	O
regulates	O
spindle	O
assembly	O
in	O
human	O
cells	O
and	O
is	O
overexpressed	O
in	O
various	O
malignancies	O
.	O

However	O
,	O
the	O
role	O
of	O
NEK2	B
in	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
remains	O
undetermined	O
.	O

We	O
performed	O
RNA	O
-	O
seq	O
of	O
the	O
HCC	O
cell	O
line	O
SMMC	O
-	O
7721	O
and	O
the	O
normal	O
liver	O
cell	O
line	O
HL	O
-	O
7702	O
using	O
the	O
Ion	O
Proton	O
System	O
.	O

NEK2	B
expression	O
was	O
detected	O
using	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
two	O
cell	O
lines	O
and	O
5	O
matched	O
HCC	O
and	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

The	O
correlation	O
between	O
survival	O
and	O
NEK2	B
expression	O
was	O
analyzed	O
in	O
359	O
patients	O
with	O
HCC	O
using	O
RNASeqV2	O
data	O
available	O
from	O
The	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
website	O
(	O
https	O
:	O
/	O
/	O
tcga	O
-	O
data	O
.	O
nci	O
.	O
nih	O
.	O
gov	O
/	O
tcga	O
/	O
)	O
.	O

The	O
expression	O
of	O
NEK2	B
,	O
phospho	B
-	I
AKT	I
and	O
MMP	B
-	I
2	I
was	O
evaluated	O
by	O
immunohistochemistry	O
in	O
63	O
cases	O
of	O
HCC	O
and	O
matched	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

Relationships	O
between	O
protein	O
expression	O
and	O
clinicopathological	O
parameters	O
were	O
assessed	O
,	O
and	O
the	O
correlations	O
between	O
NEK2	B
with	O
phospho	B
-	I
AKT	I
and	O
MMP	B
-	I
2	I
expressions	O
were	O
evaluated	O
.	O

A	O
total	O
of	O
610	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
revealed	O
in	O
the	O
transcriptome	O
comparison	O
,	O
297	O
of	O
which	O
were	O
upregulated	O
and	O
313	O
were	O
downregulated	O
in	O
HCC	O
.	O

NEK2	B
,	O
as	O
the	O
most	O
obviously	O
different	O
DEG	B
in	O
cells	O
and	O
tissues	O
from	O
the	O
RNA	O
-	O
seq	O
data	O
,	O
was	O
listed	O
as	O
an	O
HCC	O
candidate	O
biomarker	O
for	O
further	O
verification	O
.	O

NEK2	B
was	O
overexpressed	O
in	O
HCC	O
cells	O
and	O
tissues	O
(	O
P	O
=	O
0	O
.	O
002	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
and	O
HCC	O
patients	O
with	O
a	O
high	O
expression	O
of	O
NEK2	B
had	O
a	O
poor	O
prognosis	O
(	O
P	O
=	O
0	O
.	O
0145	O
)	O
.	O

Clinical	O
analysis	O
indicated	O
that	O
the	O
overexpression	O
of	O
NEK2	B
in	O
HCC	O
was	O
significantly	O
correlated	O
with	O
diolame	O
complete	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tumor	O
nodule	O
number	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
recurrence	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

NEK2	B
expression	O
was	O
positively	O
correlated	O
with	O
the	O
expression	O
of	O
phospho	B
-	I
AKT	I
(	O
r	O
=	O
0	O
.	O
883	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
MMP	B
-	I
2	I
(	O
r	O
=	O
0	O
.	O
781	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Overexpression	O
of	O
NEK2	B
was	O
associated	O
with	O
clinicopathological	O
characteristics	O
and	O
poor	O
patient	O
outcomes	O
,	O
suggesting	O
that	O
NEK2	B
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
HCC	O
.	O

Alteration	O
of	O
NEK2	B
protein	I
levels	O
may	O
contribute	O
to	O
invasion	O
and	O
metastasis	O
of	O
HCC	O
,	O
which	O
may	O
occur	O
through	O
activation	O
of	O
AKT	B
signaling	O
and	O
promotion	O
of	O
MMP	B
-	I
2	I
expression	O
.	O

HIF	B
-	I
1α	I
induction	O
during	O
reperfusion	O
avoids	O
maladaptive	O
repair	O
after	O
renal	O
ischemia	O
/	O
reperfusion	O
involving	O
miR127	B
-	I
3p	I
.	O

Ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
leads	O
to	O
Acute	O
Kidney	O
Injury	O
.	O

HIF	B
-	I
1α	I
is	O
a	O
key	O
factor	O
during	O
organ	O
response	O
to	O
I	O
/	O
R	O
.	O
We	O
previously	O
demonstrated	O
that	O
HIF	B
-	I
1α	I
is	O
induced	O
during	O
renal	O
reperfusion	O
,	O
after	O
ischemia	O
.	O

Here	O
we	O
investigate	O
the	O
role	O
of	O
HIF	B
-	I
1α	I
and	O
the	O
HIF	B
-	I
1α	I
dependent	O
mechanisms	O
in	O
renal	O
repair	O
after	O
ischemia	O
.	O

By	O
interference	O
of	O
HIF	B
-	I
1α	I
in	O
a	O
rat	O
model	O
of	O
renal	O
I	O
/	O
R	O
,	O
we	O
observed	O
loss	O
of	O
expression	O
and	O
mis	O
-	O
localization	O
of	O
e	B
-	I
cadherin	I
and	O
induction	O
of	O
α	B
-	I
SMA	I
,	O
MMP	B
-	I
13	I
,	O
TGFβ	B
,	O
and	O
collagen	B
I	I
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
HIF	B
-	I
1α	I
inhibition	O
promotes	O
renal	O
cell	O
infiltrates	O
by	O
inducing	O
IL	B
-	I
1β	I
,	O
TNF	B
-	I
α	I
,	O
MCP	B
-	I
1	I
and	O
VCAM	B
-	I
1	I
,	O
through	O
NFkB	B
activity	O
.	O

In	O
addition	O
,	O
HIF	B
-	I
1α	I
inhibition	O
induced	O
proximal	O
tubule	O
cells	O
proliferation	O
but	O
it	O
did	O
not	O
induce	O
compensatory	O
apoptosis	O
,	O
both	O
in	O
vivo	O
.	O

In	O
vitro	O
,	O
HIF	B
-	I
1α	I
knockdown	O
in	O
HK2	O
cells	O
subjected	O
to	O
hypoxia	O
/	O
reoxygenation	O
(	O
H	O
/	O
R	O
)	O
promote	O
cell	O
entry	O
into	O
S	O
phase	O
,	O
correlating	O
with	O
in	O
vivo	O
data	O
.	O

HIF	B
-	I
1α	I
interference	O
leads	O
to	O
downregulation	O
of	O
miR	B
-	I
127	I
-	I
3p	I
and	O
induction	O
of	O
its	O
target	O
gene	O
Bcl6	B
in	O
vivo	O
.	O

Moreover	O
,	O
modulation	O
of	O
miR	B
-	I
127	I
-	I
3p	I
in	O
HK2	O
cells	O
subjected	O
to	O
H	O
/	O
R	O
results	O
in	O
EMT	O
regulation	O
:	O
miR127	B
-	I
3p	I
inhibition	O
promote	O
loss	O
of	O
e	B
-	I
cadherin	I
and	O
induction	O
of	O
α	B
-	I
SMA	I
and	O
collagen	B
I	I
.	O

In	O
conclusion	O
,	O
HIF	B
-	I
1α	I
induction	O
during	O
reperfusion	O
is	O
a	O
protector	O
mechanism	O
implicated	O
in	O
a	O
normal	O
renal	O
tissue	O
repair	O
after	O
I	O
/	O
R	O
.	O

Higher	O
IGFBP	B
-	I
1	I
to	O
IGF	B
-	I
1	I
serum	O
ratio	O
predicts	O
unfavourable	O
survival	O
in	O
patients	O
with	O
nasopharyngeal	O
carcinoma	O
.	O

BACKGROUND	O
:	O
The	O
insulin	B
-	I
like	I
growth	I
factor	I
(	O
IGF	B
)	O
system	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
cancer	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
expression	O
of	O
the	O
IGF	B
system	I
components	I
and	O
their	O
clinicopathological	O
significance	O
and	O
prognostic	O
value	O
in	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

METHODS	O
:	O
IGF	B
system	I
components	I
(	O
IGF	B
-	I
1	I
,	O
IGF	B
-	I
2	I
,	O
IGF	B
-	I
1SR	I
,	O
IGFBP	B
-	I
1	I
,	O
IGFBP	B
-	I
2	I
,	O
IGFBP	B
-	I
3	I
,	O
IGFBP	B
-	I
4	I
and	O
IGFBP	B
-	I
6	I
)	O
were	O
quantified	O
from	O
the	O
plasma	O
of	O
NPC	O
patients	O
and	O
healthy	O
individuals	O
using	O
the	O
RayBio	O
Human	O
Cytokine	O
Antibody	O
Array	O
.	O

IGFBP	B
-	I
1	I
and	O
IGF	B
-	I
1	I
mRNA	I
levels	O
were	O
quantified	O
by	O
real	O
-	O
time	O
qPCR	O
,	O
and	O
protein	O
expression	O
was	O
detected	O
by	O
western	O
blot	O
in	O
nine	O
NPC	O
cell	O
lines	O
and	O
four	O
immortalized	O
nasopharyngeal	O
epithelial	O
(	O
NPE	O
)	O
cell	O
lines	O
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
IGFBP	B
-	I
1	I
and	O
IGF	B
-	I
1	I
was	O
detected	O
by	O
immunohistochemistry	O
in	O
paraffin	O
-	O
embedded	O
NPC	O
tissues	O
.	O

ELISA	O
analysis	O
was	O
used	O
to	O
measure	O
the	O
serum	O
levels	O
of	O
IGFBP	B
-	I
1	I
and	O
IGF	B
-	I
1	I
in	O
142	O
NPC	O
patients	O
and	O
128	O
healthy	O
controls	O
and	O
determine	O
potential	O
correlation	O
with	O
clinicopathological	O
parameters	O
.	O

RESULTS	O
:	O
Significantly	O
higher	O
levels	O
of	O
circulating	O
IGFBP	B
-	I
1	I
and	O
lower	O
levels	O
of	O
IGF	B
-	I
1	I
and	O
IGF	B
-	I
2	I
were	O
detected	O
in	O
NPC	O
patients	O
compared	O
to	O
healthy	O
controls	O
by	O
Cytokine	O
Antibody	O
Array	O
analyses	O
(	O
P	O
=	O
0	O
.	O
034	O
,	O
0	O
.	O
012	O
,	O
0	O
.	O
046	O
,	O
respectively	O
)	O
.	O

IGFBP	B
-	I
1	I
expression	O
was	O
detected	O
in	O
the	O
majority	O
of	O
NPC	O
cell	O
lines	O
,	O
but	O
not	O
in	O
NPE	O
cell	O
lines	O
,	O
and	O
was	O
shown	O
to	O
localize	O
to	O
the	O
nucleus	O
of	O
tumour	O
cells	O
,	O
in	O
contrast	O
to	O
the	O
cytoplasmic	O
staining	O
observed	O
in	O
normal	O
cells	O
.	O

Importantly	O
,	O
IGFBP	B
-	I
1	I
expression	O
was	O
stronger	O
in	O
NPC	O
tumour	O
tissues	O
compared	O
to	O
peritumoural	O
tissues	O
.	O

In	O
contrast	O
,	O
IGF	B
-	I
1	I
expression	O
was	O
weak	O
or	O
absent	O
in	O
NPC	O
and	O
NPE	O
cell	O
lines	O
,	O
with	O
the	O
exception	O
of	O
the	O
EBV	O
-	O
infected	O
C666	O
cell	O
line	O
,	O
and	O
was	O
found	O
to	O
be	O
expressed	O
at	O
lower	O
levels	O
in	O
tumour	O
tissues	O
compared	O
to	O
tumour	O
-	O
adjacent	O
normal	O
tissue	O
.	O

Levels	O
of	O
serum	O
IGFBP	B
-	I
1	I
were	O
shown	O
to	O
be	O
significantly	O
higher	O
in	O
patients	O
with	O
NPCs	O
compared	O
to	O
healthy	O
control	O
individuals	O
(	O
55	O
.	O
23	O
±	O
41	O
.	O
25	O
μg	O
/	O
L	O
vs	O
.	O
32	O
.	O
08	O
±	O
29	O
.	O
73	O
μg	O
/	O
L	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
serum	O
levels	O
of	O
IGF	B
-	I
1	I
were	O
significantly	O
lower	O
in	O
NPC	O
patients	O
compared	O
to	O
healthy	O
controls	O
(	O
98	O
.	O
14	O
±	O
71	O
.	O
48	O
μg	O
/	O
L	O
vs	O
.	O
164	O
.	O
01	O
±	O
92	O
.	O
08	O
μg	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Consistently	O
,	O
the	O
IGFBP	B
-	I
1	I
/	O
IGF	B
-	I
1	I
serum	O
ratio	O
was	O
shown	O
to	O
be	O
significantly	O
higher	O
in	O
NPC	O
patients	O
compared	O
to	O
healthy	O
control	O
individuals	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

Serum	O
levels	O
of	O
IGFBP	B
-	I
1	I
and	O
the	O
IGFBP	B
-	I
1	I
/	O
IGF	B
-	I
1	I
ratio	O
significantly	O
correlated	O
with	O
age	O
(	O
P	O
=	O
0	O
.	O
020	O
;	O
P	O
=	O
0	O
.	O
016	O
)	O
,	O
WHO	O
histological	O
classification	O
(	O
P	O
=	O
0	O
.	O
044	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
,	O
titre	O
of	O
EA	B
(	O
EB	O
Virus	O
Capsid	B
Antigen	I
-	O
IgA	B
)	O
and	O
NPC	O
(	O
P	O
=	O
0	O
.	O
015	O
;	O
P	O
=	O
0	O
.	O
016	O
)	O
.	O

In	O
contrast	O
,	O
higher	O
IGFBP	B
-	I
1	I
serum	O
levels	O
and	O
IGFBP	B
-	I
1	I
/	O
IGF	B
-	I
1	I
ratio	O
significantly	O
correlated	O
with	O
poor	O
RFS	O
(	O
P	O
=	O
0	O
.	O
046	O
;	O
P	O
=	O
0	O
.	O
037	O
)	O
and	O
OS	O
(	O
P	O
=	O
0	O
.	O
038	O
;	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
the	O
IGFBP	B
-	I
1	I
/	O
IGF	B
-	I
1	I
ratio	O
,	O
but	O
not	O
serum	O
IGFBP	B
-	I
1	I
level	O
,	O
represents	O
an	O
independent	O
risk	O
factor	O
for	O
poor	O
RFS	O
(	O
P	O
=	O
0	O
.	O
044	O
)	O
and	O
OS	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
higher	O
IGFBP	B
-	I
1	I
/	O
IGF	B
-	I
1	I
serum	O
ratio	O
is	O
significantly	O
associated	O
with	O
poor	O
prognosis	O
in	O
NPC	O
patients	O
.	O

Structural	O
basis	O
of	O
Mcm2	B
-	O
7	O
replicative	O
helicase	O
loading	O
by	O
ORC	B
-	O
Cdc6	B
and	O
Cdt1	B
.	O

To	O
initiate	O
DNA	O
replication	O
,	O
the	O
origin	O
recognition	O
complex	O
(	O
ORC	O
)	O
and	O
Cdc6	B
load	O
an	O
Mcm2	B
-	I
7	I
double	I
hexamer	I
onto	O
DNA	O
.	O

Without	O
ATP	O
hydrolysis	O
,	O
ORC	B
-	O
Cdc6	B
recruits	O
one	O
Cdt1	B
-	O
bound	O
Mcm2	B
-	I
7	I
hexamer	O
,	O
thus	O
forming	O
an	O
ORC	B
-	O
Cdc6	B
-	O
Cdt1	B
-	O
Mcm2	B
-	I
7	I
(	O
OCCM	O
)	O
helicase	O
-	O
loading	O
intermediate	O
.	O

Here	O
we	O
report	O
a	O
3	O
.	O
9	O
-	O
Å	O
structure	O
of	O
Saccharomyces	B
cerevisiae	I
OCCM	I
on	O
DNA	O
.	O

Flexible	O
Mcm2	B
-	O
7	O
winged	O
-	O
helix	O
domains	O
(	O
WHDs	O
)	O
engage	O
ORC	B
-	O
Cdc6	B
.	O

A	O
three	O
-	O
domain	O
Cdt1	B
configuration	O
embraces	O
Mcm2	B
,	O
Mcm4	B
,	O
and	O
Mcm6	B
,	O
thus	O
comprising	O
nearly	O
half	O
of	O
the	O
hexamer	O
.	O

The	O
Cdt1	B
C	I
-	I
terminal	I
domain	I
extends	O
to	O
the	O
Mcm6	B
WHD	O
,	O
which	O
binds	O
the	O
Orc4	B
WHD	O
.	O

DNA	O
passes	O
through	O
the	O
ORC	B
-	O
Cdc6	B
and	O
Mcm2	B
-	I
7	I
rings	I
.	O

Origin	O
DNA	O
interaction	O
is	O
mediated	O
by	O
an	O
α	O
-	O
helix	O
within	O
Orc4	B
and	O
positively	O
charged	O
loops	O
within	O
Orc2	B
and	O
Cdc6	B
.	O

The	O
Mcm2	B
-	I
7	I
C	I
-	I
tier	I
AAA	I
+	I
ring	I
is	O
topologically	O
closed	O
by	O
an	O
Mcm5	B
loop	O
that	O
embraces	O
Mcm2	B
,	O
but	O
the	O
N	O
-	O
tier	O
-	O
ring	O
Mcm2	B
-	O
Mcm5	B
interface	O
remains	O
open	O
.	O

This	O
structure	O
suggests	O
a	O
loading	O
mechanism	O
of	O
the	O
first	O
Cdt1	B
-	O
bound	O
Mcm2	B
-	I
7	I
hexamer	I
by	O
ORC	B
-	O
Cdc6	B
.	O

ZRF1	B
is	O
a	O
novel	O
S6	B
kinase	I
substrate	O
that	O
drives	O
the	O
senescence	O
programme	O
.	O

The	O
inactivation	O
of	O
S6	B
kinases	I
mimics	O
several	O
aspects	O
of	O
caloric	O
restriction	O
,	O
including	O
small	O
body	O
size	O
,	O
increased	O
insulin	B
sensitivity	O
and	O
longevity	O
.	O

However	O
,	O
the	O
impact	O
of	O
S6	B
kinase	I
activity	O
on	O
cellular	O
senescence	O
remains	O
to	O
be	O
established	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
constitutive	O
activation	O
of	O
mammalian	B
target	I
of	I
rapamycin	I
complex	I
1	I
(	O
mTORC1	B
)	O
by	O
tuberous	B
sclerosis	I
complex	I
(	O
TSC	B
)	O
mutations	O
induces	O
a	O
premature	O
senescence	O
programme	O
in	O
fibroblasts	O
that	O
relies	O
on	O
S6	B
kinases	I
.	O

To	O
determine	O
novel	O
molecular	O
targets	O
linking	O
S6	B
kinase	I
activation	O
to	O
the	O
control	O
of	O
senescence	O
,	O
we	O
set	O
up	O
a	O
chemical	O
genetic	O
screen	O
,	O
leading	O
to	O
the	O
identification	O
of	O
the	O
nuclear	O
epigenetic	O
factor	O
ZRF1	B
(	O
also	O
known	O
as	O
DNAJC2	B
,	O
MIDA1	B
,	O
Mpp11	B
)	O
.	O

S6	B
kinases	I
phosphorylate	O
ZRF1	B
on	O
Ser47	O
in	O
cultured	O
cells	O
and	O
in	O
mammalian	O
tissues	O
in	O
vivo	O
Knock	O
-	O
down	O
of	O
ZRF1	B
or	O
expression	O
of	O
a	O
phosphorylation	O
mutant	O
is	O
sufficient	O
to	O
blunt	O
the	O
S6	B
kinase	I
-	O
dependent	O
senescence	O
programme	O
.	O

This	O
is	O
traced	O
by	O
a	O
sharp	O
alteration	O
in	O
p16	B
levels	O
,	O
the	O
cell	O
cycle	O
inhibitor	O
and	O
a	O
master	O
regulator	O
of	O
senescence	O
.	O

Our	O
findings	O
reveal	O
a	O
mechanism	O
by	O
which	O
nutrient	O
sensing	O
pathways	O
impact	O
on	O
cell	O
senescence	O
through	O
the	O
activation	O
of	O
mTORC1	B
-	O
S6	B
kinases	I
and	O
the	O
phosphorylation	O
of	O
ZRF1	B
.	O

Protective	O
effect	O
of	O
naringin	O
against	O
the	O
LPS	O
-	O
induced	O
apoptosis	O
of	O
PC12	O
cells	O
:	O
Implications	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
increased	O
apoptosis	O
plays	O
an	O
essential	O
role	O
in	O
neurodegenerative	O
disorders	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
apoptosis	O
largely	O
through	O
the	O
production	O
of	O
intracellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
inflammatory	O
mediators	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
protective	O
mechanisms	O
of	O
naringin	O
(	O
Nar	O
)	O
,	O
a	O
pummelo	O
peel	O
extract	O
,	O
on	O
LPS	O
-	O
induced	O
PC12	O
cell	O
apoptosis	O
.	O

Nar	O
pre	O
-	O
conditioning	O
prior	O
to	O
stimulation	O
with	O
LPS	O
for	O
18	O
h	O
was	O
a	O
prerequisite	O
for	O
evaluating	O
PC12	O
cell	O
viability	O
and	O
the	O
protective	O
mechanisms	O
of	O
Nar	O
.	O

Nar	B
significantly	O
improved	O
cell	O
survival	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

On	O
the	O
one	O
hand	O
,	O
Nar	B
downregulated	O
cytochrome	B
P450	I
2E1	I
(	O
CYP2E1	B
)	O
,	O
inhibited	O
the	O
release	O
of	O
ROS	O
,	O
mitigated	O
the	O
stimulation	O
of	O
oxidative	O
stress	O
,	O
and	O
rectified	O
the	O
antioxidant	O
protein	O
contents	O
of	O
nuclear	B
factor	I
erythroid	I
2	I
-	I
related	I
factor	I
2	I
(	O
Nrf2	B
)	O
,	O
heme	B
oxygenase	I
-	I
1	I
(	O
HO	B
-	I
1	I
)	O
,	O
superoxide	B
dismutase	I
(	I
SOD	I
)	I
2	I
and	O
glutathione	B
synthetase	I
(	O
GSS	B
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Nar	O
downregulated	O
inflammatory	O
gene	O
and	O
protein	O
expression	O
,	O
including	O
interleukin	B
(	I
IL	I
)	I
-	I
1β	I
,	O
IL	B
-	I
6	I
,	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-	I
α	I
,	O
HMGB1	B
,	O
high	B
mobility	I
group	I
box	I
1	I
protein	I
(	O
HMGB1	B
)	O
,	O
cyclooxygenase	B
-	I
2	I
(	O
COX	B
-	I
2	I
)	O
,	O
the	O
Toll	B
-	I
like	I
receptor	I
4	I
(	O
TLR4	B
)	O
-	O
myeloid	B
differentiation	I
factor	I
88	I
(	O
MyD88	B
)	O
-	O
TNF	B
receptor	I
‑	I
associated	I
factor	I
6	I
(	O
TRAF6	B
)	O
path	O
-	O
way	O
and	O
downstream	O
mitogen	B
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
phosphorylation	O
,	O
activator	B
protein	I
transcription	I
factor	I
-	I
1	I
(	O
AP	B
-	I
1	I
)	O
and	O
nuclear	B
factor	I
(	I
NF	I
)	I
-	I
κB	I
.	O

Moroever	O
,	O
Nar	O
markedly	O
attenuated	O
the	O
cytochrome	B
c	I
shift	O
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
and	O
regulated	O
caspase	B
-	I
3	I
-	I
related	I
protein	I
expression	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
the	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
apoptotic	O
effects	O
of	O
Nar	O
in	O
neuronal	O
-	O
like	O
PC12	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
Nar	O
can	O
be	O
utilized	O
as	O
a	O
potential	O
drug	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

Reversal	O
of	O
DDK	B
-	O
Mediated	O
MCM	B
Phosphorylation	O
by	O
Rif1	B
-	O
PP1	B
Regulates	O
Replication	O
Initiation	O
and	O
Replisome	O
Stability	O
Independently	O
of	O
ATR	B
/	O
Chk1	B
.	O

Dbf4	B
-	I
dependent	I
kinases	I
(	O
DDK	B
s	I
)	O
are	O
required	O
for	O
the	O
initiation	O
of	O
DNA	O
replication	O
,	O
their	O
essential	O
targets	O
being	O
the	O
MCM2	B
-	I
7	I
proteins	I
.	O

We	O
show	O
that	O
,	O
in	O
Xenopus	O
laevis	O
egg	O
extracts	O
and	O
human	O
cells	O
,	O
hyper	O
-	O
phosphorylation	O
of	O
DNA	O
-	O
bound	O
Mcm4	B
,	O
but	O
not	O
phosphorylation	O
of	O
Mcm2	B
,	O
correlates	O
with	O
DNA	O
replication	O
.	O

These	O
phosphorylations	O
are	O
differentially	O
affected	O
by	O
the	O
DDK	B
inhibitors	O
PHA	O
-	O
767491	O
and	O
XL413	O
.	O

We	O
show	O
that	O
DDK	B
-	O
dependent	O
MCM	B
phosphorylation	O
is	O
reversed	O
by	O
protein	B
phosphatase	I
1	I
(	O
PP1	B
)	O
targeted	O
to	O
chromatin	O
by	O
Rif1	B
.	O

Loss	O
of	O
Rif1	B
increased	O
MCM	B
phosphorylation	O
and	O
the	O
rate	O
of	O
replication	O
initiation	O
and	O
also	O
compromised	O
the	O
ability	O
of	O
cells	O
to	O
block	O
initiation	O
when	O
challenged	O
with	O
replication	O
inhibitors	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
Rif1	B
can	O
mediate	O
MCM	B
dephosphorylation	O
at	O
replication	O
forks	O
and	O
that	O
the	O
stability	O
of	O
dephosphorylated	O
replisomes	O
strongly	O
depends	O
on	O
Chk1	B
activity	O
.	O

We	O
propose	O
that	O
both	O
replication	O
initiation	O
and	O
replisome	O
stability	O
depend	O
on	O
MCM	B
phosphorylation	O
,	O
which	O
is	O
maintained	O
by	O
a	O
balance	O
of	O
DDK	B
-	O
dependent	O
phosphorylation	O
and	O
Rif1	B
-	O
mediated	O
dephosphorylation	O
.	O

GLUT4	B
Is	O
Not	O
Necessary	O
for	O
Overload	O
-	O
Induced	O
Glucose	O
Uptake	O
or	O
Hypertrophic	O
Growth	O
in	O
Mouse	O
Skeletal	O
Muscle	O
.	O

GLUT4	B
is	O
necessary	O
for	O
acute	O
insulin	B
-	O
and	O
contraction	O
-	O
induced	O
skeletal	O
muscle	O
glucose	O
uptake	O
,	O
but	O
its	O
role	O
in	O
chronic	O
muscle	O
loading	O
(	O
overload	O
)	O
-	O
induced	O
glucose	O
uptake	O
is	O
unknown	O
.	O

Our	O
goal	O
was	O
to	O
determine	O
whether	O
GLUT4	B
is	O
required	O
for	O
overload	O
-	O
induced	O
glucose	O
uptake	O
.	O

Overload	O
was	O
induced	O
in	O
mouse	O
plantaris	O
muscle	O
by	O
unilateral	O
synergist	O
ablation	O
.	O

After	O
5	O
days	O
,	O
muscle	O
weights	O
and	O
ex	O
vivo	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
uptake	O
were	O
assessed	O
.	O

Overload	O
-	O
induced	O
muscle	O
glucose	O
uptake	O
and	O
hypertrophic	O
growth	O
were	O
not	O
impaired	O
in	O
muscle	O
-	O
specific	O
GLUT4	B
knockout	O
mice	O
,	O
demonstrating	O
that	O
GLUT4	B
is	O
not	O
necessary	O
for	O
these	O
processes	O
.	O

To	O
assess	O
which	O
transporters	O
mediate	O
overload	O
-	O
induced	O
glucose	O
uptake	O
,	O
chemical	O
inhibitors	O
were	O
used	O
.	O

The	O
facilitative	O
GLUT	B
inhibitor	O
cytochalasin	O
B	O
,	O
but	O
not	O
the	O
sodium	O
-	O
dependent	O
glucose	O
cotransport	O
inhibitor	O
phloridzin	O
,	O
prevented	O
overload	O
-	O
induced	O
uptake	O
demonstrating	O
that	O
GLUTs	B
mediate	O
this	O
effect	O
.	O

To	O
assess	O
which	O
GLUT	B
,	O
hexose	O
competition	O
experiments	O
were	O
performed	O
.	O

Overload	O
-	O
induced	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
uptake	O
was	O
not	O
inhibited	O
by	O
d	O
-	O
fructose	O
,	O
demonstrating	O
that	O
the	O
fructose	O
-	O
transporting	O
GLUT2	B
,	O
GLUT5	B
,	O
GLUT8	B
,	O
and	O
GLUT12	B
do	O
not	O
mediate	O
this	O
effect	O
.	O

To	O
assess	O
additional	O
GLUTs	B
,	O
immunoblots	O
were	O
performed	O
.	O

Overload	O
increased	O
GLUT1	B
,	O
GLUT3	B
,	O
GLUT6	B
,	O
and	O
GLUT10	B
protein	O
levels	O
twofold	O
to	O
fivefold	O
.	O

Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
GLUT4	B
is	O
not	O
necessary	O
for	O
overload	O
-	O
induced	O
muscle	O
glucose	O
uptake	O
or	O
hypertrophic	O
growth	O
and	O
suggest	O
that	O
GLUT1	B
,	O
GLUT3	B
,	O
GLUT6	B
,	O
and	O
/	O
or	O
GLUT10	B
mediate	O
overload	O
-	O
induced	O
glucose	O
uptake	O
.	O

The	O
drebrin	B
/	O
EB3	B
pathway	O
drives	O
invasive	O
activity	O
in	O
prostate	O
cancer	O
.	O

Prostate	O
cancer	O
is	O
the	O
most	O
common	O
cancer	O
in	O
men	O
and	O
the	O
metastatic	O
form	O
of	O
the	O
disease	O
is	O
incurable	O
.	O

We	O
show	O
here	O
that	O
the	O
drebrin	B
/	O
EB3	B
pathway	O
,	O
which	O
co	O
-	O
ordinates	O
dynamic	O
microtubule	O
/	O
actin	B
filament	O
interactions	O
underlying	O
cell	O
shape	O
changes	O
in	O
response	O
to	O
guidance	O
cues	O
,	O
plays	O
a	O
role	O
in	O
prostate	O
cancer	O
cell	O
invasion	O
.	O

Drebrin	B
expression	O
is	O
restricted	O
to	O
basal	O
epithelial	O
cells	O
in	O
benign	O
human	O
prostate	O
but	O
is	O
upregulated	O
in	O
luminal	O
epithelial	O
cells	O
in	O
foci	O
of	O
prostatic	O
malignancy	O
.	O

Drebrin	B
is	O
also	O
upregulated	O
in	O
human	O
prostate	O
cancer	O
cell	O
lines	O
and	O
co	O
-	O
localizes	O
with	O
actin	B
filaments	O
and	O
dynamic	O
microtubules	O
in	O
filopodia	O
of	O
pseudopods	O
of	O
invading	O
cells	O
under	O
a	O
chemotactic	O
gradient	O
of	O
the	O
chemokine	O
CXCL12	B
.	O

Disruption	O
of	O
the	O
drebrin	B
/	O
EB3	B
pathway	O
using	O
BTP2	O
,	O
a	O
small	O
molecule	O
inhibitor	O
of	O
drebrin	B
binding	O
to	O
actin	B
filaments	O
,	O
reduced	O
the	O
invasion	O
of	O
prostate	O
cancer	O
cell	O
lines	O
in	O
3D	O
in	O
vitro	O
assays	O
.	O

Furthermore	O
,	O
gain	O
-	O
or	O
loss	O
-	O
of	O
-	O
function	O
of	O
drebrin	B
or	O
EB3	B
by	O
over	O
-	O
expression	O
or	O
siRNA	O
-	O
mediated	O
knockdown	O
increases	O
or	O
decreases	O
invasion	O
of	O
prostate	O
cancer	O
cell	O
lines	O
in	O
3D	O
in	O
vitro	O
assays	O
,	O
respectively	O
.	O

Finally	O
,	O
expression	O
of	O
a	O
dominant	O
-	O
negative	O
construct	O
that	O
competes	O
with	O
EB3	B
binding	O
to	O
drebrin	B
,	O
also	O
inhibited	O
invasion	O
of	O
prostate	O
cancer	O
cell	O
lines	O
in	O
3D	O
in	O
vitro	O
assays	O
.	O

Our	O
findings	O
show	O
that	O
co	O
-	O
ordination	O
of	O
dynamic	O
microtubules	O
and	O
actin	B
filaments	O
by	O
the	O
drebrin	B
/	O
EB3	B
pathway	O
drives	O
prostate	O
cancer	O
cell	O
invasion	O
and	O
is	O
therefore	O
implicated	O
in	O
disease	O
progression	O
.	O

GPR143	B
mutations	O
in	O
Chinese	O
patients	O
with	O
ocular	O
albinism	O
type	O
1	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
mutations	O
of	O
the	O
G	B
protein	I
-	I
coupled	I
receptor	I
143	I
(	O
GPR143	B
)	O
gene	O
for	O
ocular	O
albinism	O
type	O
1	O
(	O
OA1	O
)	O
in	O
Chinese	O
patients	O
.	O

For	O
the	O
current	O
study	O
,	O
8	O
patients	O
with	O
OA1	O
were	O
selected	O
from	O
the	O
database	O
of	O
ocular	O
genetic	O
diseases	O
.	O

Genomic	O
DNA	O
of	O
OA1	B
was	O
prepared	O
from	O
venous	O
leukocytes	O
collected	O
from	O
the	O
patients	O
.	O

Cycle	O
sequencing	O
was	O
used	O
to	O
analyze	O
the	O
exons	O
and	O
adjacent	O
introns	O
of	O
GPR143	B
.	O

The	O
variation	O
detected	O
was	O
analyzed	O
by	O
bidirectional	O
DNA	O
sequencing	O
and	O
further	O
evaluated	O
in	O
96	O
controls	O
using	O
heteroduplex	O
‑	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
.	O

Additionally	O
,	O
slit	O
lamp	O
photography	O
of	O
anterior	O
segment	O
,	O
fundus	O
photography	O
and	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
were	O
performed	O
to	O
identify	O
the	O
clinical	O
features	O
of	O
OA1	O
.	O

In	O
five	O
patients	O
with	O
OA1	O
,	O
5	O
GPR143	B
gene	I
mutations	O
were	O
identified	O
and	O
four	O
of	O
them	O
there	O
were	O
novel	O
mutations	O
.	O

The	O
screening	O
rate	O
is	O
62	O
.	O
5	O
%	O
,	O
including	O
c	O
.	O
333G	O
>	O
A	O
(	O
p	O
.	O
W111X	O
)	O
,	O
c	O
.	O
353G	O
>	O
A	O
(	O
p	O
.	O
G118E	O
)	O
(	O
known	O
mutation	O
)	O
,	O
C	O
.	O
658	O
+	O
2T	O
>	O
G	O
(	O
splice	O
mutation	O
)	O
,	O
c	O
.	O
215_216insCGCTGC	O
(	O
p	O
.	O
71	O
‑	O
72insAA	O
)	O
and	O
c	O
.	O
17T	O
>	O
C	O
(	O
p	O
.	O
L6P	O
)	O
.	O

These	O
mutations	O
were	O
absent	O
in	O
the	O
96	O
normal	O
controls	O
.	O

Only	O
one	O
patient	O
with	O
OA1	O
in	O
the	O
present	O
study	O
was	O
female	O
.	O

Patients	O
with	O
OA1	O
often	O
have	O
congenital	O
nystagmus	O
,	O
refractive	O
error	O
,	O
severe	O
decline	O
of	O
visual	O
acuity	O
(	O
from	O
0	O
.	O
1	O
to	O
0	O
.	O
4	O
)	O
and	O
foveal	O
hypoplasia	O
.	O

Different	O
degrees	O
of	O
pigment	O
loss	O
were	O
evident	O
in	O
the	O
patients	O
'	O
iris	O
and	O
retina	O
,	O
whereas	O
macular	O
structure	O
was	O
not	O
identified	O
in	O
the	O
OCT	O
examination	O
.	O

The	O
findings	O
of	O
the	O
present	O
study	O
expanded	O
the	O
gene	O
mutation	O
spectrum	O
of	O
GPR143	B
and	O
investigated	O
the	O
clinical	O
phenotype	O
of	O
patients	O
with	O
OA1	B
in	O
the	O
Chinese	O
population	O
.	O

Additional	O
evidence	O
for	O
clinical	O
diagnosis	O
was	O
provided	O
along	O
with	O
differential	O
diagnosis	O
and	O
genetic	O
counseling	O
.	O

Deletion	O
of	O
endothelial	B
cell	I
-	I
specific	I
liver	I
kinase	I
B1	I
increases	O
angiogenesis	O
and	O
tumor	O
growth	O
via	O
vascular	B
endothelial	I
growth	I
factor	I
.	O

Liver	B
kinase	I
B1	I
(	O
LKB1	B
)	O
is	O
a	O
serine	B
/	I
threonine	I
protein	I
kinase	I
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
.	O

It	O
was	O
first	O
identified	O
in	O
Peutz	B
-	I
Jeghers	I
syndrome	I
as	O
a	O
tumor	B
suppressor	I
gene	I
.	O

Whether	O
endothelial	B
LKB1	I
regulates	O
angiogenesis	O
and	O
tumor	O
growth	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
endothelial	O
cell	O
-	O
specific	O
LKB1	B
-	O
knockout	O
(	O
LKB1	B
(	I
endo	I
-	I
/	I
-	I
)	I
)	O
mice	O
by	O
crossbreeding	O
vascular	B
endothelial	I
-	I
cadherin	I
-	O
Cre	B
mice	O
with	O
LKB1	B
(	O
flox	B
/	I
flox	I
)	O
mice	O
.	O

Vascular	B
endothelial	I
growth	I
factor	I
(	O
VEGF	B
)	O
level	O
was	O
highly	O
co	O
-	O
stained	O
in	O
endothelial	O
cells	O
but	O
not	O
in	O
macrophages	O
in	O
LKB1	B
(	O
endo	O
-	O
/	O
-	O
)	O
mice	O
.	O

Consistently	O
,	O
LKB1	B
(	O
endo	O
-	O
/	O
-	O
)	O
mouse	O
tissues	O
including	O
the	O
lung	O
,	O
skin	O
,	O
kidney	O
and	O
liver	O
showed	O
increased	O
vascular	O
permeability	O
.	O

Tumors	O
implanted	O
in	O
LKB1	B
(	O
endo	O
-	O
/	O
-	O
)	O
mice	O
but	O
not	O
macrophage	B
-	O
specific	O
LKB1	B
-	O
knockout	O
mice	O
grew	O
faster	O
and	O
showed	O
enhanced	O
vascular	O
permeability	O
and	O
increased	O
angiogenesis	O
as	O
compared	O
with	O
those	O
implanted	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Injection	O
of	O
VEGF	B
-	O
neutralizing	O
antibody	O
but	O
not	O
the	O
isotype	O
-	O
matched	O
control	O
antibody	O
decreased	O
endothelial	O
-	O
cell	O
angiogenesis	O
and	O
tumor	O
growth	O
in	O
vivo	O
.	O

Furthermore	O
,	O
LKB1	B
deletion	O
enhanced	O
mouse	O
retinal	O
and	O
cell	O
angiogenesis	O
,	O
and	O
knockdown	O
of	O
VEGF	B
by	O
small	O
-	O
interfering	O
RNA	O
decreased	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
.	O

Re	O
-	O
expression	O
of	O
LKB1	B
or	O
knockdown	O
of	O
VEGF	B
receptor	I
2	I
decreased	O
the	O
overproliferation	O
and	O
-	O
migration	O
observed	O
in	O
LKB1	B
(	I
endo	I
-	I
/	I
-	I
)	I
cells	O
.	O

Mechanistically	O
,	O
LKB1	B
could	O
bind	O
to	O
the	O
VEGF	B
transcription	I
factor	I
,	O
specificity	B
protein	I
1	I
(	O
Sp1	B
)	O
,	O
which	O
then	O
inhibited	O
the	O
binding	O
of	O
Sp1	B
to	O
the	O
VEGF	B
promoter	I
to	O
reduce	O
VEGF	B
expression	O
.	O

Endothelial	O
LKB1	B
may	O
regulate	O
endothelial	O
angiogenesis	O
and	O
tumor	O
growth	O
by	O
modulating	O
Sp1	B
-	O
mediated	O
VEGF	B
expression	O
.	O

Tissue	O
-	O
Specific	O
Ablation	O
of	O
the	O
LIF	B
Receptor	I
in	O
the	O
Murine	O
Uterine	O
Epithelium	O
Results	O
in	O
Implantation	O
Failure	O
.	O

The	O
cytokine	O
leukemia	B
inhibitory	I
factor	I
(	O
LIF	B
)	O
is	O
essential	O
for	O
rendering	O
the	O
uterus	O
receptive	O
for	O
blastocyst	O
implantation	O
.	O

In	O
mice	O
,	O
LIF	B
receptor	I
expression	O
(	O
LIFR	B
)	O
is	O
largely	O
restricted	O
to	O
the	O
uterine	O
luminal	O
epithelium	O
(	O
LE	O
)	O
.	O

LIF	B
,	O
secreted	O
from	O
the	O
endometrial	O
glands	O
(	O
GEs	O
)	O
,	O
binds	O
to	O
the	O
LIFR	B
,	O
activating	O
the	O
Janus	B
kinase	I
-	O
signal	B
transducer	I
and	I
activation	I
of	I
transcription	I
(	I
STAT	I
)	I
3	I
(	O
Jak	B
-	O
Stat3	B
)	O
signaling	O
pathway	O
in	O
the	O
LE	O
.	O

JAK	B
-	O
STAT	B
activation	O
converts	O
the	O
LE	O
to	O
a	O
receptive	O
state	O
so	O
that	O
juxtaposed	O
blastocysts	O
begin	O
to	O
implant	O
.	O

To	O
specifically	O
delete	O
the	O
LIFR	B
in	O
the	O
LE	O
,	O
we	O
derived	O
a	O
line	O
of	O
mice	O
in	O
which	O
Cre	O
recombinase	O
was	O
inserted	O
into	O
the	O
endogenous	B
lactoferrin	I
gene	I
(	O
Ltf	B
-	O
Cre	B
)	O
.	O

Lactoferrin	B
expression	O
in	O
the	O
LE	O
is	O
induced	O
by	O
E2	O
,	O
and	O
we	O
demonstrate	O
that	O
Cre	B
recombinase	I
activity	O
is	O
restricted	O
to	O
the	O
LE	O
and	O
GE	O
.	O

To	O
determine	O
the	O
requirement	O
of	O
the	O
LIFR	B
in	O
implantation	O
,	O
we	O
derived	O
an	O
additional	O
mouse	O
line	O
carrying	O
a	O
conditional	O
(	O
floxed	O
)	O
Lifr	B
flx	I
/	O
flx	B
gene	O
.	O

Crossing	O
Ltf	B
-	O
Cre	B
mice	O
with	O
Lifr	B
flx	I
/	O
flx	B
mice	O
generated	O
Lifr	B
flx	I
/	O
Δ	B
:	O
Ltf	B
Cre	I
/	O
+	O
females	O
that	O
were	O
overtly	O
normal	O
but	O
infertile	O
.	O

Many	O
of	O
these	O
females	O
,	O
despite	O
repeated	O
matings	O
,	O
did	O
not	O
become	O
pregnant	O
.	O

Unimplanted	O
blastocysts	O
were	O
recovered	O
from	O
the	O
Lifr	B
flx	O
/	O
Δ	O
:	O
Ltf	B
Cre	O
/	O
+	O
uteri	O
and	O
,	O
when	O
transferred	O
to	O
wild	O
-	O
type	O
recipients	O
,	O
implanted	O
normally	O
,	O
indicating	O
that	O
uterine	O
receptivity	O
rather	O
than	O
the	O
embryo	O
'	O
s	O
competency	O
is	O
compromised	O
.	O

The	O
loss	O
of	O
Lifr	B
results	O
in	O
both	O
the	O
failure	O
for	O
STAT3	B
to	O
translocate	O
to	O
the	O
LE	O
nuclei	O
and	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
LIF	B
regulated	O
gene	O
Msx1	B
that	O
regulates	O
uterine	O
receptivity	O
.	O

These	O
results	O
reveal	O
that	O
uterine	O
expression	O
of	O
the	O
LIFR	B
is	O
essential	O
for	O
embryo	O
implantation	O
and	O
further	O
define	O
the	O
components	O
of	O
the	O
LIF	B
signaling	O
pathway	O
necessary	O
for	O
effective	O
implantation	O
.	O

Defining	O
a	O
Novel	O
Role	O
for	O
the	O
Coxsackievirus	B
and	I
Adenovirus	I
Receptor	I
in	O
Human	O
Adenovirus	O
Serotype	O
5	O
Transduction	O
In	O
Vitro	O
in	O
the	O
Presence	O
of	O
Mouse	O
Serum	O
.	O

Human	O
adenoviral	O
serotype	O
5	O
(	O
HAdV	O
-	O
5	O
)	O
vectors	O
have	O
predominantly	O
hepatic	O
tropism	O
when	O
delivered	O
intravascularly	O
,	O
resulting	O
in	O
immune	O
activation	O
and	O
toxicity	O
.	O

Coagulation	B
factor	I
X	I
(	O
FX	B
)	O
binding	O
to	O
HAdV	O
-	O
5	O
mediates	O
liver	O
transduction	O
and	O
provides	O
protection	O
from	O
virion	O
neutralization	O
in	O
mice	O
.	O

FX	B
is	O
dispensable	O
for	O
liver	O
transduction	O
in	O
mice	O
lacking	O
IgM	B
antibodies	I
or	O
complement	O
,	O
suggesting	O
that	O
alternative	O
transduction	O
pathways	O
exist	O
.	O

To	O
identify	O
novel	O
factor	O
(	O
s	O
)	O
mediating	O
HAdV	O
-	O
5	O
FX	B
-	O
independent	O
entry	O
,	O
we	O
investigated	O
HAdV	O
-	O
5	O
transduction	O
in	O
vitro	O
in	O
the	O
presence	O
of	O
serum	O
from	O
immunocompetent	O
C57BL	O
/	O
6	O
or	O
immunocompromised	O
mice	O
lacking	O
IgM	B
antibodies	I
(	O
Rag	B
2	I
(	I
-	I
/	I
-	I
)	I
and	O
NOD	O
-	O
scid	O
-	O
gamma	O
[	O
NSG	O
]	O
)	O
.	O

Sera	O
from	O
all	O
three	O
mouse	O
strains	O
enhanced	O
HAdV	O
-	O
5	O
transduction	O
of	O
A549	O
cells	O
.	O

While	O
inhibition	O
of	O
HAdV	B
-	I
5	I
-	I
FX	I
interaction	O
with	O
FX	B
-	I
binding	I
protein	I
(	O
X	B
-	I
bp	I
)	O
inhibited	O
transduction	O
in	O
the	O
presence	O
of	O
C57BL	O
/	O
6	O
serum	O
,	O
it	O
had	O
negligible	O
effect	O
on	O
the	O
enhanced	O
transduction	O
observed	O
in	O
the	O
presence	O
of	O
Rag	O
2	O
(	O
-	O
/	O
-	O
)	O
or	O
NSG	O
serum	O
.	O

Rag	B
2	I
(	I
-	I
/	I
-	I
)	I
serum	O
also	O
enhanced	O
transduction	O
of	O
the	O
FX	B
binding	I
-	I
deficient	I
HAdV	I
-	I
5HVR5	I
*	I
HVR7	I
*	I
E451Q	I
(	O
AdT	O
*	O
)	O
.	O

Interestingly	O
,	O
Rag	B
2	I
(	I
-	I
/	I
-	I
)	I
serum	O
enhanced	O
HAdV	O
-	O
5	O
transduction	O
in	O
a	O
FX	B
-	O
independent	O
manner	O
in	O
CHO	O
-	O
CAR	B
and	O
SKOV3	O
-	O
CAR	B
cells	O
(	O
CHO	O
or	O
SKOV3	O
cells	O
transfected	O
to	O
stably	O
express	O
human	B
coxsackievirus	I
and	I
adenovirus	I
receptor	I
[	O
CAR	B
]	O
)	O
.	O

Additionally	O
,	O
blockade	O
of	O
CAR	B
with	O
soluble	B
HAdV	I
-	I
5	I
fiber	I
knob	I
inhibited	O
mouse	O
serum	O
-	O
enhanced	O
transduction	O
in	O
A549	O
cells	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
CAR	B
.	O

Transduction	O
of	O
HAdV	O
-	O
5	O
KO1	O
and	O
HAdV	O
-	O
5	O
/	O
F35	O
(	O
CAR	O
binding	O
deficient	O
)	O
in	O
the	O
presence	O
of	O
Rag	B
2	I
(	O
-	O
/	O
-	O
)	O
serum	O
was	O
equivalent	O
to	O
that	O
of	O
HAdV	O
-	O
5	O
,	O
indicating	O
that	O
direct	O
interaction	O
between	O
HAdV	O
-	O
5	O
and	O
CAR	B
is	O
not	O
required	O
.	O

These	O
data	O
suggest	O
that	O
FX	B
may	O
protect	O
HAdV	O
-	O
5	O
from	O
neutralization	O
but	O
has	O
minimal	O
contribution	O
to	O
HAdV	O
-	O
5	O
transduction	O
in	O
the	O
presence	O
of	O
immunocompromised	O
mouse	O
serum	O
.	O

Alternatively	O
,	O
transduction	O
occurs	O
via	O
an	O
unidentified	O
mouse	O
serum	O
protein	O
capable	O
of	O
bridging	O
HAdV	O
-	O
5	O
to	O
CAR	B
.	O
IMPORTANCE	O
The	O
intravascular	O
administration	O
of	O
HAdV	O
-	O
5	O
vectors	O
can	O
result	O
in	O
acute	O
liver	O
toxicity	O
,	O
transaminitis	O
,	O
thrombocytopenia	O
,	O
and	O
injury	O
to	O
the	O
vascular	O
endothelium	O
,	O
illustrating	O
challenges	O
yet	O
to	O
overcome	O
for	O
HAdV	O
-	O
5	O
-	O
mediated	O
systemic	O
gene	O
therapy	O
.	O

The	O
finding	O
that	O
CAR	B
and	O
potentially	O
an	O
unidentified	O
factor	O
present	O
in	O
mouse	O
serum	O
might	O
be	O
important	O
mediators	O
of	O
HAdV	O
-	O
5	O
transduction	O
highlights	O
that	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
biology	O
defining	O
the	O
interplay	O
between	O
adenovirus	O
immune	O
recognition	O
and	O
cellular	O
uptake	O
mechanisms	O
is	O
still	O
required	O
.	O

These	O
findings	O
are	O
important	O
to	O
inform	O
future	O
optimization	O
and	O
development	O
of	O
HAdV	O
-	O
5	O
-	O
based	O
adenoviral	O
vectors	O
for	O
gene	O
therapy	O
.	O

Biophysical	O
and	O
functional	O
characterization	O
of	O
hippocalcin	B
mutants	I
responsible	O
for	O
human	O
dystonia	O
.	O

Dystonia	O
is	O
a	O
neurological	O
movement	O
disorder	O
that	O
forces	O
the	O
body	O
into	O
twisting	O
,	O
repetitive	O
movements	O
or	O
sometimes	O
painful	O
abnormal	O
postures	O
.	O

With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
,	O
the	O
homozygous	O
mutations	O
T71N	O
and	O
A190T	O
in	O
the	O
neuronal	B
calcium	I
sensor	I
(	O
NCS	B
)	O
hippocalcin	B
were	O
identified	O
as	O
the	O
genetic	O
cause	O
of	O
primary	O
isolated	O
dystonia	O
(	O
DYT2	O
dystonia	O
)	O
.	O

However	O
,	O
the	O
effect	O
of	O
these	O
mutations	O
on	O
the	O
physiological	O
role	O
of	O
hippocalcin	B
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Using	O
a	O
multidisciplinary	O
approach	O
,	O
we	O
demonstrated	O
that	O
hippocalcin	B
oligomerises	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
and	O
binds	O
to	O
voltage	O
-	O
gated	O
calcium	O
channels	O
.	O

Mutations	O
T71N	O
and	O
A190T	O
in	O
hippocalcin	B
did	O
not	O
affect	O
stability	O
,	O
calcium	O
-	O
binding	O
affinity	O
or	O
translocation	O
to	O
cellular	O
membranes	O
(	O
Ca2	O
+	O
/	O
myristoyl	O
switch	O
)	O
.	O

We	O
obtained	O
the	O
first	O
crystal	O
structure	O
of	O
hippocalcin	B
and	O
alignment	O
with	O
other	O
NCS	B
proteins	I
showed	O
significant	O
variability	O
in	O
the	O
orientation	O
of	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
molecule	O
,	O
the	O
region	O
expected	O
to	O
be	O
important	O
for	O
target	O
binding	O
.	O

We	O
demonstrated	O
that	O
the	O
disease	O
-	O
causing	O
mutations	O
did	O
not	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
,	O
however	O
both	O
mutants	O
showed	O
a	O
defect	O
in	O
oligomerisation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
an	O
increased	O
calcium	O
influx	O
in	O
KCl	O
-	O
depolarised	O
cells	O
expressing	O
mutated	O
hippocalcin	B
,	O
mostly	O
driven	O
by	O
N	O
-	O
type	O
voltage	O
-	O
gated	O
calcium	O
channels	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
dystonia	O
-	O
causing	O
mutations	O
strongly	O
affect	O
hippocalcin	B
cellular	O
functions	O
which	O
suggest	O
a	O
central	O
role	O
for	O
perturbed	O
calcium	O
signalling	O
in	O
DYT2	O
dystonia	O
.	O

miR	B
-	I
21	I
ablation	O
and	O
obeticholic	O
acid	O
ameliorate	O
nonalcoholic	O
steatohepatitis	O
in	O
mice	O
.	O

microRNAs	O
were	O
recently	O
suggested	O
to	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
a	O
disease	O
lacking	O
specific	O
pharmacological	O
treatments	O
.	O

In	O
that	O
regard	O
,	O
nuclear	O
receptors	O
are	O
arising	O
as	O
key	O
molecular	O
targets	O
for	O
the	O
treatment	O
of	O
nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
.	O

Here	O
we	O
show	O
that	O
,	O
in	O
a	O
typical	O
model	O
of	O
NASH	O
-	O
associated	O
liver	O
damage	O
,	O
microRNA	O
-	O
21	O
(	O
miR	O
-	O
21	O
)	O
ablation	O
results	O
in	O
a	O
progressive	O
decrease	O
in	O
steatosis	O
,	O
inflammation	O
and	O
lipoapoptosis	O
,	O
with	O
impairment	O
of	O
fibrosis	O
.	O

In	O
a	O
complementary	O
fast	O
food	O
(	O
FF	O
)	O
diet	O
NASH	O
model	O
,	O
mimicking	O
features	O
of	O
the	O
metabolic	O
syndrome	O
,	O
miR	B
-	I
21	I
levels	O
increase	O
in	O
both	O
liver	O
and	O
muscle	O
,	O
concomitantly	O
with	O
decreased	O
expression	O
of	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
a	I
(	O
PPARa	B
)	O
,	O
a	O
key	O
miR	B
-	I
21	I
target	O
.	O

Strikingly	O
,	O
miR	B
-	I
21	I
knockout	O
mice	O
fed	O
the	O
FF	O
diet	O
supplemented	O
with	O
farnesoid	B
X	I
receptor	I
(	O
FXR	B
)	O
agonist	O
obeticholic	O
acid	O
(	O
OCA	O
)	O
display	O
minimal	O
steatosis	O
,	O
inflammation	O
,	O
oxidative	O
stress	O
and	O
cholesterol	O
accumulation	O
.	O

In	O
addition	O
,	O
lipoprotein	O
metabolism	O
was	O
restored	O
,	O
including	O
decreased	O
fatty	O
acid	O
uptake	O
and	O
polyunsaturation	O
,	O
and	O
liver	O
and	O
muscle	O
insulin	B
sensitivity	O
fully	O
reinstated	O
.	O

Finally	O
,	O
the	O
miR	B
-	I
21	I
/	O
PPARa	B
axis	O
was	O
found	O
amplified	O
in	O
liver	O
and	O
muscle	O
biopsies	O
,	O
and	O
in	O
serum	O
,	O
of	O
NAFLD	O
patients	O
,	O
co	O
-	O
substantiating	O
its	O
role	O
in	O
the	O
development	O
of	O
the	O
metabolic	O
syndrome	O
.	O

By	O
unveiling	O
that	O
miR	B
-	I
21	I
abrogation	O
,	O
together	O
with	O
FXR	B
activation	O
by	O
OCA	O
,	O
significantly	O
improves	O
whole	O
body	O
metabolic	O
parameters	O
in	O
NASH	O
,	O
our	O
results	O
highlight	O
the	O
therapeutic	O
potential	O
of	O
nuclear	O
receptor	O
multi	O
-	O
targeting	O
therapies	O
for	O
NAFLD	O
.	O

Associations	O
Between	O
Cancer	O
Predisposition	O
Testing	O
Panel	O
Genes	O
and	O
Breast	O
Cancer	O
.	O

Importance	O
:	O
Germline	O
pathogenic	O
variants	O
in	O
BRCA1	O
and	O
BRCA2	O
predispose	O
to	O
an	O
increased	O
lifetime	O
risk	O
of	O
breast	O
cancer	O
.	O

However	O
,	O
the	O
relevance	O
of	O
germline	O
variants	O
in	O
other	O
genes	O
from	O
multigene	O
hereditary	O
cancer	O
testing	O
panels	O
is	O
not	O
well	O
defined	O
.	O

Objective	O
:	O
To	O
determine	O
the	O
risks	O
of	O
breast	O
cancer	O
associated	O
with	O
germline	O
variants	O
in	O
cancer	O
predisposition	O
genes	O
.	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
:	O
A	O
study	O
population	O
of	O
65	O
057	O
patients	O
with	O
breast	O
cancer	O
receiving	O
germline	O
genetic	O
testing	O
of	O
cancer	O
predisposition	O
genes	O
with	O
hereditary	O
cancer	O
multigene	O
panels	O
.	O

Associations	O
between	O
pathogenic	O
variants	O
in	O
non	O
-	O
BRCA1	O
and	O
non	O
-	O
BRCA2	O
predisposition	O
genes	O
and	O
breast	O
cancer	O
risk	O
were	O
estimated	O
in	O
a	O
case	O
-	O
control	O
analysis	O
of	O
patients	O
with	O
breast	O
cancer	O
and	O
Exome	O
Aggregation	O
Consortium	O
reference	O
controls	O
.	O

The	O
women	O
underwent	O
testing	O
between	O
March	O
15	O
,	O
2012	O
,	O
and	O
June	O
30	O
,	O
2016	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Breast	O
cancer	O
risk	O
conferred	O
by	O
pathogenic	O
variants	O
in	O
non	O
-	O
BRCA1	B
and	O
non	O
-	O
BRCA2	B
predisposition	O
genes	O
.	O

Results	O
:	O
The	O
mean	O
(	O
SD	O
)	O
age	O
at	O
diagnosis	O
for	O
the	O
65	O
057	O
women	O
included	O
in	O
the	O
analysis	O
was	O
48	O
.	O
5	O
(	O
11	O
.	O
1	O
)	O
years	O
.	O

The	O
frequency	O
of	O
pathogenic	O
variants	O
in	O
21	O
panel	O
genes	O
identified	O
in	O
41	O
611	O
consecutively	O
tested	O
white	O
women	O
with	O
breast	O
cancer	O
was	O
estimated	O
at	O
10	O
.	O
2	O
%	O
.	O

After	O
exclusion	O
of	O
BRCA1	B
,	O
BRCA2	B
,	O
and	O
syndromic	O
breast	O
cancer	O
genes	O
(	O
CDH1	B
,	O
PTEN	B
,	O
and	O
TP53	B
)	O
,	O
observed	O
pathogenic	O
variants	O
in	O
5	O
of	O
16	O
genes	O
were	O
associated	O
with	O
high	O
or	O
moderately	O
increased	O
risks	O
of	O
breast	O
cancer	O
:	O
ATM	B
(	O
OR	O
,	O
2	O
.	O
78	O
;	O
95	O
%	O
CI	O
,	O
2	O
.	O
22	O
-	O
3	O
.	O
62	O
)	O
,	O
BARD1	B
(	O
OR	O
,	O
2	O
.	O
16	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
31	O
-	O
3	O
.	O
63	O
)	O
,	O
CHEK2	B
(	O
OR	O
,	O
1	O
.	O
48	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
31	O
-	O
1	O
.	O
67	O
)	O
,	O
PALB2	B
(	O
OR	O
,	O
7	O
.	O
46	O
;	O
95	O
%	O
CI	O
,	O
5	O
.	O
12	O
-	O
11	O
.	O
19	O
)	O
,	O
and	O
RAD51D	B
(	O
OR	O
,	O
3	O
.	O
07	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
-	O
7	O
.	O
88	O
)	O
.	O

Conversely	O
,	O
variants	O
in	O
the	O
BRIP1	B
and	O
RAD51C	B
ovarian	O
cancer	O
risk	O
genes	O
;	O
the	O
MRE11A	B
,	O
RAD50	B
,	O
and	O
NBN	B
MRN	O
complex	O
genes	O
;	O
the	O
MLH1	B
and	O
PMS2	B
mismatch	O
repair	O
genes	O
;	O
and	O
NF1	B
were	O
not	O
associated	O
with	O
increased	O
risks	O
of	O
breast	O
cancer	O
.	O

Conclusions	O
and	O
Relevance	O
:	O
This	O
study	O
establishes	O
several	O
panel	O
genes	O
as	O
high	O
-	O
and	O
moderate	O
-	O
risk	O
breast	O
cancer	O
genes	O
and	O
provides	O
estimates	O
of	O
breast	O
cancer	O
risk	O
associated	O
with	O
pathogenic	O
variants	O
in	O
these	O
genes	O
among	O
individuals	O
qualifying	O
for	O
clinical	O
genetic	O
testing	O
.	O

Distinct	O
immunophenotypes	O
and	O
prognostic	O
factors	O
in	O
renal	O
cell	O
carcinoma	O
with	O
sarcomatoid	O
differentiation	O
:	O
a	O
systematic	O
study	O
of	O
19	O
immunohistochemical	O
markers	O
in	O
42	O
cases	O
.	O

BACKGROUND	O
:	O
Renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
with	O
sarcomatoid	O
differentiation	O
is	O
a	O
relatively	O
rare	O
tumor	O
containing	O
both	O
carcinoma	O
and	O
sarcomatoid	O
components	O
.	O

However	O
,	O
there	O
has	O
not	O
been	O
a	O
systemic	O
study	O
on	O
immunophenotypes	O
of	O
renal	O
cell	O
carcinoma	O
with	O
sarcomatoid	O
differentiation	O
,	O
especially	O
using	O
some	O
renal	O
specific	O
immunohistochemical	O
markers	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
comprehensively	O
investigate	O
the	O
distinct	O
immunophenotypes	O
of	O
RCC	O
with	O
sarcomatoid	O
differentiation	O
to	O
analyze	O
the	O
pathogenesis	O
of	O
sarcomatoid	O
differentiation	O
and	O
identify	O
new	O
prognostic	O
factors	O
in	O
RCC	O
with	O
sarcomatoid	O
differentiation	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
42	O
cases	O
of	O
RCCs	O
with	O
sarcomatoid	O
differentiation	O
were	O
enrolled	O
into	O
the	O
study	O
.	O

Immunohistochemistry	O
study	O
was	O
performed	O
on	O
tissue	O
microarrays	O
to	O
evaluate	O
the	O
expressions	O
of	O
19	O
immunohistochemical	O
markers	O
including	O
a	O
series	O
of	O
epithelial	O
,	O
mesenchymal	O
markers	O
and	O
RCC	O
specific	O
markers	O
.	O

Kaplan	O
-	O
Meier	O
method	O
was	O
applied	O
to	O
assess	O
the	O
prognostic	O
values	O
of	O
CD10	B
,	O
CAIX	B
,	O
p53	B
and	O
Bcl	B
-	I
2	I
.	O

RESULTS	O
:	O
Histologically	O
,	O
42	O
cases	O
of	O
RCCs	O
with	O
sarcomatoid	O
differentiation	O
presented	O
with	O
different	O
proportions	O
of	O
carcinoma	O
and	O
sarcomatoid	O
components	O
.	O

The	O
cohort	O
contained	O
35	O
cases	O
of	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
CCRCC	O
)	O
and	O
7	O
cases	O
of	O
chromophobe	O
renal	O
cell	O
carcinoma	O
(	O
ChRCC	O
)	O
based	O
on	O
the	O
carcinoma	O
components	O
.	O

Immunohistochemically	O
,	O
all	O
cases	O
were	O
positive	O
for	O
vimentin	B
,	O
and	O
80	O
%	O
of	O
cases	O
showed	O
immunostaining	O
for	O
at	O
least	O
one	O
epithelial	B
marker	I
,	O
such	O
as	O
CK	B
,	O
EMA	B
,	O
CK7	B
and	O
CK18	B
.	O

Notably	O
,	O
the	O
expression	O
rates	O
of	O
CAIX	B
,	O
CD10	B
and	O
PAX8	B
in	O
sarcomatoid	O
cells	O
were	O
76	O
%	O
,	O
76	O
%	O
and	O
64	O
%	O
,	O
respectively	O
.	O

The	O
carcinoma	O
component	O
of	O
the	O
tumors	O
showed	O
differentient	O
labeling	O
for	O
CAIX	B
,	O
CD10	B
,	O
vimentin	B
,	O
CK7	B
and	O
CD117	B
in	O
CCRCC	O
vs	O
ChRCC	O
,	O
but	O
the	O
sarcomatoid	O
component	O
lost	O
the	O
specificity	O
for	O
these	O
markers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Patients	O
with	O
positive	O
expressions	O
of	O
CAIX	B
,	O
p53	B
and	O
Bcl	B
-	I
2	I
had	O
a	O
poor	O
prognosis	O
.	O

CONCLUSIONS	O
:	O
The	O
sarcomatoid	O
cells	O
in	O
RCC	O
with	O
sarcomatoid	O
differentiation	O
express	O
both	O
epithelial	O
and	O
mesenchymal	O
markers	O
,	O
supporting	O
their	O
epithelial	O
origin	O
.	O

PAX8	B
,	O
CAIX	B
and	O
CD10	B
could	O
be	O
used	O
as	O
the	O
reliable	O
and	O
useful	O
markers	O
to	O
determine	O
the	O
renal	O
origin	O
of	O
sarcomatoid	O
cells	O
such	O
as	O
in	O
fine	O
needle	O
aspiration	O
cases	O
and	O
metastatic	O
RCC	O
with	O
sarcomatoid	O
differentiation	O
.	O

CAIX	B
,	O
p53	B
and	O
Bcl	B
-	I
2	I
might	O
play	O
important	O
roles	O
in	O
the	O
transformation	O
from	O
renal	O
cell	O
carcinoma	O
to	O
high	O
malignant	O
sarcomatoid	O
differentiation	O
,	O
and	O
these	O
three	O
immunohistochemical	O
markers	O
are	O
adverse	O
prognostic	O
factors	O
for	O
the	O
survival	O
of	O
patients	O
with	O
RCC	O
with	O
sarcomatoid	O
differentiation	O
.	O

Hypoglycemic	O
Effect	O
of	O
Combined	O
Ghrelin	B
and	O
Glucagon	B
Receptor	I
Blockade	O
.	O

Glucagon	B
receptor	I
(	O
GcgR	B
)	O
blockade	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
insulin	B
monotherapy	O
for	O
treating	O
type	O
1	O
diabetes	O
since	O
deletion	O
or	O
inhibition	O
of	O
GcgR	B
s	O
corrects	O
hyperglycemia	O
in	O
models	O
of	O
diabetes	O
.	O

The	O
factors	O
regulating	O
glycemia	O
in	O
a	O
setting	O
devoid	O
of	O
insulin	B
and	O
glucagon	B
function	O
remain	O
unclear	O
but	O
may	O
include	O
the	O
hormone	O
ghrelin	B
.	O

Not	O
only	O
is	O
ghrelin	B
release	O
controlled	O
by	O
glucose	O
but	O
also	O
ghrelin	B
has	O
many	O
actions	O
that	O
can	O
raise	O
or	O
reduce	O
falls	O
in	O
blood	O
glucose	O
level	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
ghrelin	B
rises	O
to	O
prevent	O
hypoglycemia	O
in	O
the	O
absence	O
of	O
glucagon	B
function	O
.	O

Both	O
GcgR	B
knockout	O
(	O
Gcgr	B
(	I
-	I
/	I
-	I
)	I
)	O
mice	O
and	O
db	O
/	O
db	O
mice	O
that	O
were	O
administered	O
GcgR	B
monoclonal	I
antibody	I
displayed	O
lower	O
blood	O
glucose	O
levels	O
accompanied	O
by	O
elevated	O
plasma	B
ghrelin	I
levels	O
.	O

Although	O
treatment	O
with	O
the	O
pancreatic	O
β	O
-	O
cell	O
toxin	O
streptozotocin	O
induced	O
hyperglycemia	O
and	O
raised	O
plasma	O
ghrelin	B
levels	O
in	O
wild	O
-	O
type	O
mice	O
,	O
hyperglycemia	O
was	O
averted	O
in	O
similarly	O
treated	O
Gcgr	B
(	I
-	I
/	I
-	I
)	I
mice	O
and	O
the	O
plasma	O
ghrelin	B
level	O
was	O
further	O
increased	O
.	O

Notably	O
,	O
administration	O
of	O
a	O
ghrelin	B
receptor	I
antagonist	O
further	O
reduced	O
blood	O
glucose	O
levels	O
into	O
the	O
markedly	O
hypoglycemic	O
range	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	O
-	O
treated	O
Gcgr	B
(	I
-	I
/	I
-	I
)	I
mice	O
.	O

A	O
lowered	O
blood	O
glucose	O
level	O
also	O
was	O
observed	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	O
-	O
treated	O
ghrelin	B
receptor	I
-	O
null	O
mice	O
that	O
were	O
administered	O
GcgR	B
monoclonal	O
antibody	O
.	O

These	O
data	O
suggest	O
that	O
when	O
glucagon	B
activity	O
is	O
blocked	O
in	O
the	O
setting	O
of	O
type	O
1	O
diabetes	O
,	O
the	O
plasma	O
ghrelin	B
level	O
rises	O
,	O
preventing	O
hypoglycemia	O
.	O

Urinary	O
Levels	O
of	O
IL	B
-	I
1β	I
and	O
GDNF	B
in	O
Preterm	O
Neonates	O
as	O
Potential	O
Biomarkers	O
of	O
Motor	O
Development	O
:	O
A	O
Prospective	O
Study	O
.	O

Objectives	O
.	O
To	O
evaluate	O
the	O
association	O
between	O
inflammatory	O
biomarkers	O
,	O
neurotrophic	O
factors	O
,	O
birth	O
conditions	O
,	O
and	O
the	O
presence	O
of	O
motor	O
development	O
abnormalities	O
in	O
preterm	O
neonates	O
.	O

Methods	O
.	O

Plasma	O
and	O
urinary	O
levels	O
of	O
cytokines	B
(	O
IL	B
-	I
1β	I
,	O
IL	B
-	I
6	I
,	O
IL	B
-	I
10	I
,	O
TNF	B
,	O
and	O
IL	B
-	I
12p70	I
)	O
,	O
chemokines	B
(	O
CXCL8	B
/	O
IL	B
-	I
8	I
,	O
CCL2	B
/	O
MCP	B
-	I
1	I
,	O
CCL5	B
/	O
RANTES	B
,	O
CXCL10	B
/	O
IP	B
-	I
10	I
,	O
and	O
CXCL9	B
/	O
MIG	B
)	O
,	O
and	O
neurotrophic	O
factors	O
(	O
BDNF	B
and	O
GDNF	B
)	O
were	O
evaluated	O
in	O
40	O
preterm	O
neonates	O
born	O
between	O
28	O
and	O
32	O
incomplete	O
weeks	O
of	O
gestation	O
,	O
at	O
four	O
distinct	O
time	O
points	O
:	O
at	O
birth	O
(	O
umbilical	O
cord	O
blood	O
)	O
(	O
T0	O
)	O
,	O
at	O
48	O
(	O
T1	O
)	O
,	O
at	O
72	O
hours	O
(	O
T2	O
)	O
,	O
and	O
at	O
3	O
weeks	O
after	O
birth	O
(	O
T3	O
)	O
.	O

Biomarkers	O
levels	O
were	O
compared	O
between	O
different	O
time	O
points	O
and	O
then	O
associated	O
with	O
Test	O
of	O
Infant	O
Motor	O
Performance	O
(	O
TIMP	O
)	O
percentiles	O
.	O

Results	O
.	O

Maternal	O
age	O
,	O
plasma	O
,	O
and	O
urinary	O
concentrations	O
of	O
inflammatory	O
molecules	O
and	O
neurotrophic	O
factors	O
were	O
significantly	O
different	O
between	O
groups	O
with	O
normal	O
versus	O
lower	O
than	O
expected	O
motor	O
development	O
.	O

Higher	O
levels	O
of	O
GDNF	B
were	O
found	O
in	O
the	O
group	O
with	O
lower	O
than	O
expected	O
motor	O
development	O
,	O
while	O
IL	B
-	I
1β	I
and	O
CXCL8	B
/	O
IL	B
-	I
8	I
values	O
were	O
higher	O
in	O
the	O
group	O
with	O
typical	O
motor	O
development	O
.	O

Conclusion	O
.	O

Measurements	O
of	O
cytokines	O
and	O
neurotrophic	O
factors	O
in	O
spot	O
urine	O
may	O
be	O
useful	O
in	O
the	O
follow	O
-	O
up	O
of	O
motor	O
development	O
in	O
preterm	O
neonates	O
.	O

UBASH3A	B
Mediates	O
Risk	O
for	O
Type	O
1	O
Diabetes	O
Through	O
Inhibition	O
of	O
T	B
-	I
Cell	I
Receptor	I
-	O
Induced	O
NF	B
-	I
κB	I
Signaling	O
.	O

Although	O
over	O
40	O
type	O
1	O
diabetes	O
(	O
T1D	O
)	O
risk	O
loci	O
have	O
been	O
mapped	O
in	O
humans	O
,	O
the	O
causative	O
genes	O
and	O
variants	O
for	O
T1D	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
investigated	O
a	O
candidate	O
gene	O
in	O
the	O
21q22	O
.	O
3	O
risk	O
locus	O
-	O
UBASH3A	B
,	O
which	O
is	O
primarily	O
expressed	O
in	O
T	O
cells	O
where	O
it	O
is	O
thought	O
to	O
play	O
a	O
largely	O
redundant	O
role	O
.	O

Genetic	O
variants	O
in	O
UBASH3A	B
have	O
been	O
shown	O
to	O
be	O
associated	O
with	O
several	O
autoimmune	O
diseases	O
in	O
addition	O
to	O
T1D	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
these	O
genetic	O
associations	O
is	O
unresolved	O
.	O

Our	O
study	O
reveals	O
a	O
previously	O
unrecognized	O
role	O
of	O
UBASH3A	B
in	O
human	O
T	O
cells	O
:	O
UBASH3A	B
attenuates	O
the	O
NF	B
-	I
κB	I
signal	O
transduction	O
upon	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
stimulation	O
by	O
specifically	O
suppressing	O
the	O
activation	O
of	O
the	O
IκB	B
kinase	I
complex	O
.	O

We	O
identify	O
novel	O
interactions	O
of	O
UBASH3A	B
with	O
nondegradative	O
polyubiquitin	O
chains	O
,	O
TAK1	B
and	O
NEMO	B
,	O
suggesting	O
that	O
UBASH3A	B
regulates	O
the	O
NF	B
-	I
κB	I
signaling	O
pathway	O
by	O
an	O
ubiquitin	O
-	O
dependent	O
mechanism	O
.	O

Finally	O
,	O
we	O
show	O
that	O
risk	O
alleles	O
at	O
rs11203203	O
and	O
rs80054410	O
,	O
two	O
T1D	O
-	O
associated	O
variants	O
in	O
UBASH3A	B
,	O
increase	O
UBASH3A	B
expression	O
in	O
human	O
primary	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
upon	O
TCR	B
stimulation	O
,	O
inhibiting	O
NF	B
-	I
κB	I
signaling	O
via	O
its	O
effects	O
on	O
the	O
IκB	B
kinase	I
complex	I
and	O
resulting	O
in	O
reduced	O
IL2	B
gene	I
expression	O
.	O

Domain	O
-	O
specific	O
control	O
of	O
germ	O
cell	O
polarity	O
and	O
migration	O
by	O
multifunction	O
Tre1	B
GP	I
Tre1	I
m	I
GPCR	I
.	O

The	O
migration	O
of	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
from	O
their	O
place	O
of	O
origin	O
to	O
the	O
embryonic	O
gonad	O
is	O
an	O
essential	O
reproductive	O
feature	O
in	O
many	O
animal	O
species	O
.	O

In	O
Drosophila	O
melanogaster	O
,	O
a	O
single	O
G	B
protein	I
-	I
coupled	I
receptor	I
,	O
Trapped	B
in	I
endoderm	I
1	I
(	O
Tre1	B
)	O
,	O
mediates	O
germ	O
cell	O
polarization	O
at	O
the	O
onset	O
of	O
active	O
migration	O
and	O
directs	O
subsequent	O
migration	O
of	O
PGCs	O
through	O
the	O
midgut	O
primordium	O
.	O

How	O
these	O
different	O
aspects	O
of	O
cell	O
behavior	O
are	O
coordinated	O
through	O
a	O
single	O
receptor	O
is	O
not	O
known	O
.	O

We	O
demonstrate	O
that	O
two	O
highly	O
conserved	O
domains	O
,	O
the	O
E	O
/	O
N	O
/	O
DRY	O
and	O
NPxxY	O
motifs	O
,	O
have	O
overlapping	O
and	O
unique	O
functions	O
in	O
Tre1	B
.	O

The	O
Tre1	B
-	O
NRY	B
domain	O
via	O
G	B
protein	I
signaling	O
is	O
required	O
for	O
reading	O
and	O
responding	O
to	O
guidance	O
and	O
survival	O
cues	O
controlled	O
by	O
the	O
lipid	B
phosphate	I
phosphatases	I
Wunen	I
and	O
Wunen2	B
.	O

In	O
contrast	O
,	O
the	O
Tre1	B
-	O
NPIIY	B
domain	O
has	O
a	O
separate	O
role	O
in	O
Rho1	B
-	O
and	O
E	B
-	I
cadherin	I
-	O
mediated	O
polarization	O
at	O
the	O
initiation	O
stage	O
independent	O
of	O
G	B
protein	I
signaling	O
.	O

We	O
propose	O
that	O
this	O
bifurcation	O
of	O
the	O
Tre1	B
G	I
protein	I
-	I
coupled	I
receptor	I
signaling	O
response	O
via	O
G	B
protein	I
-	O
dependent	O
and	O
independent	O
branches	O
enables	O
distinct	O
spatiotemporal	O
regulation	O
of	O
germ	O
cell	O
migration	O
.	O

Novel	O
function	O
of	O
a	O
dynein	B
light	I
chain	I
in	O
actin	B
assembly	O
during	O
clathrin	B
-	O
mediated	O
endocytosis	O
.	O

Clathrin	B
-	O
and	O
actin	B
-	O
mediated	O
endocytosis	O
is	O
essential	O
in	O
eukaryotic	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tda2	B
is	O
a	O
novel	O
protein	O
of	O
the	O
endocytic	O
machinery	O
necessary	O
for	O
normal	O
internalization	O
of	O
native	O
cargo	O
in	O
yeast	O
.	O

Tda2	B
has	O
not	O
been	O
classified	O
in	O
any	O
protein	O
family	O
.	O

Unexpectedly	O
,	O
solving	O
the	O
crystal	O
structure	O
of	O
Tda2	B
revealed	O
it	O
belongs	O
to	O
the	O
dynein	B
light	O
chain	O
family	O
.	O

However	O
,	O
Tda2	B
works	O
independently	O
of	O
the	O
dynein	B
motor	I
complex	I
and	O
microtubules	O
.	O

Tda2	B
forms	O
a	O
tight	O
complex	O
with	O
the	O
polyproline	O
motif	O
-	O
rich	O
protein	O
Aim21	B
,	O
which	O
interacts	O
physically	O
with	O
the	O
SH3	B
domain	I
of	O
the	O
Arp2	B
<	O
/	O
m	O
Arp2	B
/	O
3	O
compl	O
3	O
x	O
regulator	O
Bbc1	I
.	O

The	O
Tda2	B
-	O
Aim21	B
complex	O
localizes	O
to	O
endocytic	O
sites	O
in	O
a	O
Bbc1	B
-	O
and	O
filamentous	O
actin	B
-	O
dependent	O
manner	O
.	O

Importantly	O
,	O
the	O
Tda2	B
-	O
Aim21	B
complex	O
interacts	O
directly	O
with	O
and	O
facilitates	O
the	O
recruitment	O
of	O
actin	B
-	I
capping	I
protein	I
,	O
revealing	O
barbed	O
-	O
end	O
filament	O
capping	O
at	O
endocytic	O
sites	O
to	O
be	O
a	O
regulated	O
event	O
.	O

Thus	O
,	O
we	O
have	O
uncovered	O
a	O
new	O
layer	O
of	O
regulation	O
of	O
the	O
actin	B
cytoskeleton	O
by	O
a	O
member	O
of	O
a	O
conserved	O
protein	O
family	O
that	O
has	O
not	O
been	O
previously	O
associated	O
with	O
a	O
function	O
in	O
endocytosis	O
.	O

Yeast	B
silencing	I
factor	I
Sir4	I
and	O
a	O
subset	O
of	O
nucleoporins	O
form	O
a	O
complex	O
distinct	O
from	O
nuclear	O
pore	O
complex	O
es	O
.	O

Interactions	O
occurring	O
at	O
the	O
nuclear	O
envelope	O
(	O
NE	O
)	O
-	O
chromatin	O
interface	O
influence	O
both	O
NE	O
structure	O
and	O
chromatin	O
organization	O
.	O

Insights	O
into	O
the	O
functions	O
of	O
NE	O
-	O
chromatin	O
interactions	O
have	O
come	O
from	O
the	O
study	O
of	O
yeast	O
subtelomeric	O
chromatin	O
and	O
its	O
association	O
with	O
the	O
NE	O
,	O
including	O
the	O
identification	O
of	O
various	O
proteins	O
necessary	O
for	O
tethering	O
subtelomeric	O
chromatin	O
to	O
the	O
NE	O
and	O
the	O
silencing	O
of	O
resident	O
genes	O
.	O

Here	O
we	O
show	O
that	O
four	O
of	O
these	O
proteins	O
-	O
the	O
silencing	O
factor	O
Sir4	B
,	O
NE	B
-	I
associated	I
Esc1	I
,	O
the	O
SUMO	B
E3	I
ligase	I
Siz2	I
,	O
and	O
the	O
nuclear	O
pore	O
complex	O
(	O
NPC	O
)	O
protein	O
Nup170	B
-	O
physically	O
and	O
functionally	O
interact	O
with	O
one	O
another	O
and	O
a	O
subset	O
of	O
NPC	O
components	O
(	O
nucleoporins	O
or	O
Nups	O
)	O
.	O

Importantly	O
,	O
this	O
group	O
of	O
Nups	B
is	O
largely	O
restricted	O
to	O
members	O
of	O
the	O
inner	O
and	O
outer	O
NPC	O
rings	O
,	O
but	O
it	O
lacks	O
numerous	O
others	O
including	O
cytoplasmically	O
and	O
nucleoplasmically	O
positioned	O
Nups	B
.	O

We	O
propose	O
that	O
this	O
Sir4	B
-	O
associated	O
Nup	B
complex	O
is	O
distinct	O
from	O
holo	O
-	O
NPCs	O
and	O
that	O
it	O
plays	O
a	O
role	O
in	O
subtelomeric	O
chromatin	O
organization	O
and	O
NE	O
tethering	O
.	O

IRF	B
-	I
8	I
regulates	O
expansion	O
of	O
myeloid	O
-	O
derived	O
suppressor	O
cells	O
and	O
Foxp3	B
+	O
regulatory	O
T	O
cells	O
and	O
modulates	O
Th2	O
immune	O
responses	O
to	O
gastrointestinal	O
nematode	O
infection	O
.	O

Interferon	B
regulatory	I
factor	I
-	I
8	I
(	O
IRF	B
-	I
8	I
)	O
is	O
critical	O
for	O
Th1	O
cell	O
differentiation	O
and	O
negatively	O
regulates	O
myeloid	O
cell	O
development	O
including	O
myeloid	O
-	O
derived	O
suppressor	O
cells	O
(	O
MDSC	O
)	O
.	O

MDSC	O
expand	O
during	O
infection	O
with	O
various	O
pathogens	O
including	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
nematode	O
Heligmosomoides	O
polygyrus	O
bakeri	O
(	O
Hpb	O
)	O
.	O

We	O
investigated	O
if	O
IRF	B
-	I
8	I
contributes	O
to	O
Th2	O
immunity	O
to	O
Hpb	O
infection	O
.	O

Irf8	B
expression	O
was	O
down	O
-	O
regulated	O
in	O
MDSC	O
from	O
Hpb	O
-	O
infected	O
C57BL	O
/	O
6	O
(	O
B6	O
)	O
mice	O
.	O

IRF	B
-	I
8	I
deficient	O
Irf8	B
-	I
/	I
-	I
and	O
BXH	O
-	O
2	O
mice	O
had	O
significantly	O
higher	O
adult	O
worm	O
burdens	O
than	O
B6	O
mice	O
after	O
primary	O
or	O
challenge	O
Hpb	O
infection	O
.	O

During	O
primary	O
infection	O
,	O
MDSC	O
expanded	O
to	O
a	O
significantly	O
greater	O
extent	O
in	O
mesenteric	O
lymph	O
nodes	O
(	O
MLN	O
)	O
and	O
spleens	O
of	O
Irf8	B
-	I
/	I
-	I
and	O
BXH	O
-	O
2	O
than	O
B6	O
mice	O
.	O

CD4	B
+	O
GATA3	B
+	O
T	O
cells	O
numbers	O
were	O
comparable	O
in	O
MLN	O
of	O
infected	O
B6	O
and	O
IRF	B
-	I
8	I
deficient	O
mice	O
,	O
but	O
MLN	O
cells	O
from	O
infected	O
IRF	B
-	I
8	I
deficient	O
mice	O
secreted	O
significantly	O
less	O
parasite	O
-	O
specific	O
IL	B
-	I
4	I
ex	O
vivo	O
.	O

The	O
numbers	O
of	O
alternatively	O
activated	O
macrophages	O
in	O
MLN	O
and	O
serum	O
levels	O
of	O
Hpb	B
-	O
specific	O
IgG1	B
and	O
IgE	B
were	O
also	O
significantly	O
less	O
in	O
infected	O
Irf8	B
-	O
/	O
-	O
than	O
B6	O
mice	O
.	O

The	O
frequencies	O
of	O
antigen	O
-	O
experienced	O
CD4	B
+	I
CD11a	I
hi	I
CD49d	I
hi	I
cells	I
that	O
were	O
CD44	B
hi	I
CD62L	I
-	I
were	O
similar	O
in	O
MLN	O
of	O
infected	O
Irf8	B
-	I
/	I
-	I
and	O
B6	O
mice	O
,	O
but	O
the	O
proportions	O
of	O
CD4	B
+	I
GATA3	I
+	O
and	O
CD4	B
+	I
IL	I
-	I
4	I
+	O
T	O
cells	O
were	O
lower	O
in	O
infected	O
Irf8	B
-	I
/	I
-	I
mice	O
.	O

CD11b	B
+	O
Gr1	B
+	O
cells	O
from	O
naïve	O
or	O
infected	O
Irf8	B
-	I
/	I
-	I
mice	O
suppressed	O
CD4	B
+	I
T	O
cell	O
proliferation	O
and	O
parasite	O
-	O
specific	O
IL	B
-	I
4	I
secretion	O
in	O
vitro	O
albeit	O
less	O
efficiently	O
than	O
B6	O
mice	O
.	O

Surprisingly	O
,	O
there	O
were	O
significantly	O
more	O
CD4	B
+	I
T	O
cells	O
in	O
infected	O
Irf8	B
-	I
/	I
-	I
mice	O
,	O
with	O
a	O
higher	O
frequency	O
of	O
CD4	B
+	I
CD25	I
+	I
Foxp3	I
+	I
T	O
(	O
Tregs	O
)	O
cells	O
and	O
significantly	O
higher	O
numbers	O
of	O
Tregs	O
than	O
B6	O
mice	O
.	O

In	O
vivo	O
depletion	O
of	O
MDSC	O
and	O
/	O
or	O
Tregs	O
in	O
Irf8	B
-	O
/	O
-	O
mice	O
did	O
not	O
affect	O
adult	O
worm	O
burdens	O
,	O
but	O
Treg	O
depletion	O
resulted	O
in	O
higher	O
egg	O
production	O
and	O
enhanced	O
parasite	O
-	O
specific	O
IL	B
-	I
5	I
,	O
IL	B
-	I
13	I
,	O
and	O
IL	B
-	I
6	I
secretion	O
ex	O
vivo	O
.	O

Our	O
data	O
thus	O
provide	O
a	O
previously	O
unrecognized	O
role	O
for	O
IRF	B
-	I
8	I
in	O
Th2	O
immunity	O
to	O
a	O
GI	O
nematode	O
.	O

Arginase	B
1	I
deletion	O
in	O
myeloid	O
cells	O
affects	O
the	O
inflammatory	O
response	O
in	O
allergic	O
asthma	O
,	O
but	O
not	O
lung	O
mechanics	O
,	O
in	O
female	O
mice	O
.	O

BACKGROUND	O
:	O
(	O
Over	O
-	O
)	O
expression	O
of	O
arginase	B
may	O
limit	O
local	O
availability	O
of	O
arginine	O
for	O
nitric	O
oxide	O
synthesis	O
.	O

We	O
investigated	O
the	O
significance	O
of	O
arginase1	B
(	O
ARG1	B
)	O
for	O
the	O
development	O
of	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
and	O
lung	O
inflammation	O
in	O
female	O
mice	O
with	O
ovalbumin	B
(	O
OVA	B
)	O
-	O
induced	O
allergic	O
asthma	O
.	O

METHODS	O
:	O
Arg1	B
was	O
ablated	O
in	O
the	O
lung	O
by	O
crossing	O
Arg1	B
fl	I
/	I
fl	I
and	O
Tie2	B
Cre	I
tg	I
/	I
-	I
mice	O
.	O

OVA	B
sensitization	O
and	O
challenge	O
were	O
conducted	O
,	O
and	O
AHR	O
to	O
methacholine	O
was	O
determined	O
using	O
the	O
Flexivent	O
system	O
.	O

Changes	O
in	O
gene	O
expression	O
,	O
chemokine	O
and	O
cytokine	O
secretion	O
,	O
plasma	B
IgE	I
,	O
and	O
lung	O
histology	O
were	O
quantified	O
using	O
RT	O
-	O
qPCR	O
,	O
ELISA	O
,	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Arg1	B
ablation	O
had	O
no	O
influence	O
on	O
the	O
development	O
of	O
OVA	B
-	O
induced	O
AHR	O
,	O
but	O
attenuated	O
OVA	B
-	O
induced	O
increases	O
in	O
expression	O
of	O
Arg2	B
and	O
Nos2	B
,	O
Slc7a1	B
,	O
Slc7a2	B
,	O
and	O
Slc7a7	B
(	O
arginine	B
transporters	I
)	O
,	O
Il4	B
,	O
Il5	B
and	O
Il13	B
(	O
TH2	B
-	I
type	I
cytokines	I
)	O
,	O
Ccl2	B
and	O
Ccl11	B
(	O
chemokines	B
)	O
,	O
Ifng	B
(	O
TH1	B
-	I
type	I
cytokine	I
)	O
,	O
Clca3	B
and	O
Muc5ac	B
(	O
goblet	O
cell	O
markers	O
)	O
,	O
and	O
OVA	B
-	O
specific	O
IgE	B
.	O

Pulmonary	O
IL	B
-	I
10	I
protein	I
content	O
increased	O
,	O
but	O
IL	B
-	I
4	I
,	O
IL	B
-	I
5	I
,	O
IL	B
-	I
13	I
,	O
TNFalpha	B
and	O
IFNgamma	B
content	O
,	O
and	O
lung	O
histopathology	O
,	O
were	O
not	O
affected	O
.	O

Arg1	B
elimination	O
also	O
decreased	O
number	O
and	O
tightness	O
of	O
correlations	O
between	O
adaptive	O
changes	O
in	O
lung	O
function	O
and	O
inflammatory	O
parameters	O
in	O
OVA	O
/	O
OVA	O
-	O
treated	O
female	O
mice	O
.	O

OVA	B
/	O
OVA	B
-	O
treated	O
female	O
mice	O
mounted	O
a	O
higher	O
OVA	B
-	O
IgE	B
response	O
than	O
males	O
,	O
but	O
the	O
correlation	O
between	O
lung	O
function	O
and	O
inflammation	O
was	O
lower	O
.	O

Arg1	B
-	O
deficient	O
OVA	B
/	O
OVA	B
-	O
treated	O
females	O
differed	O
from	O
males	O
in	O
a	O
more	O
pronounced	O
decline	O
of	O
arginine	O
-	O
metabolizing	O
and	O
-	O
transporting	O
genes	O
,	O
higher	O
plasma	O
arginine	O
levels	O
,	O
a	O
smaller	O
OVA	B
-	O
specific	O
IgE	B
response	O
,	O
and	O
no	O
improvement	O
of	O
peripheral	O
lung	O
function	O
.	O

CONCLUSION	O
:	O
Complete	O
ablation	O
of	O
Arg1	B
in	O
the	O
lung	O
affects	O
mRNA	O
abundance	O
of	O
arginine	O
-	O
transporting	O
and	O
-	O
metabolizing	O
genes	O
,	O
and	O
pro	O
-	O
inflammatory	O
genes	O
,	O
but	O
not	O
methacholine	O
responsiveness	O
or	O
accumulation	O
of	O
inflammatory	O
cells	O
.	O

HEB	B
is	O
required	O
for	O
the	O
specification	O
of	O
fetal	B
IL	I
-	I
17	I
-	O
producing	O
γδ	O
T	O
cells	O
.	O

IL	B
-	I
17	I
-	O
producing	O
γδ	O
T	O
(	O
γδT17	O
)	O
cells	O
are	O
critical	O
components	O
of	O
the	O
innate	O
immune	O
system	O
.	O

However	O
,	O
the	O
gene	O
networks	O
that	O
control	O
their	O
development	O
are	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
HEB	B
(	O
HeLa	B
E	I
-	I
box	I
binding	I
protein	I
,	O
encoded	O
by	O
Tcf12	B
)	O
is	O
required	O
for	O
the	O
generation	O
of	O
a	O
newly	O
defined	O
subset	O
of	O
fetal	B
-	I
derived	I
CD73	I
-	I
γδT17	I
cells	I
.	O

HEB	B
is	O
required	O
in	O
immature	O
CD24	B
+	I
CD73	I
-	I
γδ	I
T	I
cells	I
for	O
the	O
expression	O
of	O
Sox4	B
,	O
Sox13	B
,	O
and	O
Rorc	B
,	O
and	O
these	O
genes	O
are	O
repressed	O
by	O
acute	O
expression	O
of	O
the	O
HEB	B
antagonist	I
Id3	I
.	O

HEB	B
-	I
deficiency	I
also	O
affects	O
mature	O
CD73	B
+	O
γδ	O
T	O
cells	O
,	O
which	O
are	O
defective	O
in	O
RORγt	B
expression	O
and	O
IL	B
-	I
17	I
production	O
.	O

Additionally	O
,	O
the	O
fetal	B
TCRγ	I
chain	I
repertoire	I
is	O
altered	O
,	O
and	O
peripheral	O
Vγ4	B
γδ	I
T	I
cells	I
are	O
mostly	O
restricted	O
to	O
the	O
IFNγ	B
-	I
producing	I
phenotype	I
in	O
HEB	B
-	O
deficient	O
mice	O
.	O

Therefore	O
,	O
our	O
work	O
identifies	O
HEB	B
-	O
dependent	O
pathways	O
for	O
the	O
development	O
of	O
CD73	B
+	O
and	O
CD73	B
-	O
γδT17	O
cells	O
,	O
and	O
provides	O
mechanistic	O
evidence	O
for	O
control	O
of	O
the	O
γδT17	B
gene	I
network	I
by	O
HEB	B
.	O

Loss	O
of	O
solute	B
carrier	I
family	I
7	I
member	I
2	I
exacerbates	O
inflammation	O
-	O
associated	O
colon	O
tumorigenesis	O
.	O

Solute	B
carrier	I
family	I
7	I
member	I
2	I
(	O
SLC7A2	B
,	O
also	O
known	O
as	O
CAT2	B
)	O
is	O
an	O
inducible	O
transporter	O
of	O
the	O
semi	O
-	O
essential	O
amino	O
acid	O
L	O
-	O
arginine	O
(	O
L	O
-	O
Arg	O
)	O
,	O
which	O
has	O
been	O
implicated	O
in	O
wound	O
repair	O
.	O

We	O
have	O
reported	O
that	O
both	O
SLC7A2	B
expression	O
and	O
L	O
-	O
Arg	O
availability	O
are	O
decreased	O
in	O
colonic	O
tissues	O
from	O
inflammatory	O
bowel	O
disease	O
patients	O
and	O
that	O
mice	O
lacking	O
Slc7a2	B
exhibit	O
a	O
more	O
severe	O
disease	O
course	O
when	O
exposed	O
to	O
dextran	O
sulfate	O
sodium	O
(	O
DSS	O
)	O
compared	O
to	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
SLC7A2	B
plays	O
a	O
role	O
in	O
modulating	O
colon	O
tumorigenesis	O
in	O
the	O
azoxymethane	O
(	O
AOM	O
)	O
-	O
DSS	O
model	O
of	O
colitis	O
-	O
associated	O
carcinogenesis	O
(	O
CAC	O
)	O
.	O

SLC7A2	B
was	O
localized	O
predominantly	O
to	O
colonic	O
epithelial	O
cells	O
in	O
WT	O
mice	O
.	O

Utilizing	O
the	O
AOM	O
-	O
DSS	O
model	O
,	O
Slc7a2	B
-	O
/	O
-	O
mice	O
had	O
significantly	O
increased	O
tumor	O
number	O
,	O
burden	O
,	O
and	O
risk	O
of	O
high	O
-	O
grade	O
dysplasia	O
vs	O
.	O
WT	O
mice	O
.	O

Tumors	O
from	O
Slc7a2	B
-	O
/	O
-	O
mice	O
exhibited	O
significantly	O
increased	O
levels	O
of	O
the	O
proinflammatory	O
cytokines	O
/	O
chemokines	O
IL	B
-	I
1beta	I
,	O
CXCL1	B
,	O
CXCL5	B
,	O
IL	B
-	I
3	I
,	O
CXCL2	B
,	O
CCL3	B
,	O
and	O
CCL4	B
,	O
but	O
decreased	O
levels	O
of	O
IL	B
-	I
4	I
,	O
CXCL9	B
,	O
and	O
CXCL10	B
compared	O
to	O
tumors	O
from	O
WT	O
mice	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
shift	O
toward	O
pro	O
-	O
tumorigenic	O
M2	O
macrophage	O
activation	O
in	O
Slc7a2	B
-	O
deficient	O
mice	O
,	O
as	O
marked	O
by	O
increased	O
colonic	O
CD11b	B
+	O
F4	B
/	I
80	I
+	O
ARG1	B
+	O
cells	O
with	O
no	O
alteration	O
in	O
CD11b	B
+	O
F4	B
/	I
80	I
+	O
NOS2	B
+	O
cells	O
by	O
flow	O
cytometry	O
and	O
immunofluorescence	O
microscopy	O
.	O

The	O
shift	O
toward	O
M2	O
macrophage	O
activation	O
was	O
confirmed	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
from	O
Slc7a2	B
-	O
/	O
-	O
mice	O
.	O

In	O
bone	O
marrow	O
chimeras	O
between	O
Slc7a2	B
-	I
/	I
-	I
and	O
WT	O
mice	O
,	O
the	O
recipient	O
genotype	O
drove	O
the	O
CAC	O
phenotype	O
,	O
suggesting	O
the	O
importance	O
of	O
epithelial	O
SLC7A2	B
in	O
abrogating	O
neoplastic	O
risk	O
.	O

These	O
data	O
reveal	O
that	O
SLC7A2	B
has	O
a	O
significant	O
role	O
in	O
the	O
protection	O
from	O
CAC	O
in	O
the	O
setting	O
of	O
chronic	O
colitis	O
,	O
and	O
suggest	O
that	O
the	O
decreased	O
SLC7A2	B
in	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
may	O
contribute	O
to	O
CAC	O
risk	O
.	O

Strategies	O
to	O
enhance	O
L	O
-	O
Arg	O
availability	O
by	O
supplementing	O
L	O
-	O
Arg	O
and	O
/	O
or	O
increasing	O
L	O
-	O
Arg	O
uptake	O
could	O
represent	O
a	O
therapeutic	O
approach	O
in	O
IBD	O
to	O
reduce	O
the	O
substantial	O
long	O
-	O
term	O
risk	O
of	O
colorectal	O
carcinoma	O
.	O

Overexpression	O
of	O
small	B
ubiquitin	I
-	I
like	I
modifier	I
2	I
ameliorates	O
high	O
glucose	O
-	O
induced	O
reductions	O
in	O
cardiomyocyte	O
proliferation	O
via	O
the	O
transforming	B
growth	I
factor	I
-	I
beta	I
/	O
Smad	B
pathway	O
.	O

Hyperglycemia	O
may	O
induce	O
diabetic	O
cardiomyopathy	O
(	O
DC	O
)	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
mechanism	O
underlying	O
the	O
alleviation	O
of	O
high	O
glucose	O
(	O
HG	O
)	O
-	O
induced	O
impairments	O
in	O
the	O
proliferation	O
of	O
H9c2	O
embryo	O
cardiomyocyte	O
proliferation	O
by	O
small	B
ubiquitin	I
-	I
like	I
modifier	I
2	I
(	O
SUMO2	B
)	O
overexpression	O
was	O
investigated	O
.	O

H9c2	O
cell	O
morphology	O
was	O
identified	O
as	O
classical	O
long	O
shuttle	O
type	O
by	O
optical	O
microscopy	O
.	O

The	O
viability	O
of	O
HG	O
-	O
injured	O
H9c2	O
cells	O
was	O
evaluated	O
by	O
a	O
Cell	O
Counting	O
Kit	O
-	O
8	O
assay	O
and	O
the	O
results	O
indicated	O
that	O
viability	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
(	O
5	O
.	O
6	O
,	O
10	O
,	O
20	O
and	O
30	O
mmol	O
/	O
l	O
)	O
and	O
time	O
-	O
dependent	O
(	O
6	O
,	O
12	O
and	O
24	O
h	O
)	O
manner	O
.	O

H9c2	O
cells	O
treated	O
with	O
20	O
mmol	O
/	O
l	O
HG	O
for	O
24	O
h	O
were	O
selected	O
for	O
subsequent	O
experiments	O
due	O
to	O
the	O
extent	O
of	O
injury	O
caused	O
at	O
a	O
low	O
density	O
.	O

Flow	O
cytometry	O
was	O
conducted	O
to	O
confirm	O
cell	O
cycle	O
arrest	O
between	O
G1	O
/	O
S	O
phases	O
and	O
apoptosis	O
promotion	O
in	O
HG	O
-	O
injured	O
H9c2	O
cells	O
,	O
and	O
the	O
subsequent	O
alleviating	O
effect	O
of	O
SUMO2	B
overexpression	O
on	O
these	O
HG	O
-	O
induced	O
effects	O
.	O

Reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
western	O
blot	O
analysis	O
were	O
performed	O
to	O
detect	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
cell	O
cycle	O
-	O
and	O
apoptosis	O
-	O
associated	O
factors	O
.	O

The	O
results	O
indicated	O
that	O
the	O
expression	O
ofthe	O
cell	O
cycle	O
-	O
associated	O
factors	O
CyclinA2	B
and	O
C	B
-	I
Myc	I
was	O
upregulated	O
,	O
and	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	I
1a	I
was	O
downregulated	O
.	O

The	O
expression	O
of	O
the	O
apoptosis	O
-	O
associated	O
factor	O
Bcl	B
-	I
2	I
was	O
upregulated	O
,	O
while	O
Bcl	B
-	I
2	I
-	I
associated	I
X	I
and	O
caspase	B
-	I
3	I
expression	O
was	O
downregulated	O
,	O
by	O
SUMO2	B
overexpression	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
SUMO2	B
overexpression	O
on	O
the	O
transforming	B
growth	I
factor	I
(	O
TGF	B
)	O
-	O
beta	O
/	O
Smad	B
pathway	O
was	O
also	O
determined	O
using	O
RT	O
-	O
qPCR	O
and	O
western	O
blot	O
analysis	O
.	O

The	O
results	O
indicated	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
TGF	B
-	I
beta1	I
and	O
Smad3	B
in	O
HG	O
-	O
injured	O
H9c2	O
cells	O
were	O
significantly	O
decreased	O
following	O
SUMO2	B
overexpression	O
.	O

Thus	O
,	O
the	O
results	O
demonstrated	O
that	O
overexpression	O
of	O
SUMO2	B
may	O
alleviate	O
H9c2	O
cardiomyocyte	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
promotion	O
induced	O
by	O
HG	O
via	O
regulation	O
of	O
cell	O
cycle	O
-	O
and	O
apoptosis	O
-	O
associated	O
factors	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
the	O
TGF	B
-	I
beta	I
/	O
Smad	B
pathway	O
.	O

These	O
results	O
may	O
therefore	O
provide	O
a	O
novel	O
strategy	O
for	O
the	O
protection	O
of	O
cardiomyocytes	O
and	O
may	O
aid	O
the	O
diagnosis	O
and	O
prognosis	O
of	O
patients	O
with	O
DC	O
.	O

Salidroside	O
Ameliorates	O
Renal	O
Interstitial	O
Fibrosis	O
by	O
Inhibiting	O
the	O
TLR4	B
/	O
NF	B
-	I
kappaB	I
and	O
MAPK	B
Signaling	O
Pathways	O
.	O

Salidroside	O
(	O
Sal	O
)	O
is	O
an	O
active	O
ingredient	O
that	O
is	O
isolated	O
from	O
Rhodiola	O
rosea	O
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
anti	O
-	O
inflammatory	O
activities	O
and	O
a	O
renal	O
protective	O
effect	O
.	O

However	O
,	O
the	O
role	O
of	O
Sal	O
on	O
renal	O
fibrosis	O
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Here	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
is	O
to	O
test	O
the	O
protective	O
effects	O
of	O
Sal	O
against	O
renal	O
interstitial	O
fibrosis	O
(	O
RIF	O
)	O
,	O
and	O
to	O
explore	O
the	O
underlying	O
mechanisms	O
using	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
the	O
unilateral	O
ureteric	O
obstruction	O
(	O
UUO	O
)	O
or	O
folic	O
acid	O
(	O
FA	O
)	O
-	O
induced	O
mice	O
renal	O
interstitial	O
fibrosis	O
in	O
vivo	O
and	O
the	O
transforming	B
growth	I
factor	I
(	I
TGF	I
)	I
-	I
beta1	I
-	O
stimulated	O
human	O
proximal	O
tubular	O
epithelial	O
cell	O
(	O
HK	O
-	O
2	O
)	O
model	O
in	O
vitro	O
.	O

The	O
levels	O
of	O
kidney	O
functional	O
parameters	O
and	O
inflammatory	O
cytokines	O
in	O
serum	O
are	O
examined	O
.	O

The	O
degree	O
of	O
renal	O
damage	O
and	O
fibrosis	O
is	O
determined	O
by	O
histological	O
assessment	O
.	O

Immunohistochemistry	O
and	O
western	O
blotting	O
are	O
used	O
to	O
determine	O
the	O
mechanisms	O
of	O
Sal	O
against	O
RIF	O
.	O

Our	O
results	O
show	O
that	O
treatment	O
with	O
Sal	O
can	O
ameliorate	O
tubular	O
injury	O
and	O
deposition	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
(	O
including	O
collagen	B
SH	I
and	O
collagen	B
I	I
)	O
.	O

Furthermore	O
,	O
Sal	O
administration	O
significantly	O
suppresses	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
expression	O
of	O
alpha	B
-	I
SMA	I
,	O
vimentin	B
,	O
TGF	B
-	I
beta1	I
,	O
snail	B
,	O
slug	B
,	O
and	O
a	O
largely	O
restored	O
expression	O
of	O
E	B
-	I
cadherin	I
.	O

Additionally	O
,	O
Sal	B
also	O
reduces	O
the	O
levels	O
of	O
serum	O
biochemical	O
markers	O
(	O
serum	O
creatinine	O
,	O
Scr	O
;	O
blood	O
urea	O
nitrogen	O
,	O
BUN	O
;	O
and	O
uric	B
acid	I
,	O
UA	O
)	O
and	O
decreases	O
the	O
release	O
of	O
inflammatory	O
cytokines	O
(	O
IL	B
-	I
1beta	I
,	O
IL	B
-	I
6	I
,	O
TNF	B
-	I
alpha	I
)	O
.	O

Further	O
study	O
revealed	O
that	O
the	O
effect	O
of	O
Sal	O
on	O
renal	O
interstitial	O
fibrosis	O
is	O
associated	O
with	O
the	O
lower	O
expression	O
of	O
TLR4	B
,	O
p	B
-	I
IkappaBalpha	I
,	O
p	B
-	I
NF	I
-	I
kappaB	I
and	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
(	O
MAPK	B
)	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
Sal	O
treatment	O
improves	O
kidney	O
function	O
,	O
ameliorates	O
the	O
deposition	O
of	O
the	O
ECM	O
components	O
and	O
relieves	O
the	O
protein	O
levels	O
of	O
EMT	O
markers	O
in	O
mouse	O
kidneys	O
and	O
HK	O
-	O
2	O
cells	O
.	O

Furthermore	O
,	O
Sal	O
treatment	O
significantly	O
decreases	O
the	O
release	O
of	O
inflammatory	O
cytokines	O
and	O
inhibits	O
the	O
TLR4	B
/	O
NF	B
-	I
kappaB	I
and	O
MAPK	B
signaling	O
pathways	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
Sal	O
could	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
treating	O
renal	O
fibrosis	O
.	O